Biodegradable polymer

专利摘要:

公开号:AU2009301646A1
申请号:U2009301646
申请日:2009-10-09
公开日:2010-04-15
发明作者:Florian Hans Maximilian Graichen；Justine Leigh Jeffery；Michael Shane O'shea；Heng Chy Taing；Russell John Tait
申请人:Bionic Ear Inst；
IPC主号:A61K31-045

专利说明:
WO 2010/040188 PCT/AU2009/001342 BIODEGRADABLE POLYMER - BIOACTIVE MOIETY CONJUGATES FIELD OF INVENTION The present invention relates to biodegradable polymer-bioactive moiety conjugates, to methods for preparing the polymers, and to monomer-bioactive moiety conjugates suitable 5 for preparing the polymers. The conjugates can be used as coatings, scaffolds, stents and dressings for biomedical applications and in drug delivery devices. The invention also relates to a sustained bioactive moiety delivery system comprising the conjugate, and also to a method of delivering a bioactive moiety to a subject. BACKGROUND 10 The targeted and controlled delivery of small molecule therapeutics is an area of considerable current interest. The site-specific delivery of a therapeutic agent is a highly desirable feature for the treatment of many different conditions. In particular, products may be implanted in the body of humans or animals which contain therapeutics. However, there is a need to increase the efficacy and safety of such products. 15 One form of drug delivery involves the use of polymers to carry/retain the drug moiety to/at a specific location. Several approaches to this have been developed. Early controlled release methods involved drug-polymer formulations that released the drug upon breakdown of the polymer structure under physiological conditions, particularly through oral administration. Later developments included the preparation of drug-polymer systems 20 based on admixing or on covalent linking. The admixture approach involves the preparation of a polymer drug mixture that is then compounded into a solid device. The linking approach involves using drug molecules as monomers in formation of the polymer so that they form part of the polymer backbone, or covalently attaching drug molecules to a pre-formed polymer backbone. The linking 25 approach gives rise to so called drug-polymer conjugate. A major disadvantage of the admixture approach is that the release of the therapeutic agent is largely dependent on the breakdown of the polymer structure. This results in poor WO 2010/040188 PCT/AU2009/001342 -2 control of the rate of drug release with the possibility of uncontrolled dosages being delivered. Furthermore, the amount of drug that can be loaded into an admixture is limited (typically <10% by weight). The linking approach also has a number of problems associated with it. Where the drug 5 forms part of the polymer backbone, the polymer structure must degrade in order to release the drug. This will of course be disadvantageous where it is desirable to at least maintain the polymer structure while the drug is being released. Covalently attaching drug molecules to a pre-formed polymer backbone can also be problematic. In particular, steric and thermodynamic constraints can affect the amount of bioactive moiety that can be 10 covalently attached, and also impact on the distribution of the bioactive moiety along the polymer backbone, which in turn can reduce control over the release of the bioactive moiety. An opportunity therefore remains to develop new polymer - bioactive moiety conjugates which address or ameliorate one or more disadvantages or shortcomings associated with 15 existing materials and/or their method of manufacture, or to at least provide a useful alternative to such materials and their method of manufacture. SUMMARY OF THE INVENTION The present invention therefore provides a biodegradable polymer comprising a plurality of releasable bioactive moieties, the releasable bioactive moieties being pendant from and 20 covalently bonded to the biodegradable polymer backbone, wherein the biodegradable polymer backbone is formed from monomeric units that are each coupled via a biodegradable moiety, and wherein the bioactive moieties are capable of being released at a rate equal to or faster than the rate of biodegradation of the polymer backbone. An important feature of the invention is that the bioactive moieties are capable of being 25 released at a rate equal to or faster than the rate of biodegradation of the polymer backbone. By providing the biodegradable polymer with such relative rates of release and biodegradation it can advantageously release bioactive moiety without the polymer backbone undergoing substantial biodegradation.
WO 2010/040188 PCT/AU2009/001342 -3 It has been found that the biodegradable polymers according to the invention are particularly useful in applications where controlled delivery of bioactive moieties is required while maintaining the structural integrity of the polymer backbone. For example, in providing a coating for use in infection control, the biodegradable polymers according to 5 the invention retain the material properties of the polymer backbone for periods of time sufficient to allow substantial delivery of a bioactive moiety. The polymer backbone according to the invention is also biodegradable such that after a period of time the backbone degrades into biocompatible degradation products. The polymer backbone is preferably resorbable in vivo. 10 The biodegradable polymers in accordance with the invention may also be defined in terms a molecular structure. The invention therefore also provides a biodegradable polymer comprising as part of its 15 polymer backbone a plurality of moieties of general formula (I): A-X-R-Y-B 7 o (1) where: A and B, which are the same or different, represent the remainder of the polymer 20 backbone and (i) comprise one or more -X-R(ZD)-Y- moieties as shown in formula (I), and (ii) are each formed from monomeric units that are coupled via a biodegradable moiety; X and Y are each independently a biodegradable moiety; R represents a linear or branched optionally substituted hydrocarbon; 25 Z is a spacer moiety; and D is a releasable bioactive moiety; wherein the bioactive moieties (D) are capable of being released at a rate equal to or faster than the rate of biodegradation of the polymer backbone. 30 Each -X-R(ZD)-Y- moiety of the biodegradable polymers may be the same or different.
WO 2010/040188 PCT/AU2009/001342 -4 Each X, Y, R, Z and D in a given -X-R(ZD)-Y- moiety of the biodegradable polymers may be the same or different. For avoidance of any doubt, the "moiety of general formula (I)" is intended to be a 5 reference to:
J-X-R-Y
Iz D with A and B being presented in formula (I) to (i) more clearly depict that the "moiety" forms part of the polymer backbone, and (ii) define the nature of the remainder of the polymer backbone. 10 As used herein the expression forming "part of the polymer backbone" means that the moiety of formula (I) (i.e. excluding A and B) is part of the string of atoms that are each connected so as to form the polymer chain (i.e. including A and B). In other words, the moiety of formula (I) is not pendant from the polymer backbone. Having said this, it will 15 be appreciated that groups Z and D in the moiety of formula (I) will be pendant from the polymer backbone. Examples of A and B are discussed in more detail below, but include polyurethane, polyanhydride, polycarbonate, polyurea, polyamide, polyimide and polyester polymer 20 chains, as well as copolymers thereof. For example, the moiety of general formula (I) may in conjunction with a suitable comonomer form a repeat unit of a polyester, polyurethane or polyanhydride as illustrated below in general formula (Ia), (Ib) and (Ic), respectively: 25 0 0 || II z (1a) D where R, Z and D are as herein defined and Rx is an optionally substituted alkyl, aryl or WO 2010/040188 PCT/AU2009/001342 -5 alkylaryl group, wherein for each repeat unit of the polyester each R, Z, D and R' may be the same or different; 0 0 H || II H -Rx-N-C-O-R-O--C--N (Ib) D where R, Z and D are as herein defined and R' is an optionally substituted alkyl, aryl or 5 alkylaryl group, wherein for each repeat unit of the polyurethane each R, Z, D and Rx may be the same or different; 0 0 00 RN-C--O-C--R-C-O-C (Ic) D where R, Z and D are as herein defined and Rx is an optionally substituted alkyl, aryl or alkylaryl group, wherein for each repeat unit of the polyurethane each R, Z, D and RX may 10 be the same or different. Those skilled in the art will appreciate that the respective ester, carbamate and anhydride moieties in general formulae (Ia), (Ib) and (Ic) are examples of the X and Y biodegradable moieties defined in general formula (I). The biodegradable polymer in accordance with the invention may form part of or be 15 formed into an article or device per se or can be presented as a coating on an existing article or device. The biodegradable polymer provides an effective and efficient means for delivering bioactive moieties to a subject. In another aspect, the invention provides a method of delivering a bioactive moiety to a 20 subject, the method comprising administering to the subject a biodegradable polymer in accordance with the invention.
WO 2010/040188 PCT/AU2009/001342 -6 Through the bioactive moiety release function of the biodegradable polymers, the polymers can also advantageously function as or form part of a sustained bioactive moiety delivery system. In further aspect, the invention therefore provides a sustained bioactive moiety delivery 5 system, the system comprising a biodegradable polymer in accordance with the invention. In one embodiment of the invention the releasable bioactive moieties are covalently bonded to the polymer backbone via one or more spacer moieties. In a further embodiment of the invention the biodegradable polymers have a content of releasable bioactive moieties relative to total polymer of at least 10% by weight, preferably 10 at least 20% by weight, more preferably at least 30% by weight. In a yet further embodiment of the invention the biodegradable polymers contain two or more different releasable bioactive moieties. In an even yet further embodiment of the invention the releasable bioactive moieties are capable of being released from the polymer backbone such that they are unencumbered by 15 excess molecular fragments. In a preferred form of any one of the foregoing embodiments the release of bioactive moieties from the polymer backbone is substantially complete prior to significant breakdown of the polymer backbone. In a further preferred form of any one of the foregoing embodiments the polymer backbone 20 is substantially degradable to its constituent monomers under in vivo conditions. In an even further preferred form of any one of the foregoing embodiments the bioactive moiety is a drug moiety. The invention also provides a method for preparing a biodegradable polymer according to the invention, said method comprising the step of polymerising a monomer - bioactive 25 moiety conjugate of formula (II): WO 2010/040188 PCT/AU2009/001342 -7 X'-R-Y' I (11) where: X' and Y' are each independently functional groups that (a) are capable of undergoing polymerisation with monomer having compatible chemical 5 functionality, and (b) react with the compatible chemical functionality to afford a biodegradable moiety; R represents a linear or branched optionally substituted hydrocarbon; Z is a spacer moiety; and D is a releasable bioactive moiety; 10 with at least one monomer comprising compatible chemical functionality. In a further aspect there is provided a method for preparing the biodegradable polymer of the present invention by providing at least one first monomer comprising at least one releasable bioactive moiety and at least one polymerisable moiety; optionally providing at least one second monomer comprising at least one polymerisable moiety reactive with at 15 least one polymerisable moiety of said first monomer; polymerising said first monomer and optionally said second monomer optionally in the presence of one or more spacer moieties comprising two or more functionalities under conditions which are substantially non-interfering to the therapeutic efficacy of the bioactive moieties. There is yet further provided a use of the biodegradable polymers of the invention in the 20 preparation of an implantable scaffold, stent or a biomedical coating or dressing or an adhesive. There is even yet further provided a method of using the biodegradable polymer of the invention to deliver a bioactive moiety, preferably a drug moiety. The present invention also provides a monomer - bioactive moiety conjugate comprising: 25 a) one or more releasable bioactive moieties; b) two or more polymerisable moieties; wherein one or more of the releasable bioactive moieties are capable of being released WO 2010/040188 PCT/AU2009/001342 -8 from the monomer before or after polymerisation under conditions which are non interfering to the therapeutic efficacy of the bioactive moieties. The monomer - bioactive moiety conjugate in accordance with the invention may also be defined in terms a molecular structure. 5 In another aspect, the invention therefore provides a monomer - bioactive moiety conjugate that is suitable for use in preparing a biodegradable polymer - bioactive moiety conjugate, the monomer - bioactive moiety conjugate having a structure of general formula (II): X'-R-Y' Z 10 D where: X' and Y' are each independently functional groups that (a) are capable of undergoing polymerisation with monomer having compatible chemical functionality so as to form a biodegradable polymer, and (b) react with the 15 compatible chemical functionality to afford a biodegradable moiety; R represents a linear or branched optionally substituted hydrocarbon; Z is a spacer moiety; and D is a releasable bioactive moiety. In one embodiment, the two or more polymerisable moieties of the monomer - bioactive 20 moiety conjugate (e.g. X' and Y' of general formula (II)) may each be independently selected from hydroxyl, amine, carboxylic acid, isocyanate, and carboxylic acid halide. The monomer - bioactive moiety conjugates of the invention have been found to be particularly versatile and can advantageously be polymerised with one or more monomers using techniques well known in the art. 25 Further aspects of the invention appear below in the detailed description of the invention.
WO 2010/040188 PCT/AU2009/001342 -9 BRIEF DESCRIPTION OF THE DRAWINGS Preferred embodiments of the invention will herein be illustrated by way of example only with reference to the accompanying drawings in which: Figure 1 illustrates weight loss of biodegradable polymers after incubation in physiological 5 conditions at 37 0 C demonstrating bioerosion; Figure 2 illustrates in vitro release of Levofloxacin and the corresponding Levofloxacin containing monomer, Levofloxacin-monoglyceride, from a Levofloxacin-polyurethane conjugate produced from a 1:1 molar ratio of Levofloxacin monoglyceride and hexamethyl diisocyanate (Example 20); 10 Figure 3 illustrates in vitro release of Levofloxacin from biodegradable polymers described in examples 25, 26, 27 amd'28 showing cumulative amount of levofixacin released verus time; Figure 4 illustrates antimicrobial activity of levofloxacin-conjugate polymer films against S. aureus. Six mm diameter discs coated on a single side (10% w/w levofloxacin 15 example 36) (A) of different geometries (57%w/w levofloxacin- example 20) (0 - disc; M - square) were transferred daily to a freshly inoculated bacterial lawn, incubated and the zone of inhibition measured. Data are the mean zone of inhibition (mm) + standard error measured from six discs; Figure 5 illustrates in vitro release of Valproic Acid from polymers described in CE1, 13, 20 14, 16 and 17 showing cumulative amount of Valproic Acid released verus time; Figure 6 illustrates a simplified structure of a biodegradable polymer in accordance with the invention; Figure 7 illustrates a simplified structure of a biodegradable polymer according to the invention with multiple drugs; and WO 2010/040188 PCT/AU2009/001342 -9a Figure 8 illustrates a simplified structure of a biodegradable polymer according to the invention with multiple linker types and drugs, DETAILED DESCRIPTION OF THE INVENTION The terms "labile" and releasablee" may be used herein synonymously. 5 .Polymers having bioactive moieties covalently attached thereto are often referred to in the art as "polymer - bioactive moiety conjugates". It may therefore be convenient to refer to WO 2010/040188 PCT/AU2009/001342 -10 a biodegradable polymer of the invention as biodegradable polymer - bioactive moiety conjugate or simply as a conjugate. A biodegradable polymer of the invention may also be described as being a "functionalised" biodegradable polymer by virtue of the bioactive moieties being 5 covalently attached to or "functionalising" the polymer backbone. An important feature of the conjugates in accordance with the invention is that they are "biodegradable". By being "biodegradable" in the context of the invention is meant that polymer or polymer backbone undergoes with the passage of time substantial degradation under physiological conditions or in a biological environment. In other words, the polymer 10 backbone has a molecular structure that is susceptible to break down (i.e. a reduction in molecular weight) by chemical decomposition in a biological environment (e.g. within a subject or in contact with biological material such as blood, tissue etc), as opposed to physical degradation. Such chemical decomposition will typically be via the hydrolysis of labile or biodegradable moieties that form part of the molecular structure of the backbone. 15 Accordingly, such labile or biodegradable moieties will generally be susceptible to hydrolytic cleavage. Reference herein to biological material such as "biological tissue" is intended to include cells or tissue in vivo (e. g. cells or tissue of a subject) and in vitro (e.g. cultured cells). By being biodegradable, the conjugates in accordance with the invention can 20 advantageously be used to release bioactive moieties, for example within a subject, without the need to subsequently remove the remaining conjugate structure from the subject. An important feature of the biodegradable properties of the polymers is its backbone is formed from monomeric units that are each coupled via a biodegradable moiety. By having such characteristics, the polymers in accordance with the invention can 25 advantageously biodegrade into substantially non-toxic residues. For example, the -X-R(ZD)-Y- moiety as shown in formula (I) is attached to the remainder of the polymer backbone (represented by A and B) via a biodegradable moieties X and Y, WO 2010/040188 PCT/AU2009/001342 - 11 and A and B in their own right are each formed from monomeric units that are coupled via a biodegradable moiety. As used herein the expression "biodegradable moiety" is intended to mean a moiety that can undergo chemical decomposition under physiological conditions or in a biological 5 environment. Such chemical decomposition will typically be via hydrolysis. In other words, the biodegradable moiety with be susceptible to hydrolytic cleavage. In the context of the present invention; the biodegradable moieties function to link or couple the monomeric units that form the polymer backbone. Accordingly, it will be appreciated that the biodegradable moieties give rise to the biodegradable property of the polymer. 10 Those skilled in the art will appreciate the type of moieties that are typically susceptible to hydrolytic cleavage under physiological conditions or in a biological environment. Such moieties (represented by X and Y in general formula (I)) may include amide, urethane (carbamate), ester, anhydride, urea and carbonate. The biodegradable polymers in accordance with the invention may include a combination of such moieties. 15 In one embodiment, X and Y of all -X-R(ZD)-Y- moieties in the biodegradable polymer are each independently an ester or urethane moiety. Those skilled in the art will appreciate the type of moieties that are not typically 20 susceptible to hydrolytic cleavage in a biological environment. Such moieties may include carbonyl, siloxane, sulfone, ether, olefin (i.e. C-C, e.g. alkylene, alkenylene and alkynylene) and halogeninated olefin. As noted above, the biodegradable polymer in accordance with the invention will only include monomeric units that are coupled to each other via a biodegradable moiety. By 25 "monomeric units" is meant the building blocks that are polymerised to form the polymer. The monomeric units may in their own right be macro-monomeric units (i.e. monomeric units that are typically low molecular weight polymers and contain monomeric units in their own right - commonly referred to as macromers). Where the monomeric units are WO 2010/040188 PCT/AU2009/001342 - 12 macromers, they too must be formed only from monomeric units that are coupled via a biodegradable moiety. For example, the biodegradable polymer may be a polyester. In that case, the monomeric units that are polymerised to form the polyester, typically a diacid and a diol, will each be 5 coupled via a biodegradable ester moiety. The biodegradable polymer may also be a polyurethane. In that case, the monomeric units that are polymerised to form the polyurethane, typically a diisocyanate and a diol, will each be coupled via a biodegradable urethane moiety. The biodegradable polymer may also be a poly(urethane-ester) formed by polymerising a diisocyanate with a polyester macromer. In that case, the polyester 10 macromer will be formed from monomeric units that are coupled via a biodegradable moiety (as discussed above), and the polymerisation of it with the diisocyanate will give rise to the poly(urethane-ester) having monomeric units that are all coupled via a biodegradable urethane or ester moiety. Accordingly, it will be appreciated that the present invention is not intended to embrace the 15 situation where the biodegradable polymer comprises monomeric units that are coupled to each other via a non-biodegradable moiety. For example, the biodegradable polymer can not be a polyether. The biodegradable polymer also can not be a polymer comprising a polyether such as a poly(urethane-ether) or poly(ester-ether) formed by polymerising a diisocyanate and diacid, respectively, with a polyether macromer (e.g. polyalkyleneglycols 20 such as polyethyeneglycol and polypropyleneglycol). In that case, the polyether macromer will be formed from monomeric units (e.g. -(OR)n-) that are coupled via a non biodegradable moiety (i.e. an ether), and the polymerisation of it with the diisocyanate or diacid will give rise to the poly(urethane-ether) or poly(ester-ether), respectively, that has monomeric units coupled via non-biodegradable moieties. 25 The biodegradable characteristics of the conjugates in accordance with the invention advantageously enable its polymer backbone to degrade into substantially non-toxic residues. This is in contrast with polymer - bioactive moiety conjugates that comprise within their polymer backbone a non-biodegradable polymer segment such as a polyether WO 2010/040188 PCT/AU2009/001342 - 13 or polyvinyl that may give rise to toxic residues. For example, some polyethers are known to be toxic to humans and animals. Furthermore, low molecular weight diols such as C 2
-
10 , C 2
-
6 , C 2
-
3 , C 2 diols (e.g. ethylene glycol and propylene glycol) can also be toxic to humans and animals. Low molecular 5 weight diols are commonly used as comonomers or chain extenders in the manufacture of polylmers such polyurethanes and polyesters. If such diols are used in preparing the bidegradable polymers of the invention they can subsequently be liberated upon its biodegradation. Accordingly, it can be desirable to limit their use in the bidegradable polymers of the invention. In contrast, higher alcohols such as triols are typically less 10 toxic to humans and animals. In one embodiment, the biodegradable polymers of the invention comprise polymerised residues of a diol and less than 25 mol%, less than 10 mol%, or less than 5 mol% of those polymerised residues are derived from a low molecular weight diol (C 2
-
10 , C 2
-
6 , C 2 .3, or C 2 diol). 15 In a further embodiment, the biodegradable polymers of the invention comprise substantially no polymerised residues of a low molecular weight diol (C 2
..
10 , C 2
-
6 , C 2
-
3 , or
C
2 diol). In still a further embodiment, where the biodegradable polymers of the invention are prepared using diol monomer, less than 25 mol%, less than 10 mol%, or less than 5 mol% 20 of that monomer comprises a low molecular weight diol (C 2
-
10 , C 2
-
6 , C 2
-
3 , or C 2 diol). In yet a further embodiment, where the biodegradable polymers of the invention are prepared using diol monomer, that monomer comprises substantially no low molecular weight diol (C 2
-
10 , C 2
-
6 , C 2
-
3 , or C 2 diol). The mol% diol/diol residue values referred to herein are those relative to the total moles of 25 diol/diol residue. In addition to the polymer backbone of the conjugates being biodegradable, it has covalently attached to it in pendant form a plurality of releasable bioactive moieties.
WO 2010/040188 PCT/AU2009/001342 - 14 By the bioactive moieties being in "pendant form" is meant that they do not directly form part of the polymer backbone and as such can be released without causing a reduction in the chain length of the polymer backbone. This is more clearly illustrated by general formula (I). 5 By the bioactive moieties being "releasable", "labile", or "capable of being released" is meant that they can be covalently decoupled or cleaved from the polymer backbone so as to present in a biologically active form. In the context of general formulae I and II above, the moiety will therefore be capable of being released or cleaved from the Z group to afford D per se. Release of the moieties will generally be promoted by the conjugates 10 being exposed to physiological conditions or a biological environment. The ability of the bioactive moieties to be releasable will generally be as result of them being coupled in pendant form via a biodegradable moiety either directly or through a spacer moiety to the polymer backbone. Hydrolytic cleavage of the biodegradable moiety as herein described therefore will promote release of the bioactive moiety. Further detail 15 in relation to this is discussed below. The biodegradable polymers in accordance with the invention can advantageously be prepared such that they are suitable for administration to a subject (i.e. suitable for in vivo applications). According to one embodiment there is provided a method of delivering a bioactive moiety 20 to a subject, the method comprising administering to the subject a biodegradable polymer in accordance with the invention. By the biodegradable polymer being "suitable" for administration to a subject is meant that administration of the conjugate to a subject will not result in unacceptable toxicity, including allergenic responses and disease states. 25 By the term "subject" is meant either an animal or human subject. By "animal" is meant primates, livestock animals (including cows, horses, sheep, pigs and goats), companion animals (including dogs, cats, rabbits and guinea pigs), and captive wild animals (including WO 2010/040188 PCT/AU2009/001342 - 15 those commonly found in a zoo environment). Laboratory animals such as rabbits, mice, rats, guinea pigs and hamsters are also contemplated as they may provide a convenient test system. Generally, the subject will be a human subject. By "administration" of the conjugate to a subject is meant that the composition is 5 transferred to the subject such that the bioactive agent will be released. Provided the bioactive agent can be released, there is no particular limitation on the mode of administration, but this will generally be by way of oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, intrathecal, and intraspinal), inhalation (including nebulisation), buccal, pulmonary, aural, ocular, nasal, topical, rectal 10 and vaginal modes. The biodegradable polymers may be provided in particulate form and blended with a pharmacologically acceptable carrier to facilitate administration. By "pharmacologically acceptable" is meant that the carrier is suitable for administration to a subject in its own right. In other words, administration of the carrier to a subject will not result in 15 unacceptable toxicity, including allergenic responses and disease states. The term "carrier" refers to the vehicle with which the conjugate is contained prior to being administered. As a guide only, a person skilled in the art may consider "pharmacologically acceptable" as an entity approved by a regulatory agency of a federal or state government or listed in the US Pharmacopeia or other generally recognised pharmacopeia for use in animals, and 20 more particularly humans. Suitable pharmacologically acceptable carriers are described in Martin, Remington's Pharmaceutical Sciences, 18th Ed., Mack Publishing Co., Easton, PA, (1990), and include, but are not limited to, liquids that may be sterilised such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soya bean oil, 25 mineral oil, sesame oil, and the like. The biodegradable polymers may also form part of or be formed into an article or device, or be applied as a coating on an article or device, and implanted in a subject. By being "implanted" is meant that the article or device is totally or partly introduced medically into WO 2010/040188 PCT/AU2009/001342 - 16 a subject's body, or by medical intervention into a natural orifice of a subject, and which is intended to remain there after the procedure. Suitable dosage amounts of the bioactive moiety and dosing regimens of the biodegradable polymers can be determined by a physician and may depend on the particular condition 5 being treated, the rate of release of the moiety form the polymer backbone, the severity of the condition as well the general age, health and weight of the subject. Dosing may occur at intervals of minutes, hours, days, weeks, months or years or continuously over any one of these periods. Suitable dosages of the bioactive moiety per se (i.e. that which is to be release from the polymer backbone within a given time frame) 10 may lie within the range of about 0.1 ng per kg of body weight to 1 g per kg of body weight per dosage. The dosage may be in the range of 1 pg to 1 g per kg of body weight per dosage, such as is in the range of 1 mg to 1 g per kg of body weight per dosage. In one embodiment, the dosage may be in the range of 1 mg to 500 mg per kg of body weight per dosage. In another embodiment, the dosage may be in the range of 1 mg to 250 mg per kg 15 of body weight per dosage. In yet another embodiment, the dosage may be in the range of 1 mg to 100 mg per kg of body weight per dosage, such as up to 50 mg per body weight per dosage. The biodegradable polymers in accordance with the invention may be administered in a single dose or a series of doses. 20 Dosage forms adapted for administration by the above modes may also be formulated with the biodegradable polymer as one of the components of the dose formulation. In the case of ocular, aural or nasal administration the biodegradable polymer may be a component of a drop, cream or ointment or take the form of an implant, ointment or gel. In the case of 25 oral administration the biodegradable polymer could take the form of or be a component in a tablet, capsule or liquid. In the case of topical administration the biodegradable polymer could take the form of or be a component in a cream, ointment, gel or liquid (e.g eye drop). Parenteral administration would involve the biodegradable polymer to be part of or take the form of an injectable product or implantable device (e.g coating on a pacemaker) that WO 2010/040188 PCT/AU2009/001342 - 17 can be administered subcutaneously, intramuscularly, intravenously or by direct surgical placement within the body. The form of the biodegradable polymer may be adjusted to be suited to the required 5 application such as a coating, film, pellet, capsule, fibres, laminate, foam etc. The difference in the form of the biodegradable polymer provides a means to alter the release profile of the bioactive moiety. For example the amount of polymer and bioactive moiety may *be the same in two different structures e.g. (a) polymer film, and (b) woven multifilament mat. The differences in the surface area to volume, rates of hydration and 10 diffusion paths from the different physical structures can result in different rates of bioactive moiety release from essentially the same polymer. The adjustment of the form of the polymer to suit the application and further to adjust the form to further control the bioactive moiety release profile provide an additional advantage 15 over purely compositional and polymer structural means to control the release profile of the bioactive moiety. Some of the compositional / structural means to control the release of the bioactive moiety include: controlling the loading of the bioactive; composition of the other comonomers to 20 adjust criteria such as hydrophobicity, flexibility, susceptibility to degradation, ability of the fragments to autocatalyse the polymer degradation, thermal stability of the polymer, mouldability, polymer solubility to assist casting etc. Additionally, the ability to produce the biodegradable polymers into a range of forms 25 provide a means to produce three dimensional structures that can be beneficial is providing structural integrity to their application as well as providing a means to control cell growth by control of the placement of the conjugate in structures to allow release of the bioactive moiety at specific places (e.g. fibre coating or fibres in a stent to prevent or control restinosis) Other examples include the ability of the structures to be formed into porous 30 three dimensional structures to control cell phenotype as well as the filter or limit different types of cell bodily fluid ingress.
WO 2010/040188 PCT/AU2009/001342 - 18 The biodegradable polymers in accordance with the invention may also be used in in vitro applications such as assays. Such in vitro applications could involve the use of the biodegradable polymers as a coating of a reaction chamber that would have an affect on 5 chamber constituents (e.g. encourage cell growth, discourage growth of contaminating organisms, etc) or as a component within the assay to provide a source of the bioactive moiety (e.g. as an antigen for an ELIZA test). The use of the biodegradable polymers for in vitro applications could allow the use of the 10 formed polymer to provide a host for bio-signals, essential additives drugs etc for the interaction controlled growth, cell segregation, controlled cell differentiation etc of cells / tissue components etc. The formed biodegradable polymer could be made into a structure that is compatible with 15 cell culture ware or in vitro devices used to act as indicators etc of certain conditions. The forms of the conjugate could range from simple pellets or films through to multilayer films, fibrous knitted, woven or electrospun structures, printed, spun cast, deposited or cast structures through to foams or composite type structures having multiple forms or components. 20 The expression "bioactive moiety" (also represented as "D" in certain formulae herein) is used to define any substance that is of medical or veterinary therapeutic, prophylactic or diagnostic utility capable of forming a conjugate in accordance with the invention. For example a bioactive moiety may be a drug or therapeutically active agent, including pharmacologically active agents (e.g. receptor binding agonist or antagonists, cytotoxic 25 agents), pharmacologically inactive agents (e.g. antibiotics) and prodrugs thereof. The bioactive moiety will generally be a substance (e.g. pharmaceutical substance) for therapeutic use whose application (or one or more applications) involves: a chemical interaction, or physico-chemical interaction, with a subject's physiological system; or an action on an infectious agent, or on a toxin or other poison, in subject's body; or with 30 biological material such as cells in vitro.
WO 2010/040188 PCT/AU2009/001342 - 19 As used herein, a "therapeutic agent" refers to a bioactive moiety that, when administered to a subject, will cure, or at least relieve to some extent, one or more symptoms of, a disease or disorder. As used herein, a "prophylactic agent" refers to a bioactive moiety that, when administered 5 to a subject either prevents the occurrence of a disease or disorder or, if administered subsequent to a therapeutic agent, prevents or retards the recurrence of the disease or disorder. Upon being released, the bioactive moiety will either be bioactive or will be converted in vivo or in vitro to a bioactive moiety (e.g. as in the case of a prodrug). Despite the 10 bioactive moiety being releasable from the monomer of formula II, it will be appreciated that the intention of the present invention is for the moiety to be released after the monomer has been polymerised to form polymer. The bioactive moiety may be released from the biodegradable polymer such that it provides for a sustained bioactive delivery system. Such a delivery system may in its 15 simplest form be the polymer provided in a desired shape, for example a pellet or more intricate shape. To promote surface area contact of the polymer under physiological conditions or with a biological environment, it may also be provided in the form of a foamed product or a coating on substrate. By "sustained bioactive moiety delivery" is meant that the bioactive moiety is released 20 from the biodegradable polymer over a period of time, for example over a period of 10 or more minutes, 30 or more minutes, 60 or more minutes, 2 or more hours, 4 or more hours, 12 or more hours, 24 or more hours, 2 or more days, 5 or more days, 10 or more days, 30 or more days, 2 or more months, 4 or more months or over 6 or more months. In order for the bioactive moiety (also denoted by D in certain formulae herein) to be 25 released, the covalent bond that (a) directly couples the moiety to the polymer backbone, or (b) directly couples the moiety to a spacer moiety which itself is attached to the polymer backbone; (e.g. the covalent bond between D and the Z group in formula (I)), will of WO 2010/040188 PCT/AU2009/001342 - 20 course need to be cleaved. For convenience, this covalent bond may be referred to as the "coupling" covalent bond. In one embodiment the coupling covalent bond is not a carbon-carbon bond. In such an embodiment, the coupling covalent bond will generally form part of a functional group 5 selected from: esters; amides; anhydrides; imides; carbonates; peroxides; peroxyesters; phosphates; thioesters; sulfates; disulfides; carbamates; ethers; siloxanes; azo; orthoesters; phosphonates; peroxy; and boronate esters. Of these functional groups, anhydrides, esters, imides, carbonates, carbamates, and boronate esters are preferred. Cleavage of the coupling covalent bond can be promoted hydrolytically (i.e. hydrolytic 10 cleavage) and may take place in the presence of water and an acid or a base. In some embodiments the cleavage may take place in the presence of one or more hydrolytic enzymes or other endogenous biological compounds that catalyze or at least assist in the cleavage process. For example, an ester bond may be hydrolytically cleaved to produce a carboxylic acid and an alcohol, and an aide bond may be hydrolytically cleaved to 15 produce a carboxylic acid and an amine. Those skilled in the art will appreciate that such cleavage amounts to the hydrolytic cleavage of the biodegradable moieties discussed herein. Accordingly, the bioactive moiety (D) may also be described as being coupled to the polymer backbone, optionally through a spacer moiety (Z) via a biodegradable moiety. As indicated above, on being released the bioactive moiety may be in the form of a 20 prodrug. As used herein, the term "prodrug" refers to a derivative of a bioactive moiety, wherein the derivative may have little or none of the activity of the bioactive moiety per se yet is capable of being converted in vivo or in vitro into a bioactive moiety. An example of such derivatisation is the acetylation of one or more hydroxyl groups on a bioactive moiety, such that subsequent to being released in vivo the released prodrug is deactylated 25 to produce the bioactive moiety. The terms "spacer", "spacer group" or "spacer moiety" refer to an atom or any straight chain or branched, symmetric or asymmetric compound capable of linking or coupling the bioactive moiety to a monomer or a polymer backbone.
WO 2010/040188 PCT/AU2009/001342 -21 For example, in the structures of formulae (I) and (II), the bioactive moiety (D) is coupled to R through a spacer moiety denoted by Z. Thus, "spacer", "spacer group" or "spacer moiety" refers to a substituent which is generally divalent and that couples D to R. As outlined above, the covalent bond between the spacer moiety and the bioactive moiety is 5 cleavable so that the bioactive moiety is releasable. Examples of suitable spacer moieties include the divalent form of a group selected from oxy (-0-), alkyl, alkenyl, alkynyl, aryl, acyl (including -C(O)-), carbocyclyl, heterocyclyl, heteroaryl, alkyloxy, alkenyloxy, alkynyloxy, aryloxy, acyloxy, carbocyclyloxy, 10 heterocyclyloxy, heteroaryloxy, alkylthio, alkenylthio, alkynylthio, arylthio, acylthio, carbocyclylthio, heterocyclylthio, heteroarylthio, alkylalkenyl, alkylalkynyl, alkylaryl, alkylacyl, alkylcarbocyclyl, alkylheterocyclyl, alkylheteroaryl, alkyloxyalkyl, alkenyloxyalkyl, alkynyloxyalkyl, aryloxyalkyl, alkylacyloxy, alkyloxyacylalkyl, alkylcarbocyclyloxy, alkylheterocyclyloxy, alkylheteroaryloxy, alkylthioalkyl, 15 alkenylthioalkyl, alkynylthioalkyl, arylthioalkyl, alkylacylthio, alkylcarbocyclylthio, alkylheterocyclylthio, alkylheteroarylthio, alkylalkenylalkyl, alkylalkynylalkyl, alkylarylalkyl, alkylacylalkyl, arylalkylaryl, arylalkenylaryl, arylalkynylaryl, arylacylaryl, arylacyl, arylcarbocyclyl, arylheterocyclyl, arylheteroaryl, alkenyloxyaryl, alkynyloxyaryl, aryloxyaryl, arylacyloxy, arylcarbocyclyloxy, arylheterocyclyloxy, arylheteroaryloxy, 20 alkylthioaryl, alkenylthioaryl, alkynylthioaryl, arylthioaryl, arylacylthio, arylcarbocyclylthio, arylheterocyclylthio, and arylheteroarylthio, wherein where present the or each -CH 2 - group in any alkyl chain may be replaced by a divalent group independently selected from -0-, -OP(O) 2 -, -OP(O) 2 0- -S-, -S(O)-, -S(0) 2 0-, -OS(0) 2 0-, -N=N-, -OSi(ORa) 2 0-, -Si(ORa) 2 0-, -OB(ORa)O-, -B(ORa)O-, -NRa-, -C(O)-, -C(0)0-, 25 OC(0)0-, -OC(O)NR- and -C(O)NRa-, where the or each Ra may be independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, carbocyclyl, heteroaryl, heterocyclyl, arylalkyl, and acyl. The or each Ra may also be independently selected from hydrogen, C 1salkyl, C 1 isalkenyl, C 1 ..i8alkynyl, C- 1 i8aryl, C 3
.
18 carbocyclyl, C 3 .i 8 heteroaryl, C 3 . 1 8 heterocyclyl, and C 7
.
18 arylalkyl.
WO 2010/040188 PCT/AU2009/001342 - 22 The spacer moiety may be branched. In some embodiments where the spacer moiety is branched, two or more releasable bioactive moiety may be appended to the spacer moiety. In the lists above defining groups (generally divalent) from which the or each spacer moiety may be selected, each alkyl, alkenyl, alkynyl, aryl, carbocyclyl, heteroaryl, and 5 heterocyclyl moiety may be optionally substituted. For avoidance of any doubt, where a given spacer moiety contains two or more of such moieties (e.g. alkylaryl), each of such moieties may be optionally substituted with one, two, three or more optional substituents as herein defined. In the lists above defining groups (generally divalent) from which the or each spacer 10 moiety may be selected, where a given spacer moiety contains two or more subgroups (e.g. [group A] [group B]), the order of the subgroups is not intended to be limited to the order in which they are presented. Thus, a spacer moiety with two subgroups defined as [group A][group B] (e.g. alkylaryl) is intended to also be a reference to a spacer moiety with two subgroups defined as [group B][group A] (e.g. arylalkyl). 15 The biodegradable polymer of present invention can be readily prepared using monomer bioactive moiety conjugates such as those of general formula (II). Such monomers can themselves be prepared using commonly available reagents. Examples of such reagents that may be used to construct the spacer moiety (e.g. Z) include linear or branched hydrocarbons substituted with two or more reactive functional groups such as alcohols, 20 primary and secondary amines, carboxylic acids and combinations thereof. Examples of such substituted hydrocarbons are diols, diacids, diamines, hydroxyacids, amino acids and amino alcohols. The substituted hydrocarbons may be a,o-substituted alkylenes or a,co substituted (poly)oxycarbonylalkylenes [ie a.,co-substituted polyesters]. The skilled person will appreciate that when such a,co-substituted alkylenes or a,o-substituted 25 (poly)oxycarbonylalkylenes are used as the linking group, the monomer - bioactive moiety conjugates of formula (II), and polymers produced therefrom, will typically comprise at least two functional groups that may be susceptible to cleavage so as to release the bioactive moiety. In these compounds, it is preferable that the functional group closest to WO 2010/040188 PCT/AU2009/001342 -23 the bioactive moiety is as susceptible to, or more susceptible to, cleavage than the functional group closest to the polymer backbone. Specific examples of spacer moieties include: -0-; -C(O)-; and optionally substituted:
-OC(O)-C
1 - galkylene-C(O)-; -C(O)O-C- 1
-
8 alkylene-C(O)-; -NRaC(O)-C 1 -salkylene-C(O) 5 ; -C(O)O-Ci- 8 alkylene-O-; -0-Ci.i 8 alkylene-O-; -0-C.isalkylene-NRa-; -OC(O)-C 1 18alkylene-NRa-; -C(O)-C 1 I - 8 alkylene-NRa-; -OC(O)-C 1
-
8 alkylene-O-; -C(0)-C 1 18 alkylene-O-; and -C(O)NRa-Ci.i 8 alkylene-NRa- where Ra is as defined above. Preferred examples of spacer moieties include: -0-; -C(O)-; and -OC(0)-C 1 .i 8 alkylene 10 C(O)-, such as -OC(O)-C 2 3 alkylene-C(O)-. An example of a monomer - bioactive moiety conjugate of formula (II) that comprises a
-OC(O)-C
1 .i 8 alkylene-C(O)- spacer moiety (Z) is shown below: X'-R- Y' C1.
18 alkylene 15 D where: X', Y' R and D are as herein defined. The monomer - bioactive moiety conjugate precursor (i.e. the monomer prior to conjugate addition of the bioactive moiety - herein after conveniently referred to as the precursor 20 monomer) must of course have a means for chemical attachment to the bioactive moiety or to a spacer moiety. The types of functional groups on the precursor suitable for such attachment include hydroxyl, carboxylate, amino, thiol, phosphate or combinations thereof. The precursor may be singly of multiply functionalised with bioactive moieties. As discussed above, the bioactive moiety must correspondingly have a means for chemical 25 attachment to the precursor monomer or to a spacer moiety. The types of functional groups on the bioactive moiety suitable for attachment include hydroxyl, carboxylate, amino, thiol, phosphate or combinations thereof.
WO 2010/040188 PCT/AU2009/001342 - 24 Where a spacer moiety is used, as discussed above it must have at least two functional groups for chemical attachment, one to the bioactive moiety the other to the precursor monomer. Useful spacer moiety precursors (i.e. the spacer moiety prior to being covalently attached to the polymer or bioactive moiety) may include functional groups 5 such as hydroxyl, carboxylate, amino, thiol, phosphate or combinations thereof. The spacer moieties may be derived from precursors that comprise two or more functional groups which may be the same or different. Examples of precursors from which the spacer moieties may be derived that contain a single type of functional group include dicarboxylic acids (e.g., malonic acid), diols (e.g., propylene glycol), polyols (e.g., glycerol), dithiols 10 (e.g., 1,3-propanedithiol). Examples of precursors from which the spacer moieties may be derived that contain two or more different functional groups include glycolic acid, citric acid, tartaric acid, lactic acid, salicylic acid, lysine, serine, aspartic acid, cysteine, etc. Using such precursors is advantageous when seeking to couple a bioactive moiety to a monomer precursor through the same type of functional group. For example, coupling the 15 carboxylic acid on a bioactive moiety to a carboxylic acid on a monomer precursor can be achieved with a diol or polyol spacer. Conversely, coupling a hydroxyl on a bioactive moiety to a hydroxyl on a monomer precursor can be achieved with a diarboxylic acid (e.g., malonic acid) spacer. Use of the spacer moieties can provide facile coupling of the bioactive moiety to the R 20 group. In particular, spacer moieties may provide the skilled worker with the ability to couple the bioactive moiety at a sterically hindered position that could not otherwise be achieved by directly coupling the moiety to the R group. The choice of spacer moieties will determine the spacing of the D from the X' and Y' 25 groups in the monomers of formula (II). In this respect, the use of spacer moieties can provide a means to distance D from these groups. This can facilitate polymerisation of the monomers by reducing steric crowding around the X' and Y' groups. In forming a monomer of formula (II), prior to conjugation the bioactive moiety (denoted 30 by D) necessarily comprises compatible functionality so as to promote coupling of the WO 2010/040188 PCT/AU2009/001342 - 25 bioactive moiety to the monomer through Z. Examples of such compatible functionalities in D can include: (i) carboxylic acids, sulfates and phosphates (e.g. for reacting with a spacer 5 precursor moiety comprising a primary amino, secondary amino or hydroxy group to couple the bioactive moiety to the monomer through a nitrogen atom or an oxygen atom containing spacer moiety); and (ii) carboxylic acids, hydroxyls, amines (primary and secondary) thiols and phosphates (e.g. for reacting with a spacer precursor moiety comprising a carboxylic acid 10 or acid halide group to couple the bioactive moiety to monomer through a carbonyl group containing spacer moiety). Those skilled in the art will appreciate that the process of preparing the monomer bioactive moiety conjugate will typically result in expulsion of a small molecule such as 15 water or hydrogen halide (e.g. HCl). For example, the formation of an ester bond through reaction of a carboxylic acid group with a hydroxy group liberates a water molecule. In some embodiments, the bioactive moiety comprises a carboxylic acid, hydroxyl group, thiol group, amine group, or phosphate group, or combinations thereof for conjugate 20 coupling. When conjugated through such groups, a part or the whole of the Z group can form part of an ester, an amide, an anhydride, an azo, an imide, a carbonate, a peroxyester, a thioester, a carbamate, a boronate ester, a sulfate or a phosphate linkage group. The skilled worker will recognise that each of these linkage groups comprises a covalent bond that is capable of being cleaved (for example hydrolytically, enzymatically and/or by a 25 radical mechanism). Generally, such spacer groups will comprise a covalent bond that is capable of being cleaved hydrolytically so as to release the bioactive moiety. Where a given bioactive moiety comprises more than one compatible functional group capable of conjugate coupling, the skilled worker may routinely adopt an appropriate 30 protecting group strategy so that the bioactive moiety couples to the monomer in a preselected fashion. Protection group chemistry, and strategy, is well-known in the art in, WO 2010/040188 PCT/AU2009/001342 - 26 for example, T.W. Greene and P.G.M. Wuts in "Protective Groups in Organic Chemistry", John Wiley and Sons, 1991. For example, where a bioactive moiety comprises a primary alcohol and a primary amine, the skilled worker may protect the primary amine prior to coupling the bioactive moiety so that the bioactive moiety couples through an ester moiety 5 rather than an amide moiety. In another example a primary alcohol may be protected selectively over a secondary alcohol, so that the bioactive moiety may be coupled through an ester moiety derived from the secondary alcohol. Such protecting groups may or may not be removed following coupling. For example, the protecting group may be an acetyl group, and the acetylated amine or alcohol may undergo cleavage in vivo to return the 10 unprotected amine or alcohol. Provided that a suitable conjugate can be formed, there is no particular limitation on the type of bioactive moiety that may be used in accordance with the invention. The bioactive moiety may be exemplified by 5-alpha-reductase inhibitors, amebicides, aminosalicylates, 15 anaesthetics (general and local), analgesics, angiotensin inhibitors, anorexiants, antacid agents, anti-angiogenic agents, antianginal agents, antiarrythmic agents, antiarthritic agents, antibiotics, antibacterial agents, antibodies, anticoagulants, anticonvulsants, antidepressants, antiepileptic agents, antifungals, anthelmintics, antihistamines, antihypertensives, antihyperlipidemic agents, antiinfectives, antiinflammatories, 20 antiemetics, antimalarial, antimetabolites, antimigraine, antimitotics, antiparasitic agents, antiparkinson agents, antipsychotics, antiprotozoals, antitussives, antiulcer agents, antivirals, anxiolytics, bronchodilators, decongestants and expectorants, cancer therapy and related pharmaceuticals, cardiovascular pharmaceuticals, central nervous system pharmaceuticals, benzopidazepines, beta-adrenergic blocking agents, bisphosphonates, 25 calcium channel blockers, carbonic anhydrase inhibitors, chemokine receptor antagonist, coumarins and indadiones, cox-2 inhibitors, contraceptives, cytotoxics, diuretics, diabetes therapies, growth hormones, fertility pharmaceuticals, hematinics, glucose modifying agents, growth promoters, H2 antagonists, heparin and heparin antagonists, hormone replacement therapies, hemostatics, immunosuppressants, immunostimulants, inotropic 30 agents, interferons, hormones and analogs, impotence agents, kinase inhibitors, laxatives, leukotriene modifiers, macrolides, mast cell stabilizers, muscle relaxants/stimulants, WO 2010/040188 PCT/AU2009/001342 -27 mydiratics, neuromuscular blocking agents, obesity therapeutics, ophthalmic pharmaceuticals, osteoporosis drugs, pain therapeutics (including paracetamol, opiates, nonsteroidal antinflammatory agents, tramadol), peptides and polypeptides, peripheral vasodilators, platelet inhibitors/stimulating agents, prolactin inhibitors, protease inhibitors, 5 protein therapeutics, proton pump inhibtors, radiopharmaceuticals, respiratory pharmaceuticals, sedatives, spermicides, steroids (including androgens, anabolic and adrenal cortical), smoking cessation agents, statins, stimulants and tranquilizers, sulphonamides, thyroid drugs, urinary acidifiers/alkalinisers, and vasodilators. 10 The bioactive moiety may include any drug or therapeutically active agent, including pharmacologically active agents (e.g., receptor binding agonist or antagonists, cytotoxic agents) and pharmacologically inactive agents (e.g., antibiotics). Specific examples of bioactive moieties that can be used in the present invention are listed 15 below in categories according to their functional groups that may be used in conjugate formation. This list is in no way limiting the scope of drugs covered in this invention, but given as representative examples. All the amino- (including amide-NH and sulfonamide NH, carbamate-NH, sulfamate-NH, hydrazone-NH, semicarbazone-NH, thiosemicarbazone-NH, urea-NH, phosphoramide-NH and the like), carboxyl- and 20 hydroxyl-(including oxime-OH), containing drugs under various therapeutic categories as listed in Merck Index (13.sup.th editions) and other data bases such as prous science's ensemble, integrity, and the like and also all the qualified (i.e., amino-, and /or hydroxyl-, and/or carboxyl-containing) investigational drugs as listed in databases such Merck Index (14th. edition), iddb, ensemble, integrity, and the like, are covered under this invention 25 without any limitation. ANTI-INFLAMMATORY DRUGS: Amino-containing: Ampiroxicam, Bucolome, Celecoxib, Difenpiramide, Mofebutazone, 30 Nimesulide, Paranyline, Parecoxib, Parsalmide, Piketoprofen, Talniflumate, Tenidap, Terofenamate, and Valdecoxib.
WO 2010/040188 PCT/AU2009/001342 -28 Hydroxyl-containing: 21 -Acetoxypregnenolone, Alclometasone, Betamethasone, alfa Bisabolol, Budesonide, Clobetasone, Cyclosporin, Deflazacort, Dexamethasone, Diflorasone, Desonide, Desoximetasone, Diflorasone, Diflucortolone, Difluprednate, 5 Ditazol, Everolimus, Fluazacort, Fludrocortisone, Flumethasone, Fluocinolone, Fluocinonide, Fluocortin Butyl, Fluocortolone, Fluprednidene Acetate, Glucametacin, Halcinonide, Halobetasol Propionate, Halometasone, Halopredone Acetate, Hydrocortisone, Ibuproxam, Loteprednol Etabonate, Mazipredone, Memetasone, Methylprednisolone, Mometasone Furoate, Oxyphenbutazone, Perisoxal, Pimecrolimus, 10 Prednisolone, Prednisone, Rimexolone, Sirolimus, Triamcinolone and Tacrolimus. Hydroxyl-, and Amino-containing: Bufexamac, Etofenamate, Fepradinol, Ibuproxam, Isoxicam, Lornoxicam, Meloxicam, Oxametacine, Piroxicam, and Tenoxicam. 15 Carboxyl- and Amino-containing: Aceclofenac, Alminoprofen, Amfenac, 3-Amino-4 hydroxybutyric Acid, Carprofen, Diclofenac, Enfenamic Acid, Etodolac, Flufenamic Acid, Meclofenamic Acid, Mefenamic Acid, Niflumic Acid, and Tolfenamic Acid. Carboxyl-containing: Acemetacin, Acetamidocaproic Acid, Bendazac, Benoxaprofen, 20 Bermoprofen, Bucloxic Acid , Butibufen, Cinmetacin, Clidanac, Clopirac, Felbinac, Fenbufen, Fenclozic Acid, Fenoprofen, Fentiazac, Flunoxaprofen, Flurbiprofen, Ibuprofen, Indomethacin, Isofezolac, Isoxepac, Ketoprofen, Lonazolac, Loxoprofen, Metiazinic Acid, Mofezolac, Naproxen, Oxaprozin, Pirazolac, Pirprofen, Pranoprofen, Protizinic Acid, Sulindac, Suprofen, Suxibuzone, Tiaprofenic Acid, Tolmetin, and Tropesin. Bermoprofen, 25 Bucloxic Acid, Isoxepac, Ketoprofen, Loxoprofen, and Zaltoprofen. Carboxyl- and Hydroxyl-containing: Balsalazide, Enoxolone, Fendosal, Olsalazine, Oxaceprol, and Ximoprofen. 30 Amino-, Carboxyl- and Hydroxyl-containing: 3-Amino-4-hydroxybutyric Acid, Mesalamine, and Sulfasalazine.
WO 2010/040188 PCT/AU2009/001342 - 29 ANALGESIC AND/OR ANTIPYRETIC DRUGS: Amino-containing: Aminochlorthenoxazin, Aminopropylon, Anileridine, Antrafenine, 5 Benorylate, Benzpiperylon, p-Bromoacetanilide, Butacetin, Carsalam, Difenamizole, Etersalate, Ethenzamide, Ethoxazene, Flipirtine, Isonixin, Nifenazone, Phenacetin, Phenazopyridine, Phenocoll, Phenopyrazone, Piminodine, Piritramide, Propacetamol, Ramifenazone, Piperylone, Salverine, and Tinoridine. 10 Hydroxyl-containing: Aluminum bis(acetylsalicylate), Benzylmorphine, Buprenorphine, Butorphanol, Chlorobutanol, Ciramadol, Codeine, Desomorphine, Dihydrocodeine, Dihydromorphine, Dihydroxyaluminum acetylsalicylate, Dimepheptanol, Eptazocine, Ethylmorphine, Eugenol, Hydromorphone, Hydroxypethidine, Levorphanol, Meptazinol, Metazocine, Morphine, Nalbuphine, Oxycodone Pentazocine, Phenazocine, Phenoperidine, 15 Phenylsalicylate, Salicin, Tramadol, and Viminol. Hydromorphone, Ketobemidone, Metopon, Oxycodone, and Oxymorphone. Carboxyl-containing: Acetylsalicylsalicylic acid, Alclofenac, Aspirin, Benoxaprofen, 5 Bromosalicylic acid acetate, Cinchophen, Diacerein, Dipyrocetyl, Fosfosal, Ibufenac, 20 Indoprofen, and Salicysulfuric acid. Clometacin, Ketorolac, and Zomepirac. Amino- and Hydroxyl-containing: Acetaminophen, Acetaminosalol, Bucetin, Capsaicine, Dezocine, Floctafenine, Glafenine, Isoladol, p-Lactophenetide, Norlevorphanol, Normorphine, Phenylramidol, Salacetamide, and Salicylamide. 25 Amino- and Carboxyl-containing: Actarit, Bumadizone, Clonixin, and Salicylamide 0 acetic acid. Carboxyl- and Hydroxyl-containing: Diflunisal, Gentisic acid, and Salsalate. 30 ANTIHYPERTENSIVE
DRUGS:
WO 2010/040188 PCT/AU2009/001342 -30 Amino-containing: Alfuzosin, Benzylhydrochlorothiazide, Bethanidine, Bopindolol, Budralazine, Bunazosin, Ciclosidomine, Clonidine, Clopamide, Cyclopenthiazide, Debrisoquin, Edeserpidine, Diazoxide, Dihydralazine, Doxazosin, Endralazine, 5 Guanabenz, Guanacline, Guanazodine, Guanethidine, Guanochlor, Guanadrel, Guanfacine, Guanoxan, Hydracarbazine, Hydralazine, Hydroflumethiazide, Indapamide, Indoramin, Irbesartan, Ketanserin, Lofexidine, Mebutamate, Mecamylamine, Methyl 4-pridyl ketone thiosemicarbazone, Mibefradil, Minoxidil, Monatepil, Moxonidine, Pheniprazine, Pinacidil, Prazosin, Raubasine, Rescinnamine, Reserpiline, Reserpine, Rilmenidine, 10 Syrosingopine, Tasosartan, Terazosin, Tiamenidine, Todralazine, Tolonidine, Tripamide, and Urapidil. Hydroxy-containing: Ajmaline, Cicletanine, Levcromakalim, Naftopidil, Phenactropinium chloride, and Protoveratrines. 15 Carboxyl-containing: Eprosartan, Fosinopril, and Telmisartan, Captopril, and Omapatrilat. Amino- and Carboxyl-containing: Alacepril, gama-Aminobutyric acid, Benazepril, Candesartan, Carmoxirole, Caronapril, Cilazapril, Delapril, Enalapril, Enalaprilat, 20 Imidapril, Lisinopril, Moexipril, Moveltipril, Perindopril, Quinapril, Ramipril, Saralasin, Spirapril, Temocapril, Trandolapril, and Valsartan. Amino- and Hydroxyl-containing: Acebutolol, Alprenolol, Amosulalol, Arotinolol, Atenolol, Betaxolol, Bisoprolol, Bosentan, Bucindolol, Bufeniode, Bunitrolol, Bupranolol, 25 Butofilolol, Cadralazine, Celiprolol, Carazolol, Carteolol, Cetamolol, Carvedilol, Epanolol, Indenolol, Nadolol, Dilevalol, Fenoldopam, Guanoxabenz, Labetalol, Losartan, Mepindolol, Metipranolol, Metoprolol, Moprolol, Nebivolol, Olmesartan, Oxprenolol, Penbutolol, Phentolamine, Pildralazine, Pindolol, Propranolol, Rescimetol, Sulfinalol, Talinolol, Tertatolol, Timolol, and Trimazosin. 30 Amino-, Hydroxyl- and Carboxyl-containing: Methyldopa, and Sampatrilat.
WO 2010/040188 PCT/AU2009/001342 -31 ANTIBIOTICS: All the known amino-, hydroxyl-, and carboxyl-containing antibiotics such as Amoxicillin, 5 Ampicillin, Olivanic acid, Metronidazole, and the like as listed in Merck Index. 13.sup.th edition and other drug databases integrity, ensemble, iddb, and the like. These antibiotics can be used in combination with beta-lactamase inhibitor such as clavulanic acid, penicillinic acid sulfone and the like. The following lists of antibacterial and antifungal agnets are given for clarity. 10 ANTIBACTERIAL AGENTS: Amino-containing: Acedapsone, Acetosulfone sodium, Ambazone, Bacampicillin, Benzylsulfamide, Brodimoprim, Cefcapene pivoxil, Cefpodoxime proxetil, Chloramine-B, 15 Chloramine-T, Capreomycin, Clofazimine, Cyacetacide, Cycloserine, Dapsone, Ethionamide, Furazolium chloride, N2-Formylsutfisomidine, Furonazide, Isoniazid, Lenampicillin, Linezolide, Mafenide, 4'-(Methylsulfamoyl)sulfanilanilide, Morphazinamide, Nifuradene, Nitrofurantoin, Penamecillin, Penethamate hydriodide, Pexiganan, Pivampicillin, Pivcefalexin, Picloxydine, Protionamide, Pyrazinamide, 20 Solasulfone, Subathizone, 4,4'-Sulfinyldianiline, Sulfoxone sodium, 4' Sulfanilylsulfanilamide, Sulfoniazide, Sulfabenzamide, Sulfacetamide, Sulfachlorpyridazine, Sulfacytine, Sulfadiazine, Sulfadicramide, Sulfadimethoxine, Sulfadoxine, Sulfaethidole, Sulfaguanidine, Sulfaguanole, Sulfalene, Sulfamerazine, Sulfameter, Sulfamethazine, Sulfamethizole, Sulfamethomidine, Sulfamethoxazole, 25 Sulfamethoxypyridazine, Sulfamethylthiazole, Sulfametrole, Sulfamidochrysoidine, Sulfamoxole, Sulfanilamide, p-Sulfanilylbenzylanine, Sulfanilylurea, N-Sulfanilyl-3,4 xylamide, Sulfaperine, Sulfaphenazole, Sulfaproxyline, Sulfapyrazine, Sulfasomizole, Sulfasymazine, Sulfathiazole, Sulfathiourea, Sulfisomidine, Sulfisoxazole, Sultamicillin, Sulfatolamide, Talampicillin, Taurolidine, Tetroxoprim, Thiazosulfone, Thiacetazone, 30 Tiocarlide, and Trimethoprim.
WO 2010/040188 PCT/AU2009/001342 -32 Hydroxyl-containing: Azithromycin, Chloroxylenol, Chlorquinadol, Clindamycin, Clofoctol, Cloxyquin, Diathymosulfone, Doxycycline, Glucosulfone sodium, Nifurpirinol, Nifurtoinol, Nitroxoline, Roxarsone, Roxithromycin, Xanthocillin, and Xibornol. Carbomycin, Clarithromycin, Erythromycin, all erythromycin ester derivatives, 5 Oleandomycin, and Telithromycin. Carboxyl-containing (including sulfate, phosphate and phosphonate-containing): Amdinocillin, Cinoxacin, Difloxacin, Fosfomycin, and Hydnocarpic acid. Fleroxacin, Flumequine, Miloxacin, Nalidixic acid, Ofloxacin, Oxolinic acid, Pefloxacin, Piromidic 10 acid, Prulifloxacin, Rosoxacin, and Rufloxacin. Amino- and Carboxyl-containing (including sulfate-, sulfonic acid-, phosphate and phosphonate-containing): Acediasulfone, Amphomycin, Ampicillin, Azidocillin, Azlocillin, Aztreonam, Bacitracin, Balofloxacin, Betamipron, Carbenicillin, Carindacillin, 15 Carumonam, Cefaclor, Cefazedone, Cefazolin, Cefclidin, Cefditoren, Cefepime, Cefetamet, Cefixime, Cefmenoxime, Cefmetazole, Cefodizime, Ceforanide, Cefotaxime, Cefotetan, Cefotiam, Cefoxitin, Cefozopran, Cefpimizole, Cefpirome, Cefroxadine, Cefsulodin, Ceftazidime, Cefteram, Ceftezole, Ceftibuten, Ceftizoxime, Ceftriaxone, Cefuroxime, Cefuzonam, Cephacetrile sodium, Cephalexin, Cephaloglycin, Cephaloridine, 20 Cephalosporin C, Cephalothin, Cephapirin sodium, Cephradine, Cilastatin, Ciproflaxacin, Clinafloxacin, Clometocillin, Cyclacillin, Dicloxacillin, Enoxacin, Epicillin, Fenbenicillin, Floxacillin, Hetacillin, Loracarbef, Metampicillin, Methicillin, Mezlocillin, Nafcillin, Noprysulfamide, Opiniazide, Oxacillin, Penicillin(s), Penimepicycline, Phenethicillin, Phthalylsulfacetamide, Phthalylsulfathiazole, Piperacillin, Propicillin, Quinacillin, 25 Succinylsulfathiazole, Succisulfone, Sulbenicillin, Sulfachrysoidine, Sulfanilic acid, Temocillin, Ticarcillin, and Tigemonam. Garenoxacin, Gatifloxacin, Gemifloxacin, Grepafloxacin, Lomefloxacin, Moxifloxacin, Norfloxacin, Pazufloxacin, Pipemidic acid, Sitafloxacin, Sparfloxacin, Tosufloxacin, and Trovafloxacin. 30 Amino- and Hydroxyl-containing: Amikacin, p-Aminosalicylic acid hydrazide, Arbekacin, Azidamfenicol, Bambermycins, 5-Bromosalicylhydroxamic acid, Butirosin, Clindamycin, WO 2010/040188 PCT/AU2009/001342 -33 Clomocycline, Chloramphenicol, Cloxacillin, Colistin, Demeclocycline, Deoxydihydrostreptomycin, Dibekacin, Dihydrostreptomycin, Dirithromycin, Doxycycline, Enviomycin, Ethambutol, Forimicins, Gentamycin, Glyconiazide, N4-beta D-Glucosylsulfanilamide, Gramicidin(s), Isepamicin, Kanamycin(s), Lincomycin, 5 Meclocycline, Methacycline, Micronomicin, Neomycin, Netilmicin, Novobiocin, Paromomycin, Phenyl aminosalicylate, Pipacycline, Polymyxin, Primycin, Ramoplanin, Ribostamycin, Rifabutin, Rifalazil, Rifamide, Rifamycin SV, Rifampin, Rifapentine, Rifaximin, Ristocetin, Salinazid, Sancycline, Sisomicin, Streptolydigin, Streptomycin, Streptonicozid, 2-p-Sulfanilylanilinoethanol, Thiamphenicol, Thiostrepton, Tobramycin, 10 Tuberactinomycin, Viomycin, and Virginiamycin. Chlortetracycline, Dalfopristin, Guamecycline, Mikamycin, Minocycline, Oxytetracycline, Pristinamycin, Quinupristin, Rolitetracycline, Spectinomycin, and Trospectomycin. Hydroxyl- and Carboxyl-containing (including sulfate, phosphate and phosphonate 15 containing): Fropenem, Nadifloxacin, Biapenem, Fusidic acid, and Merbromin. Amino-, Hydroxyl-, and Carboxyl-containing (including sulfate, phosphate and phosphonate-containing): p-Aminosalicylic acid, Apicycline, Amoxicillin, Apalcillin, Aspoxicillin, Benzoylpas, Cefadroxil, Cefamandole, Cefatrizine, Cefbuperazone, Cefdinir, 20 Cefminox, Cefonicid, Cefoperazone, Cefoselis, Cefpiramide, Cefprozil, Ertapenem, Flomoxef, Imipenem, Lymecycline, Meropenem, Moxalactam, Negamycin, Panipenem, Ritipenem, Salazosulfadimidine, Sulfaloxic acid, 4-Sulfanilamidosalicylic acid, Teicoplanin, Tyrocidine, and Vancomycin. 25 ANTIFUNGAL AGENTS: Amino-containing: Chlordantoin, Exalamide, Flucytosine, Loflucarban. Hydroxy-containing: Chlorphenesin, Ciclopirox, Dermostatin, Filipin, Fluconazole, 30 Fungichromin, Pecilocin, Posaconazole, Ravuconazole, Rubijervine, Siccanin, 2,4,6 Tribromo-m-cresol and Voriconazole.
WO 2010/040188 PCT/AU2009/001342 - 34 Carboxyl-containing: Undecylenic acid (10-undecenoic acid), and Propionic acid. Amino- and Carboxyl-containing: Azaserine. 5 Amino- and Hydroxyl-containing: Salicylanilide, Acrisorcin (9-Aminoacrindine compound with 4-Hexylresorcinol (1:1)), Anidulafungin, Bromosalicylchloranilide, Buclosamide, Caspofungin, Micafungin, and Tubercidin. 10 Amino-, Carboxyl- and Hydroxyl-containing: Natamycin, Amphotericin B, Lucensomycin, and Nystatin. ANTIVIRAL DRUGS: 15 Hydroxy-containing: Edoxudine, Floxuridine, Idoxuridine, Kethoxal, Podophyllotoxin, Sorivudine, Stavudine, Trifluridine, and Zidovudine. Amino-containing: Amantadine, Amidinomycin, Atevirdine, Capravirine, Delavirdine, Efavirenz, Famciclovir, Imiquimod, Lamivudine, Methisazone, Moroxydine, Nevirapine, 20 Oseltamivir, Rimantadine, Stallimycin, mantadine, and Valacyclovir. Amino- and Hydroxyl-containing: Abacavir, Acyclovir, Adefovir, Amprenavir, Atazanavir, Cidofovir, Didanosine, Dideoxyadenosine, Emtricitabine, Entecavir, Indinavir, Lamivudine, Lopinavir, 5 -(methylamino)-2-deoxyuridine (MADU), Nelfinavir, 25 Penciclovir, Resiquimod, Ribavirin, Ritonavir, Saquinavir, Tenofovir, Tipranavir, Valganciclovir, Vidarabine, and Zalcitabine. Carboxyl- and Hydroxyl-containing: Foscarnet sodium, and Ganciclovir. 30 Amino-, Carboxyl- and Hydroxyl-containing: Zanamivir.
WO 2010/040188 PCT/AU2009/001342 - 35 ANTIMALARIAL: Amino-containing: Chlorguanide, Chloroquine, Chlorproguanil, Cycloguanil, Pamaquine, Plasmocid, Primaquine, Quinocide, and Tafenoquine. 5 Hydroxyl-containing: Artemisinin alcohol, Bebeerines, Cinchonidine, Cinchonine, Dihydroartemisinin, Halofantrine, Lumefantrine, Quinine and Yingzhaosu A. Carboxyl-containing: Arteflene and Artesunate. 10 Amino-, and Hydroxyl-containing: Amodiaquin, Hydroxychloroquine, Mefloquine, and Pyronaridine. ANTINEOPLASTIC DRUGS: 15 Hydroxy-containing: Aclacinomycins, Arzoxifene, .Batimastat, Broxuridine, Calusterone, Capecitabine, CC-1065, Chromomycins, Diethylstilbestrol, Docetaxel, Doxifluridine, Droloxifene, Dromostanolone, Enocitabine, Epitiostanol, Estramustine, Etanidazole, Etoposide, Fenretinide, Flavopiridol, Formestane, Fosfestrol, Fulvestrant, Gemcitabine, 20 Irinotecan, Melengestrol, Menogaril, Miltefosine, Mitobronitol, Mitolactol, Mopidamol, Nitracrine, Nogalamycin, Nordihydroguaiaretic Acid, Olivomycins, Paclitaxel and other known paclitaxel analogs, Plicamycin, Podophyllotoxin, Retinoic acid (including all trans retinioc acid), Roquinimex, Rubitecan, Seocalcitol, Temoporfin, Teniposide, Tenuazonic Acid, Topotecan, Valrubicin, Vinblastine, Vincristine, and Zosuquidar. 25 Amino-containing (including Amide-NH and Sulphonamide-NH, Carbamate-NH, Sulfamate-NH, and Phosphomide-NH): 9-Aminocamptothecin, Aminolevulinic Acid, Amsacrine, Bisantrene, Cactinomycin, Carboquone, Carmofur, Carmustine, Cyclophosphamide, Dacarbazine, Dactinomycin, Demecolcine, Diaziquone, 6-Diazo-5 30 oxo-L-norleucine (DON), Edatrexate, Efaproxiral, Eflornithine, Eniluracil, Erlotinib, Fluorouracil, Gefitinib, Gemcitabine, Goserelin, Histamine, Ifosfamide, Imatinib, WO 2010/040188 PCT/AU2009/001342 -36 Improsulfan, Lanreotide, Leuprolide, Liarozole, Lobaplatin, Cisplatin, Carboplatin, Lomustine, Lonafarnib, Mannomustine, Melphalan, Methotrexate, Methyl Aminolevulinate, Miboplatin, Mitoguazone, Mitoxantrone, Nilutamide, Nimustine, Nolatrexed, Oxaliplatin, Pemetrexed, Phenamet, Piritrexim, Procarbazine, Raltitrexed, 5 Tariquidar, Temozolomide, Thiamiprine, Thioguanine, Tipifarnib, Tirapazamine, 3 Aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP)/ 3-Aminopyridine-4-methyl 2-carboxaldehyde thiosemicarbazone (3 -AMP/Triapine /OCX-191/OCX-0191), Trimetrexate, Uracil Mustard, Uredepa ([Bis(1-aziridinyl)phosphinyl]carbamic acid ethyl ester, ethyl carbamate and Meturedepa. 10 Both Hydroxy- & Amino- containing (including Amide-NH and Sulphonamide-NH, Carbamate-NH, Sulfamate-NH, and Phosphomide-NH): Ancitabine, Anthramycin, Azacitidine, Bleomycins, Bropirimine, Buserelin, Carubicin, Chlorozotocin, Cladribine, Cytarabine, Daunorubicin, Decitabine, Defosfamide, Docetaxel, Doxorubicin, 15 Ecteinascidins, Epirubicin, Gemcitabine, Hydroxyurea, Idarubicin, Marimastat, 6 Mercaptopurine, Pentostatin, Peplomycin, Perfosfamide, Pirarubicin, Prinomastat, Puromycin, Ranimustine, Streptonigrin, Streptozocin, Tiazofurin, Troxacitabine, Vindesine and Zorubicin. 20 Carboxyl-containing: Butyric acid. NTIGLAUCOMA AGENTS: Amino- containing: Acetazolamide, Brimonidine and Pilocarpine. 25 Amino- and Hydroxyl-containing: Bimatoprost and Timolol. Hydroxyl-containing: Latanoprost, Bimatoprost and Travoprost. 30 BENZODIAZEPINE TRANQUILIZERS AND HYPNOTICS: WO 2010/040188 PCT/AU2009/001342 - 37 Diazepam, Triazolam, Alprazolam, and the like. ANTIULCER AGENTS: 5 Amino-containing (including Amide NH and Sulphonamide NH and Phosphomide NH, etc.): Aldioxa, Benexate HCl, Cimetidine, Ebrotidine, Ecabapide, Esaprazole, Esomeprazole, Famotidine, Irsogladine, Lafutidine, Lansoprazole, Omeprazole, Pantoprazole, Pirenzepine, Polaprezinc, Rabeprazole, Ranitidine, Roxatidine, and Troxipide. 10 Hydroxyl-containing: Enprostil, Misoprostol, Ornoprostil, Plaunotol, Rioprostil, Trimoprostil, and Oryzanol A. Carboxyl-containing: Acetoxolone, Carbenoxolone, Rebamipide, and Sofalcone. 15 Amino (or Hydroxyl) - and Carboxyl-containing: Cetraxate, Ecabet, S-Methylmethionine, Rosaprostol, and Rotraxate. ANTICONVULSANTS: 20 Amino-containing (including Amide NH and Sulphonamide NH and Phosphomide NH, etc.): Acetylpheneturide, Albutoin, N-benzyl-3-chloropropionamide, Carbamazepine, Cinromide, Clonazepam, Decimemide, Dimethadione, Doxenitoin, Ethosuximide, Ethotoin, Felbamate, Fosphenytoin, Lamotrigine, Levetiracetam, Mephenytoin, 25 Mephobarbital, Metharbital, Methetoin, Nitrazepam, Oxcarbazepine, Oxicarbamazepine, Phenacemide, Phenetharbital, Pheneturide, Phenobarbital, Phenylmethylbarbituric Acid, Phenytoin, Phethenylate Sodium, Primidone, Progabide, Remacemide, Rufinamide, Suclofenide, Sulthiame, Talampanel, Tetrantoin, Topiramate, Valpromide, Zonisamide, 5 Methyl-5-(3-phenanthryl)hydantoin, and 3-Methyl-5-phenylhydantoin. 30 Hydroxyl-containing: Ganaxolone.
WO 2010/040188 PCT/AU2009/001342 -38 Hydroxyl-, and Amino-containing (including Amide NH and Sulphonamide NH and Phosphomide NH): 4-Amino-3 -hydroxybutyric Acid, Atrolactamide, and Buramate. 5 Carboxyl- and Amino-Containing (including Amide NH and Sulphonamide NH and Phosphomide NH): Gabapentin, Pregabalin, and Vigabatrin. Carboxyl-containing: Tiagabine, and Valproic Acid. 10 ANTIPARKINSON Levodopa and Carbidopa. ANTIDEPRESSANT: 15 Amino-containing (including Amide NH and Sulphonamide NH and Phosphomide NH, etc.): Amoxapine, Caroxazone, Demexiptiline, Desipramine, Duloxetine, Fluoxetine, Fluvoxamine, Indalpine, Indeloxazine Hydrochloride, Iproclozide, Iproniazid, Isocarboxazid, Levophacetoperane, Maprotiline, Metapramine, Milnacipran, Minaprine, 20 Moclobemide, Nialamide, Nomifensine, Nortriptyline, Octamoxin, Oxypertine, Paroxetine, Protriptyline, Reboxetine, Rolipram, Sertraline, Tofenacin, Tranylcypromine, Viloxazine, Benmoxine, and Rolicyprine. Hydroxyl-containing: Befloxatone, Bupropion, Fenpentadiol, Hypericin, Opipramol, 25 Pyrisuccideanol, Toloxatone, and Venlafaxine. Hydroxyl-, and Amino-containing (including Amide NH and Sulphonamide NH and Phosphomide NH): S-Adenosylmethionine, 5-Hydroxytryptophan, and Roxindole. 30 Carboxyl- and Amino-Containing (including Amide NH and Sulphonamide NH and Phosphomide NH): Amineptine, and Tianeptine.
WO 2010/040188 PCT/AU2009/001342 - 39 ANTIHISTAMINIC Amino-containing (including Amide NH and Sulphonamide NH and Phosphomide NH, 5 etc.): Antazoline, Astemizole, Clobenzepam, Desloratadine, Epinastine, Metron S, Mizolastine, and Tritoqualine. Hydroxyl-containing: Terfenadine, and N-Hydroxyethylpromethazine Chloride. 10 Hydroxyl-, and Amino-containing (including Amide NH and Sulphonamide NH and Phosphomide NH, etc.): Cetoxime. Carboxyl-containing: Acrivastine, Bepotastine, Cetirizine, and Levocabastine. 15 Carboxyl- and Hydroxyl-containing: Fexofenadine. ANTICANCER, ANTIOXIDATIVE, ANTIINFLAMMATORY, AND CARDIOPROTECTIVE AGENT: 20 Trans-Resveratrol [(E)-3,4',5-trihydroxystilbene). ANTIDIABETIC: Metformin, and Nateglinide/Glipizide/Glibenclamide (Glyburide). 25 LOCAL ANAESTHETICS Amino-containing: Benzocaine, Chloroprocaine, Proparacaine, Tetracaine,Cocaine, Propoxycaine, Procaine, Proparacaine, Tetracaine, Articaine, Bupivacaine, Carticaine, 30 Cinchocaine, Etidocaine, Levobupivacaine, Lignocaine, Mepivacaine, Piperocaine, Prilocaine, Ropivacaine, Trimecaine WO 2010/040188 PCT/AU2009/001342 - 40 It should be understood that while the lists of names of various categories of drugs have been included above, such lists are presented in a way of illustration of the structural features of the qualifying drugs in this invention and therefore, the number and types of 5 listed drugs are not necessarily limited thereto. In principal, any amino-, and /or carboxyl, and/or carbonyl-, and/or hydroxyl-containing drug (from both known and investigational drugs), irrespective of its therapeutic category and their mechanism of action, as listed in drug databases such as Merck Index, prous science's ensemble, integrity, iddb, and the like, are generally covered within the true spirit and scope of the present invention. For 10 clarity, in addition to the above lists of drugs, any amino-, and/or carboxyl-, and/or carbonyl-, and/or hydroxyl-containing drug(s) (both known and investigational drugs) from the following therapeutic areas are covered without any limitation: CENTRAL NERVOUS SYSTEM: 15 Sedatives, Hypnotics, Antidepressants, Antipsychotics and Antimanics, Analgesics & Antipyretics, Antimigraine agents, Anticonvulsants, Drugs used in parkinsonism and movement disorders, Drug for dementia, Antiemtics, drugs for Vertigo, CNS Stimulants & activators. Quetiapine, Paliperidone (active metabolite of risperidone), Fluphenazine 20 EYE: Antiinfective eye preparations, Antiinflammatory and antiallergic preparations, antiglucoma drugs and other preparations to cure eye diseases. 25 EAR, NOSE and OROPHARYNX: Drugs used aural, nasal and oropharyngeal preparation. 30 CARDIOVASCULAR
SYSTEM:
WO 2010/040188 PCT/AU2009/001342 -41 Antiarrhythemi c drugs, Antihypertensives (including alfa/beta-blockers, channel blockers, ACE inhibitors, Angiotensin II receptor antagonists, diuretics, etc.), Antianginals (includinig nitrates, calcium channel blockers, etc.), Drugs for cardiac failure and shock, Vasodilators, Coagulants, Anticoagulants, Thrombolytics and antiplatelet drugs. 5 RESPIRATORY SYSTEM: Respiratory stimulants, Antitussives, Expectorants, Mucolytics and Decongestants, Antihistamine agents, and antiasthmatics. 10 GASTRO INTESTINAL TRACT: Antiulcer and Antisecretory drugs (including H.sub.2 receptor antagonists, Proton Pump linhibitors, Prostaglandin analogues, etc.), Antacids, Antispasmodics and drugs modifying 15 intestinal motility, Antidiarrhoeals (including antimotility and antimicrobial drugs) and drugs acting on gall bladder. GENITO URINARY SYSTEM: 20 Urinary antiinfectives, Diuretics, Urinary analgesics & antispasmodics, Antiinfective drugs acting on urethra and vagina, drugs acting on uterus, Drugs for prostatic hypertrophy (including alfa blockers and antiandrogens), Drugs for erectile dysfunction, and Spermicidal & nonhormonal contraceptives. 25 SKIN: Keratolytics, topical antiinfectives, topical antifungals, topical parasiticidals, topical steroids, topical drugs for acne vulgaris, drugs for psoriasis, pigmentation disorders, and Antiseborrhoeics. 30 MUSCULO-SKELETAL
DISORDERS:
WO 2010/040188 PCT/AU2009/001342 -42 Non Steroidal Anti Inflammatory Drugs (NSAIDs) including COX-2 inhibitors, Antiarthritic agents, Immunosuppressants, Topical analgesics, Muscle relaxants and Neuromuscular Drugs. 5 INFECTIONS AND INFESTATIONS: Penicillin antibiotics, Cephalosporin antibiotics, Quinolone & Fluoroquinolone antibiotics, Macrolide antibiotics, Chloramphenicol, Tetracycline antibiotics, Sulfonamides, 10 Antianaerobics such as Metronidazole, Antitubercular drugs, Antileprosy drugs, Antifungals, Antiprotozoals, Anthelminthics & Antiinfestive Drugs, Antimalarials and Antivirals. ENDOCRINE SYSTEM: 15 Anabolic and androgenic steroids, Corticosteroids, Oestrogens, Progestogens and Hormonal contraceptives, Fertility Agents, Trophic hormones and related drugs, Thyroid and antithyroid drugs, Antidiabetics and hyperglycaemics. 20 METABOLISM: Hypolipidaernic drugs (including fibric acid derivatives, statins [(i.e., HMG CoA reductase inhibitors), nicotinic acid group, etc.], Drugs used for Gout and Drugs affecting bone metabolism (including bisphosphonates). 25 NEOPLASTIC DISORDERS: Anticancer drugs such as alkylating agents, cytotoxic antibiotics, antimetabolites such as cytarbine, Fludarbine, 5-Fluorouracil, Mercaptopurine, Thioguanine, etc., Vinca alkaloids 30 and Etoposide, Taxanes, Topoisomerase 1 inhibitors, Cytotoxic immunosuppressants, Immunostmulants, Cytoprotectives such as Amifostine, Oestrogens, Progestogens, hormon WO 2010/040188 PCT/AU2009/001342 - 43 antagonists and other antineoplastic drugs. ALLERGY AND IMMUNOLOGY: 5 Antiallurgics such as non-sedative antihistamins (e.g., Cetirizine, Desloratadine, Terfenadine, Fexofenadine, etc,), sedative histamines and histamine receptor blockers. ANAESTHETICS & SURGICALS: 10 Local anaesthetics, intravenous anaesthetics, inhalation anaesthetics and muscle relaxants. In addition to the above list of drugs, the present invention also covers newer drugs with the above mentioned active functional groups as listed in the Merck index (14.th edition) and other drug databases such as Prous Science's ensemble, integrity and the 15 investigational drugs as listed in databases such as iddb, ensemble, integrity, and the like without any limitation. Preferred bioactive agents include the flouroquinolone antibiotics, local anesthetics and valproic acid. Preferred flouroquinolone antibiotics include; alatrofloxacin, balofloxacin, 20 ciprofloxacin, clinafloxacin, danofoxacin, delafloxacin, dextrofloxacin, difloxacin, enoxacin, enrofloxacin, garenoxacin, gatifloxacin, gemifloxacin, grepafloxacin, levofloxacin, lomefloxacin, marbofloxacin, moxifloxacin, nadifloxacin, norfloxacin, ofloxacin, orbifloxacin, pefloxacin, sitafloxacin, sparfloxacin, temafloxacin, tosufloxacin, tosulfloxacin and trovafloxacin. Still further preferred are: danafloxacin, detrofloxacin, 25 difloxacin, enrofloxacin, marbofloxacin, levofloxacin, ofloxacin, pefloxacin. Still further preferred is levofloxacin and dextrofloxacin. Most preferred is levofloxacin and dextrofloxacin. The preferred local anaesthetics are benzocaine and procaine, most preferred is benzocaine.
WO 2010/040188 PCT/AU2009/001342 -44 Preferred bioactive moieties that can be utilised in the present invention are those containing one or more functional groups such as carboxylate, hydroxyl, amino, thiol, phosphate or sulphate. Examples of preferred bioactive moieties that can be utilised in the present invention are 5 levofloxacin and valproic acid. In accordance with the invention the bioactive moieties are capable of being released at a rate equal to or faster than the rate of biodegradation of the polymer backbone. By providing the biodegradable polymer with such properties, structural integrity of the polymer backbone (and hence the physical form (e.g. shape and size etc) in which the 10 polymer is provided) can be maintained while the drug is being released. By the bioactive moieties being "released at a rate equal to or faster than the rate of biodegradation of the polymer backbone" is meant that the biodegradable polymer is constructed such that under given physiological conditions or in a given biological environment the measurable concentration of the released bioactive moiety in its 15 biologically active form is equal to or greater than the measurable concentration of the corresponding monomer-bioactive moiety conjugate from which the polymer is derived (e.g. formula (II)). Such concentration measurement may be readily conducted by those skilled in the art, for example by using HPLC or GC analytical techniques. In one embodiment, the bioactive moieties are capable of being released at a rate faster 20 than the rate of biodegradation of the polymer backbone, In that case, the biodegradable polymer is constructed such that under given physiological conditions or in a given biological environment the measurable concentration of the released bioactive moiety in its biologically active form is greater than the measurable concentration of the corresponding monomer-bioactive moiety conjugate from which the polymer is derived (e.g. formula 25 (11)). In one a further embodiment, the measurable concentration of the released bioactive moiety in its biologically active form is at least 5%, at least 10%, at least 20%, at least 40%, at least 50 %, at 1 x, at least 2 x at least 5 x greater than the measurable concentration WO 2010/040188 PCT/AU2009/001342 -45 of the corresponding monomer-bioactive agent conjugate from which the polymer is derived (e.g. formula (II)). In connection with providing the biodegradable polymers with an appropriate structure to promote a desired rate of release of the bioactive moiety, those skilled in the art will 5 appreciate, for example, that hydrolysis of an ester moiety will typically occur more readily than that of an amide or carbamate moiety. Thus to promote a rate of release of the bioactive moiety from the polymer backbone that is, for example, faster than the rate of biodegradation of the polymer backbone, one might construct the conjugate such that the polymer backbone comprises only amide and/or carbamate biodegradable moieties and the 10 bioactive moiety is covalently coupled to the backbone via an ester moiety. Those skilled in the art will also appreciate that factors such as steric crowing and electronic effects around a given biodegradable moiety can alter its propensity to undergo hydrolytic cleavage. Both the polymer backbone and the pendant bioactive moiety can be a source of such effects. For example, a biodegradable moiety having a non hydrogen 15 substituent (e.g. alkyl, aryl, alkylaryl, carbocyclyl) located a and/or P to it will typically be less susceptible to hydrolytic cleavage relative to the same moiety having hydrogen substituents located a and/or P to it. Accordingly, steric crowing around a given biodegradable moiety can be used to influence the rate of release of the bioactive moiety and/or the rate bio of the polymer backbone. 20 The skilled artisan would be capable of selecting the appropriate spacer based on an evaluation of steric constraints, phase chemistry and surface chemistry. For example, larger bioactive moieties can be advantageously spaced from the monomer by the choice of a longer spacer. The skilled artisan would also be capable of selecting the appropriate linkage chemistry in 25 the synthesis of the biodegradable polymer so that the rate of bioactive moiety release was equal to or faster than the rate of polymer degradation. Generally, the rate of hydrolytic cleavage will be in the order: anhydride moiety, ester moiety (including carboxylic acid esters, sulphate esters and phosphate esters)> carbamate WO 2010/040188 PCT/AU2009/001342 - 46 > amide. By tailoring at least the rate at which the bioactive moety is released from the polymer backbone, the polymer - bioactive moiety conjugates of the invention can advantageously function as a sustained bioactive moiety delivery system. 5 At the very least the bioactive moiety must be releasable from the polymer conjugate per se. However, the polymer may also biodegrade in vivo or in vitro to a degree such that the polymer backbone fragments, with the moiety remaining tethered to such a fragment(s). In that case, the moiety will nevertheless still be capable of being released or cleaved from the fragment. Having said this, the bioactive moieties must still be released at a rate equal 10 to or faster than the rate of biodegradation of the polymer backbone as herein defined. In one embodiment, the bioactive moiety is releasable where the polymer backbone undergoes substantially no biodegradation during the release time frame. A consequence of having a higher rate of bioactive moiety release is that it avoids the situation of statistical hydrolysis of a long chain polymer (e.g., polyanhydride) wherein 15 there is the possibility to produce oligomers of the bioactive moieties in fragments that may consequently be eluted from the body as the oligomer before it can be released as the active component. As used herein, the term "constituent monomer" refers to the residue of that monomer as it appears in the polymer backbone. 20 The biodegradable polymers of the present invention may have a structure as represented in Scheme I below. The bioactive moiety, will be attached to the polymer via a labile linkage that allows release of the bioactive moiety after administration. Furthermore, the polymer backbone will also include biodegradable moieties that allow degradation of the polymer after administration. 25 The biodegradable polymer -will be designed such that release of the bioactive moiety occurs at a rate that is faster than or equal to the rate of degradation of the polymer.
WO 2010/040188 PCT/AU2009/001342 -47 Thus, with reference to Figure 6 the rate of breakdown of the linkages L2 is faster than or equal to, preferably faster than, the rate of breakdown of the linkages Li. The labile linkage Li may be characterised by a covalent bond between the bioactive moiety and the polymer backbone. Alternatively, the labile linkage may be characterised by the presence 5 of a spacer moiety between the bioactive moiety arid the polymer backbone. The linkage within the polymer backbone L2 may be- characterised by the presence of a covalent bond between backbone fragments containing one or more monomers and/or by a spacer moiety between backbone fragments containing two or more monomers. Polymer backbones containing side chains may be further characterised by labile linkages within 10 the side chains. It will be appreciated that such labile linkages are those through which the bioactive moiety is released and the polymer backbone biodegrades. The labile linkages or linkers may therefore also be referred to as biodegradable moieties. Providing the bioactive moiety with a different rate of release relative to the rate of 15 biodegradation of the polymer backbone allows for the release of substantially all the' bioactive moiety prior to the onset of significant polymer backbone degradation. The biodegradable polymers of the present invention can accommodate high bioactive moiety loadings, minimising the amount of material required to deliver a dose of bioactive moiety. Bioactive moiety loadings of at least f0% by weight, preferably at least 20% by 20 weight, more preferably. at least 30% by weight relative to the total weight of the biodegradable polymer may be achieved. The bioactive moiety loading may also be expressed in terms of its mol% relative to the total number of moles of monomer that form the polymer. Generally, the polymer bioactive moiety conjugate will comprise at least 10, at least 25 , at least 35, at least 45 or 25 up to 50 mol% of bioactive moiety, relative to the total number of moles of monomer that form the polymer.
WO 2010/040188 PCT/AU2009/001342 -48 In some embodiments, the polymer - bioactive moiety conjugate will comprise up to 60, up to 70 , up to 80, up to 90 and even up to 100 mol% of conjugated bioactive moiety, relative to the total number of moles of monomer that form the polymer. However, in that case, it will be appreciated that the amount of conjugated bioactive moiety greater than 50 mol% 5 will necessarily be derived from moieties other than-the -X-R(ZD)-Y- type moieties shown in general formula (I). For example, the other monomers which a polymerised with the monomer - bioactive moiety conjugate of the invention (formula (II)) may also comprise conjugated bioactive moiety. The biodegradable polymer may contain more- than one type of bioactive moiety as 10 illustrated in Figure 7. The biodegradable polymer may contain more than one type of linker or biodegradable moieties as illustrated in Figure 8. As discussed above, varying the lability of linker moieties provides control over the release profile of the bioactive moieties.. More than one type of linker -moiety can be used 15 combined with more than one type of bioactive moiety so as to provide a method of sequential controlled release of multiple bioactive moieties. In the context of multiple bioactive moieties, the biodegradable polymers of the present invention offer the advantage of being able to control a) the relative proportions of the bioactive moieties, b) their relative positions as attached to the polymer backbone and c) 20 their degree of dispersability (e.g. they may be linked to only certain segments in the polymer). The rate of breakdown of the labile linkages L2 may be influenced by external stimuli so as to externally modulate the release of the bioactive moiety. The biodegradable polymer can be homogeneous or heterogeneous with respect to the 25 bioactive moiety(ies) used. Preferably the biodegradable polymer is designed such that the bioactive moieties are released unencumbered by excess molecular fragments. In other words, the bioactive nrflr~rna. .rr ~* **r n.I aAA WO 2010/040188 PCT/AU2009/001342 -49 THIS PAGE IS LEFT INTENTIONALLY BLANK WO 2010/040188 PCT/AU2009/001342 - 50 mioeties are relased such that they do not comprise a residue derived from the polymer backbone or spacer moiety. By this it is meant that the bioactive moieties are released in their substantially original form (i.e. before being conjugated) and are essentially free from, for example, fragments of oligomer or polymer derived from the polymer backbone. 5 This is highly desirable in avoiding situations in which a loss of bioactive moiety efficiency occurs through loss of pharmacological effect through poor transport of, for example, sterically demanding bioactive/oligomer moieties through physiological barriers may occur, resulting in elution of the active bioactive moiety away from the target site. The biodegradable polymers of the present invention employ polymer backbones (as 10 illustrated by A and B in formula (I)) which is preferably selected from or comprises polyurethane optionally comprising one or more chain extenders (e.g. polyester), polyanhydride, polycarbonate, polyurea, polyamide, polyimide and polyester (eg PLGA (poly(lactic-co-glycolic acid)), PLA (polylactic acid), PGA (polyglycolic acid), PHB (polyhydroxybutyrate), PCL (polycaprolactone); and copolymers thereof. More preferably 15 the polymer backbones are selected from or comprise: polyurethanes, polyesters, polyamides and copolymers thereof. Provided that the polymer backbone is biodegradable, it may also include chain extenders, star compounds and dendrimers to introduce branching and spacing between segments within the polymer. The polymer backbone may be linear, substantially linear, branched, 20 hyperbranched, stars, a block polymer or co-polymer. Co-polymers may be advantageous in allowing incorporation of more that one bioactive moiety with known relative positions in the final polymer. It may also be desirable for the biodegradable polymers to be substantially amorphous and thus contain a low amount of crystalline segments. Such polymers can provide a more 25 predictable rate of bioactive moiety release as well as assisting with the production of materials that are more flexible which can assist with producing coatings as well as assisting with the rate of polymer degradation. Additional variables such as the choice of co-monomers and the means to produce the polymers can also assist with the production of highly amorphous and/or flexible WO 2010/040188 PCT/AU2009/001342 -51 polymers. For example, using monomers such as caprolactone or polyester polyols such as polycaprolactone diol can decrease the crystallinity and increase the flexibility of the resulting polymer. For the polyurethanes it may be important to limit the content of hard segment (use 5 conventional definition of hard segment - chain extenders + diisocyanates). One example of a typical class of chain extender are low lolecular weight diols. Examples of such chain extenders include ethylene glycol, propane diol, propylene glycol, butane diol etc. Apart from the potential toxicity of such chain extenders, limiting the hard segments in the polyurethanes also provides a reason to reduce the low molecular weight diol content as 10 described above. The polymer backbone of the biodegradable polymers of the present invention have a molecular weight of about 250 Daltons to about 2MM Daltons, preferably from 500 Daltons to 500,000 Daltons. In one embodiment, the biodegradable polymer in accordance with the invention 15 comprises as part of its polymer backbone a plurality of moieties of general formula (I): A-X-R-Y-B D (1) A and B, which may be the same or different, represent the remainder of the biodegradable polymer backbone. As per the discussion above in respect of the polymer backbone , A and B may be selected from or comprises polyurethane optionally comprising one or more 20 chain extenders (e.g. polyester), polyanhydride, polycarbonate, polyurea, polyamide, polyimide and polyester (eg PLGA (poly(lactic-co-glycolic acid)), PLA (polylactic acid), PGA (polyglycolic acid), PHB (polyhydroxybutyrate), PCL (polycaprolactone); and copolymers thereof. I n some embodiments, A and B are selected from or comprise: polyanhydrides; polyurethanes; polyesters; polyamides and copolymers thereof. A and/or 25 B will also comprise one or more bioactive moieties covalently coupled to the polymer backbone. Depending upon the intended application, A and B may be selected for their biocompatible WO 2010/040188 PCT/AU2009/001342 - 52 and/or their biodegradable properties. Those skilled in the art can readily select polymers to provide for such properties. As used herein, "biocompatible polymer" refers to a polymer that both in its intact, that is, 5 as synthesized, state and in its decomposed state (i.e. its degradation products), is compatible with living tissue in that it is not, or at least is minimally, toxic to living tissue; does not, or at least minimally and reparably does, injure living tissue; and/or does not, or at least minimally and/or controllably does, cause an immunological reaction in living tissue. 10 The moiety "R" present in formulae (I) and (II) represent a linear or branched optionally substituted hydrocarbon. In some embodiments the hydrocarbon may comprise between 1 and 12 carbon atoms, for example between 1 and 6 carbon atoms or 2 or 3 carbon atoms. The hydrocarbon may be partially or completely saturated or unsaturated (including 15 moieties that are aromatic). Specific examples of R include a moiety having one of the following structures: OH OH OH or 0 H A bioactive moiety can be conjugated to all monomers that form the biodegradable 20 polymer, or only to monomers of a particular character (e.g., polyalcohols) or proportions of monomers. Monomers conjugated with one bioactive moiety may be polymerised with monomers conjugated with another different bioactive moiety. 25 In one embodiment, a monomer - bioactive moiety conjugate that may be used in preparing the biodegradable polymers has general formula (II): WO 2010/040188 PCT/AU2009/001342 - 53 X'-R-Y' where, X', Y', R, Z and D are as herein defined. In some embodiments, the monomer - bioactive moiety conjugate may have a more 5 specific structure of formula (III), (IV), (V) or (Va): X' Y' X ,' Y X , Y ' X ,0V'O D Y (Va) D D 0 () (11) (IV) (V) or D where D, X' and Y' are as herein defined, and p is between 1 and 18. Monomers that are polymerised with the monomer - bioactive moiety conjugate to form 10 the biodegradable polymers of the invention will not only comprise compatible chemical functionality to react with the monomer - bioactive moiety conjugate but that reaction will of course give rise to a biodegradable moiety. The expression "compatible chemical functionality" refers to chemical functionality that is 15 capable of undergoing reaction with the monomer - bioactive moiety conjugate to form the polymer. For example, the monomers of formula (II) comprise at least two terminal reactive functional groups X' and Y'. These functional groups will react with compatible functional groups of one or more monomers to form the polymer and give rise to a biodegradable moiety. Thus, where both X' and Y' are hydroxyl groups, those skilled in 20 the art will appreciate that they will react with a variety of functional groups such as: isocyanate functionality to form carbamate or urethane linkages; carboxylic acid functionality to produce ester linkages; carboxylic acid halide functionality to produce ester linkages; ester functionality to produce trans-esterified ester linkages; and anhydride functionality (including cyclic anhydride groups) to produce ester linkages. The 25 expression "compatible chemical functionality" therefore refers to functionality or groups such as isocyanate, carboxylic acid, carboxylic acid halide, ester and anhydride (including WO 2010/040188 PCT/AU2009/001342 - 54 cyclic anhydride groups) groups. Accordingly, where both X' and Y' are hydroxyl groups, the expression "at least one other monomer comprising compatible chemical functionality" used herein typically refers to 5 monomers comprising one or more compatible chemical functional groups selected from isocyanate, carboxylic acid, carboxylic acid halide, ester, anhydride (including cyclic anhydride groups) groups and combinations thereof. Examples of such monomers are polyisocyanates and polyacids. Typically the monomers will be a diisocyanate or a diacid. 10 In some embodiments the at least one other monomer may contain one group of compatible chemical functionality (as defined herein) in addition to one group such as an amino, thio or hydroxy group which is not, of itself, compatible for undergoing polymerisation with a monomer of formula (II) where both X' and Y' are hydroxyl groups. Examples of such monomers are hydroxy-acids and amino acids. In the case of a hydroxy 15 acid, the carboxylic acid is capable of reacting with a hydroxy group of the monomer of formula (II) to produce a hydroxy-terminated compound. Likewise in the case of an amino acid, the carboxylic acid is capable of reacting with the monomer of formula (II) where both X' and Y' are hydroxyl groups to produce an amino 20 terminated compound. Likewise in the case of a thio acid, the carboxylic acid is capable of reacting with the monomer of formula (II) where both X' and Y' are hydroxyl groups to produce a thio-terminated compound. These hydoxy/amino/thio terminated compounds may subsequently undergo reaction with another monomer bearing a carboxylic acid, isocyanate group, etc. so that the polymer backbone may comprise one or more ester, 25 amide, thioester, urea, urethane, thiocarbamate functional groups. For example, polymerisation of formula (II) where both X' and Y' are hydroxyl groups with a diisocyanate produces a polyurethane. Such a polyurethane will typically comprise 50 mol% diol residue and 50 mol% diisocyanate residue. Where each diol monomer of 30 formula (II) comprises one bioactive moiety, the "loading" of the bioactive moiety in the polymer - bioactive moiety conjugate may be designated as 50%.
WO 2010/040188 PCT/AU2009/001342 - 55 The polymerisation formula (II) where both X' and Y' are hydroxyl groups with a diacid produces a polyester. Such a polyester will typically comprise 50 mol% diol residue and 50 mol% diacid residue. Where each diol monomer of formula (II) comprises one 5 bioactive moiety, the "loading" of the bioactive moiety in the polymer - bioactive moiety conjugate is designated herein as 50 mol %, relative to the monomers that form the polymer. Those skilled in the art will also recognise that polymerisation of formula (II) where both 10 X' and Y' are hydroxyl groups with a polyisocyanate, polyacid or polyester may also take place in the presence of one or more other types of polyols (e.g. polyester polyols). The structures of these one or more other types of polyols may or may not comprise one or more bioactive moieties. An example of this second type of polyol is 1,6-hexanediol. The polymer - bioactive moiety conjugate so-formed may or may not have a bioactive moeity 15 loading of less than 50 mol%. For example when formula (II) (where both X' and Y' are hydroxyl groups) is polymerised in the presence of an equimolar amount of 1,6-hexanediol and 2 molar equivalents of diisocyanate, the polyurethane so-formed will typically comprise the residues of the three components in the ratio of 1:1:2. Such conjugates are contemplated by the present invention. Such polymer systems may provide a useful means 20 of modifying the physical properties of the polymer conjugates. Similar comments also apply where X' and/or Y' represent different functional groups (i.e. other than both being hydroxyl groups). For example, X' and Y' may each be independently selected from hydroxyl, amine, carboxylic acid, isocyanate, and carboxylic acid halide. 25 Those skilled in the art will be able to selected both X' and Y' for reaction with one more monomers having compatible chemical functionality to afford the biodegradable polymers according to the invention. Where X' is a compatible chemical functionality with Y' (e.g. hydroxyl and carboxylic acid), those skilled in the art will also appreciate that the monomer - bioactive moiety conjugate may be polymerised with itself (e.g. where the 30 monomer - bioactive moiety conjugate is a hydroxy - acid).
WO 2010/040188 PCT/AU2009/001342 - 56 In one aspect, the invention provides a method for preparing a biodegradable polymer according to the invention, said method comprising the step of polymerising a monomer bioactive moiety conjugate of formula (II): X'-R-Y' o (II) 5 where: X', Y', R, Z and D are as herein defined; with at least one monomer comprising compatible chemical functionality. In a further aspect, the invention provides a method for preparing the biodegradable polymer according to the invention by providing at least one first monomer comprising at least one releasable bioactive moiety and at least one polymerisable moiety; optionally 10 providing at least one second monomer comprising at least one polymerisable moiety reactive with at least one polymerisable moiety of said first monomer; polymerising said first monomer and optionally said second monomer optionally in the presence of one or more spacer moieties comprising two or more functionalities under conditions which are substantially non-interfering to the therapeutic efficacy of the bioactive moieties. 15 Techniques, equipment and reagents well known in the art can advantageously be used to prepare the polymer - bioactive moiety conjugates in accordance with the invention. For example, polyurethanes might be prepared batch wise by mixing all components 20 together and waiting until an exotherm occurs followed by casting the mixture into a container. The mixture can be subsequently heated to drive the reaction. When adopting this approach, the components to be mixed might first be made up into two parts before mixing: Part-1 might include a compound of general formula (II) where both X' and Y' are hydroxyl groups and one or more of: a polyol (e.g. polyester polyol), a chain extender, 25 blowing agent (e.g water), catalyst, and surfactants etc. Part-2 will generally comprise the polyisocyanate. Part-1 or Part-2 can also contain other additives such as fillers, pigments etc.
WO 2010/040188 PCT/AU2009/001342 - 57 The polyurethanes might also be prepared as a prepolymer that is subsequently reacted with a chain extender. For example, through suitable adjustment of molar ratios, an isocyanate terminated pre-polymer may be prepared by mixing Parts -1 and -2 mentioned above. The isocyanate terminated polymer could then be reacted with a chain extender/ 5 branching molecule such as a short chain diol (e.g. 1,4-butanediol) or polyol (such as a triol). Alternatively, through suitable adjustment of molar ratios, the prepolymer could be produced such that it was hydroxy terminated. This hydroxy terminated prepolymer could then be reacted with a polyisocyanate to produce the desired polyurethane. 10 The polyurethane forming reactions can be carried out in a range of different equipment including batch kettles, static mixers, reactive injection moulders or extruders. It also may be advantageous to heat the reagents prior to or during the reaction process to improve their solubility or to enhance their reactivity. The reaction process may also be 15 conducted in solvent. Suitable polyisocyanates that may be used to prepare the polymer - bioactive moiety conjugates include aliphatic, aromatic and cycloaliphatic polyisocyanates and combinations thereof. Specific polyisocyanates include, but are not limited to, 20 diisocyanates such as m-phenylene diisocyanate, p-phenylene diisocyanate, 2,4-toluene diisocyanate, 2,6-toluene diisocyanate, 1,6-hexamethylene diisocyanate, 1,4 hexamethylene diisocyanate, I,3-cyclohexane diisocyanate, 1,4-cyclohexane diisocyanate, hexahydro-toluene diisocyanate and its isomers, isophorone diisocyanate, dicyclo hexylmethane diisocyanates, 1,5-napthylene diisocyanate, 4,4'-diphenylmethane 25 diisocyanate, 2,4' diphenylmethane diisocyanate, 4,4'-biphenylene diisocyanate, 3,3' dimethoxy-4,4'-biphenylene diisocyanate, and 3,3'-dimethyl-diphenylpropane-4,4' diisocyanate; triisocyanates such as 2,4,6-toluene triisocyanate; higher -isocyanates such as 4,4'-dimethyl-diphenylmethane-2,2',5,5'-tetraisocyanate, polymethylene polyphenyl polyisocyanates and alkyl esters of lysine diisocyanate (for example ethyl ester of lysine 30 diisocyanate - ELDI); and combinations thereof. It will be appreciated that the use of polyisocyanates comprising greater than two isocyanate moieties provides for branched WO 2010/040188 PCT/AU2009/001342 - 58 structures. Polyesters might be prepared batch wise by mixing all components together with heating and continued stirring. A condensate of the reaction such as water or low molecular 5 weight alcohol (depending if acids or esters are used as the co-monomer) can be removed by distillation. To promote further reaction produce higher molecular weight polyester the temperature may be increased and vacuum applied. A polycondensation catalyst well known to those skilled in the art can be included in the 10 reaction mixture to increase the rate of polymerisation. The reaction may also be conducted in an appropriate solvent to help increase the rate of polymerisation. The solvent will generally be selected to have only minimal solubility with the condensate (e.g. water or low molecular weight alcohol). For example the 15 reaction may be carried out in toluene and a toluene / condensate mixture distilled off continuously and the condensate allowed to separate in a Dean - Stark trap. To further increase the molecular weight of the polyester a second stage reaction in either a wiped film reactor or a solid state reactor may be employed. The need to use such reactors 20 will depend upon the target molecular weight as well as the suitability of the polymer for further reaction. Suitable polyacids that may be used to prepare the polymer - bioactive moiety conjugates include aliphatic, aromatic and cycloaliphatic polyacids and combinations thereof. 25 Specific polyacids include, but are not limited to the following, oxalic acid, fumaric acid, maleic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, phthalic acid, dodecanediacid, isophthalic acid, terephthalic acid, dodecylsuccinic acid, napthalene-2,6-dicarboxylic acid, naphthalene-2,7-dicarboxylic acid, cyclohexane dicarboxylic acid, fumaric acid, itaconic acid, malonic acid, mesaconic acid. 30 Esters, diesters and anhydrides of the above diacids are also suitable in the process of the invention.
WO 2010/040188 PCT/AU2009/001342 - 59 Where the polyesters are prepared using a carboxylic acid halide monomer, those skilled in the art will appreciate that the condensation reaction is driven by the removal of HX (where X is a halide). For example, if a di-acid chloride co-monomer is with the monomer 5 - bioactive moiety conjugate of formula (II) where both X' and Y" are hydroxyl groups, HCl will be liberated from the reaction. Such a reaction may be carried out in solution at an elevated temperature to drive the reaction. It is also possible to add an appropriate base to form a salt with the liberated acid halide. For example an excess of triethyl amine may be included in a reaction mixture containing a 1: 1 molar ratio of a di-acid chloride co 10 monomer and the monomer - bioactive moiety conjugate of formula (II) where both X' and Y" are hydroxyl groups. The reaction will afford the desired polymer - bioactive moiety conjugate and a triethyl-amine hydrochloride salt. With all such polycondensation reactions, it is possible to some extent to control the 15 molecular weight of the resulting polyester, its degree of branching (through control of monomer functionality) and its end group functionality by adjustment of the molar ratio's and the functionality of the monomers used in the reaction. For example, in some instances it may be desirable to produce lower molecular weight 20 polyesters that could be used as polymer - bioactive moiety conjugate polyester polyols for reaction with polyisocyanates and perhaps other reagents for the production of polyester urethanes. Additionally, it may be possible to increase the molecular weight and/or degree of 25 branching of the polyester through the inclusion in the reaction mixture of coupling/branching agents. Examples of such coupling/branching agents include: polyepoxides, polyisocyanates, polyoxazolines. The term "poly" is used to indicate a reactive functionality of 2 or more (e.g. 2 or more epoxy groups). Having a reactive functionality of 2 will tend to produce higher molecular polymers still with a significant 30 polyester-like character. Agents having a functionality of more than 2 will produce a branched polymer, still with significant polyester-like character.
WO 2010/040188 PCT/AU2009/001342 -60 As discussed in more detail in the Example section below, the synthesis monomer bioactive moiety conjugates typically required the optimization of reaction conditions and the alteration of known purification methodologies. The desired hydrolytic instability of 5 the monomer bioactive moiety conjugates restricted the usage of several traditional purification methodologies and made the development of alternative pathways necessary. The presence of any impurities in the monomer bioactive moiety conjugates can also affect the molecular weight, and structure of the final polymer as well as the release rate of the 10 bioactive moiety from the polymer conjugate. Further, the use of the monomer bioactive moiety conjugates in the formation of the polymers in some cases required specific polymerisation methodology to be developed to allow the efficient incorporation of the monomer bioactive moiety conjugates into the 15 polymer. This included selection of appropriate solvents / heating / mixing/ catalyst / order of monomer additions etc to allow the incorporation of the monomer bioactive moiety conjugates as well as to minimise the amount of degradation or premature release of the bioactive moiety. 20 Careful selection of co-monomers / reaction conditions etc may also be required for a given monomer bioactive moiety conjugate in order to produce a polymer conjugate with appropriate bioactive moiety loading as well as have mechanical properties, bioactive moiety release rate, formability etc. 25 Additionally, methods were developed to remove impurities from the polymer bioactive moiety conjugates in order provide control of the release rate of the bioactive moiety from the polymer conjugate. Irrespective of the manner in which the biodegradable polymer - bioactive moiety 30 conjugates are prepared, as discussed above all repeat units that make up the polymer backbone will be coupled via a biodegradable moiety. Accordingly, any monomer or WO 2010/040188 PCT/AU2009/001342 - 61 macoromer used in the preparation of the conjugates shall not contain repeat units that are coupled by a non-biodegradable moiety such as an ether. While the use of polyether segments can provide desirable improvements in the flexibility 5 and in some cases can provide an improvement in the desired rate of release of the bioactive the, release of p'olyethers having a moleculr weight below 1000 g/mol can result in increased toxicity from the degradation products. In most cases it is possible to use polyester polyols such as polycaprolactone diol to also 10 provide desired increase in the -flexibility of the polymer as well as providing improvements in the release of the bioactive agent. However, the polyester polyols can adavatgeously degrade into more benign monomeric components. Additioanlly the use of polyester polyols such as DLLA (DI lactide) or PLGA 15 (poly(lactic-co-glycolic acid))can provide an increase rate of degradation of the polymer as well as release of the drug through the autocatalytic effect of the- released acidic components. The biodegradable polymer may be fonned and delivered as a liquid/wax that can be injected, polymerised, cured, set or solidified in situ. 20 In one embodiment, the methods of the invention allow the formation of biodegradable moieties with multiple bioactive moieties, known loadings, evenly distributed bioactive moieties in the polymer chain, predetermined relative proportions and predetermined relative positions. Scheme 1 illustrates the method with a valproic acid-polyurethane conjugate. 25 nrn~~rn . . * fA *l A .. * WO 2010/040188 PCT/AU2009/001342 -62-. VA OCN-R'-NCO O VA O Substituted Dlisocyanate Monomer -- O--R"---C-NH--R'--NH-C-- VA Final Polymer HO-R"-OH VA: Valporic Acid (Drug) R', R': Organic groups VA (same or different) Substituted Chain Extender or polyol Scheme 1: Valporic acid-polyurethane conjugate 5 Scheme 2 illustrates the method with a ciprofloxacin-polyurethane conjugate. OCN-R'--NCO O- R"- 0 NH-R'-NH- C-- + Cipro HO-R"- OH ~ Cipro .Cipro: Ciprofloxacin R', R": organic groups (same or different) Scheme 2: Ciprofloxacin-polyurethane conjugate 10 Schemes 3 and 4 illustrate the method with a cyprofloxacin-polyester conjugate and a valproic acid-polyester conjugate respectively.
WO 2010/040188 PCT/AU2009/001342 - 63 0 0 HOOC --- R'---COOH I --- O--R"- O -C---R'-C-- + JI Cipro HO-R"- OH Cipro: Ciprofloxacin Cipro R', R": organic groups (same or different) 5 Scheme 3: Ciprofloxacin-polyester conjugate 0 O0 HOOC R'-COOH - -- C + VA HO-R"- OH VA: Valporic acid R', R": organic groups VA (same or different) 10 Scheme 4: Valporic acid-polyester conjugate The composition of the polymer can be advantageously altered to incorporate other monomers to provide appropriate polymer properties to suit a particular application (e.g. hydrophobicity, structural strength, rate of release of bioactive moieties). A further advantage is that side chain and end functional attachment of the bioactive 15 moiety to the polymer (by control- of the monomer structure) allows the control of the. polymer mechanical and other properties. -In this sense the polymer therapeutic can be viewed and used as a scaffold.
WO 2010/040188 PCT/AU2009/001342 - 64 In a further aspect the control of the mechanical properties in that the bioactive moiety attached to the polymer may have different mechanical / surface properties in the bioactive moiety attached state compared to when the bioactive moiety is not attached, i.e,, (i) as the bioactive moiety is released the polymer may alter in properties and (ii) forming a polymer 5 from monomers functionalised with bioactive moieties may have different (more desirable) properties compared to an analogous polymer without bioactive moiety functionalisation (i.e., bioactive moiety functionalisation breaks up the crystallinity to produce a more flexible polymer). The physical properties of final material can be altered through changing the composition 10 of the polymer backbone, The biodegradable polymers of the present invention may be blended with one or more other polymers (generally. biodegradable polymers). The present invention also provides a monomer comprising: a) one or more releasable bioactive moieties; -b) one or more polymerisable moieties; wherein one or more of the 15 releasable bioactive moieties are capable of being released from the monomer before or after polymerisation under conditions which are non-interfering to the therapeutic efficacy of the bioactive moieties, The skilled artisan would be able to select suitable chemistry so as protect other functionalities on the bioactive moieties during attachment to the spacer or monomer 20 during or after polymerisation. There follows potential Schemes 5 arnd 6 for the protection/deprotection and breakdown of polymer - bioactive moiety conjugates of the invention. Examples are illustrated for Ciprofloxacin attached to a polyurethane or to a polyester.
WO 2010/040188 PCT/AU2009/001342 -65 OCN-R'-NCO
O-R"-O-C---NH-R'-NH--
Polymer Formation I + L2 HO -R"- OH Cipro Deprotection Sp (prior to use or in-vitro or in-vivo) L2 Cipro P 0 0 L2 = biodegradable moiety, P = protection group O-R"- 0-C---NH-R'-NH- -C Rate of breakdown I P >= L2 2 Cipro = Ciprofloxacin Cipro R', R" = organic groups Bioactive Moiety Release (same or different) { Rate of Cipro O release >= rate . of polymer backbone breakdown O-R"--O- -- NH-R'-NH- - + Cipro X = product from Polymer Degradation cleavage of L2 (eg Hydrolysis) For an ester linkage of Ciprofloxacin X would bean OH OH HO--C---NH--R'--NH-C--OH HO- R"--OH
NH
2 -R'- NH 2 + 2CO2 Scheme 5: Example shown for polyurethane formed from the reaction of a diol and a diisocyanate, where the bioactive molecule (e.g., Ciprofloxacin) is attached to one of the 5 monomers (to the diol monomer in this case).
WO 2010/040188 PCT/AU2009/001342 - 66 0 0 11 110 -0 OH-C-R'---C - OH Polymer Formation L2 HO-R'---OH Cipro Deprotection L2 P (prior to use or in-vitro or in-vivo) Cipro L2 = biodegradable moiety, O O P = protection group Rate of breakdown P >= L2 Cipro = Ciprofloxacin R', R" = organic groups Cipro Bioactive Moiety Release (same or different) P Rate of Cipro release > rate O of polymer breakdown II O--R"- O- C-R'--C--- + Cipro X product from cleavage of linker L2 Polymer Degradation For an ester linkage of (eg Hydrolysis) Ciprofloxacin Xwould beanOH HO-R"-OH 0 + Ho--C-R'-C-OH Scheme 6: Example shown for polyester formed from the reaction of a diol and a diacid, where the bioactive molecule (e.g., Ciprofloxacin) is attached to one of the monomers (to 5 the diol monomer in this case). In one embodiment a biodegradable polymer of the present invention may be prepared by the polymerisation of a hydroxy functionalised ester of valproic acid and a diisocyanate in the presence of a suitable catalyst.
WO 2010/040188 PCT/AU2009/001342 -67 A biodegradable polymer of the present invention may also be prepared by the polymerisation of a dihydroxy functionalised ester of valproic acid, 2,3-dihydroxypropyl 2-propylpentanoate, with hexamethyldiisocyanate in the presence of a suitable catalyst. In a further aspect there is provided a functionalised biodegradable polymer comprising a 5 plurality of labile bioactive moieties pendant from and chemically bonded to a polymer backbone wherein the rate of bioactive moiety release from the polymer backbone is equal to or faster than the rate of polymer backbone breakdown and wherein the polymer backbone is substantially degradable. 10 The biodegradable polymers in accordance with the invention can be incorporated or made into coatings and scaffolds for target in vitro and in vivo applications in a variety of ways. For example, the biodegradable polymers of the invention may be used in the manufacture of sutures, dental devices, orthopaedic fixation devices, transdermal patches, ligating clips, 15 vascular grafts, stents, and tissue-engineering scaffolds. The polymers may be applied to the outside or inside of the body of the subject in need of treatment. Coatings containing the biodegradable polymers can advantageously be directly produced using techniques well known in the art including: solution casting, spray coating, melt 20 pressing, transfer moulding, lamination, moulding onto a premade film containing the conjugate, rotomoulding, spin coating, extrusion coating, electrospinning etc. Premade films for use in subsequent application as coatings can advantageously also be produced using techniques well known in the art including: film extrusion, film blowing, 25 tentering etc. The premade films may be applied as coatings by: melt pressing, vacuum forming, thermoforming, transfer lamination, adhesive bonding. 30 Coatings may be included as films, multilayer films, non-uniform or graded coatings as WO 2010/040188 PCT/AU2009/001342 - 68 dots, patterns or structures according to some form of mask or template. Three dimensional scaffolds containing the polymer-bioactive moiety conjugate(s) can also be formed in a number of means including: 5 " Fibre based structures which in turn are knitted, woven, spun bonded or formed into non-woven mats etc. Additionally, fibre structures could be formed with a binder resin into composite structures. The fibres could be formed by melt extrusion, wet spinning or the bioactive conjugate could be over-coated or 10 dispersed within fibres by bicomponent fibre extrusion, dip or spray coating etc. * Moulded structures could be produced by injection moulding, blow moulding, reactive injection moulding, casting or moulding with subsequent machining etc. * Porous structures could be made by moulding / extrusion in the presence of the porogen. Additionally porous 3D structures could be produced by moulding or 15 polymerisation in the presence of an extractable material. For example, a polyurethane containing the monomer-bioactive moiety conjugate or polymer bioactive moiety conjugate could be formed by casting around a sufficient content of polystyrene beads. The polystyrene beads could be removed by extraction with an appropriate solvent. 20 In this specification "optionally substituted" is taken to mean that a group may or may not be substituted or fused (so as to form a condensed polycyclic group) with one, two, three or more of organic and inorganic groups (i.e. the optional substituent) including those selected from: alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl, heteroaryl, acyl, aralkyl, alkaryl, alkheterocyclyl, alkheteroaryl, alkcarbocyclyl, halo, haloalkyl, 25 haloalkenyl, haloalkynyl, haloaryl, halocarbocyclyl, haloheterocyclyl, haloheteroaryl, haloacyl, haloaryalkyl, hydroxy, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, hydroxycarbocyclyl, hydroxyaryl, hydroxyheterocyclyl, hydroxyheteroaryl, hydroxyacyl, hydroxyaralkyl, alkoxyalkyl, alkoxyalkenyl, alkoxyalkynyl, alkoxycarbocyclyl, alkoxyaryl, alkoxyheterocyclyl, alkoxyheteroaryl, alkoxyacyl, alkoxyaralkyl, alkoxy, 30 alkenyloxy, alkynyloxy, aryloxy, carbocyclyloxy, aralkyloxy, heteroaryloxy, WO 2010/040188 PCT/AU2009/001342 -69 heterocyclyloxy, acyloxy, haloalkoxy, haloalkenyloxy, haloalkynyloxy, haloaryloxy, halocarbocyclyloxy, haloaralkyloxy, haloheteroaryloxy, haloheterocyclyloxy, haloacyloxy, nitro, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroaryl, nitroheterocyclyl, nitroheteroayl, nitrocarbocyclyl, nitroacyl, nitroaralkyl, amino (NH 2 ), alkylamino, dialkylamino, 5 alkenylamino, alkynylamino, arylamino, diarylamino, aralkylamino, diaralkylamino, acylamino, diacylamino, heterocyclamino, heteroarylamino, carboxy, carboxyester, amido, alkylsulphonyloxy, arylsulphenyloxy, alkylsulphenyl, arylsulphenyl, thio, alkylthio, alkenylthio, alkynylthio, arylthio, aralkylthio, carbocyclylthio, heterocyclylthio, heteroarylthio, acylthio, sulfoxide, sulfonyl, sulfonamide, aminoalkyl, aminoalkenyl, 10 aminoalkynyl, aminocarbocyclyl, aminoaryl, aminoheterocyclyl, aminoheteroaryl, aminoacyl, aminoaralkyl, thioalkyl, thioalkenyl, thioalkynyl, thiocarbocyclyl, thioaryl, thioheterocyclyl, thioheteroaryl, thioacyl, thioaralkyl, carboxyalkyl, carboxyalkenyl, carboxyalkynyl, carboxycarbocyclyl, carboxyaryl, carboxyheterocyclyl, carboxyheteroaryl, carboxyacyl, carboxyaralkyl, carboxyesteralkyl, carboxyesteralkenyl, carboxyesteralkynyl, 15 carboxyestercarbocyclyl, carboxyesteraryl, carboxyesterheterocyclyl, carboxyesterheteroaryl, carboxyesteracyl, carboxyesteraralkyl, amidoalkyl, amidoalkenyl, amidoalkynyl, amidocarbocyclyl, amidoaryl, amidoheterocyclyl, amidoheteroaryl, amidoacyl, amidoaralkyl, formylalkyl, formylalkenyl, formylalkynyl, formylcarbocyclyl, formylaryl, formylheterocyclyl, formylheteroaryl, formylacyl, formylaralkyl, acylalkyl, 20 acylalkenyl. acylalkynyl, acylcarbocyclyl, acylaryl, acylheterocyclyl, acylheteroaryl, acylacyl, acylaralkyl, sulfoxidealkyl, sulfoxidealkenyl, sulfoxidealkynyl, sulfoxidecarbocyclyl, sulfoxidearyl, sulfoxideheterocyclyl, sulfoxideheteroaryl, sulfoxideacyl, sulfoxidearalkyl, sulfonylalkyl, sulfonylalkenyl, sulfonylalkynyl, sulfonylcarbocyclyl, sulfonylaryl, sulfonylheterocyclyl, sulfonylheteroaryl, sulfonylacyl, 25 sulfonylaralkyl, sulfonamidoalkyl, sulfonamidoalkenyl, sulfonamidoalkynyl, sulfonamidocarbocyclyl, sulfonamidoaryl, sulfonamidoheterocyclyl, sulfonamidoheteroaryl, sulfonamidoacyl, sulfonamidoaralkyl, nitroalkyl, nitroalkenyl, nitroalkynyl, nitrocarbocyclyl, nitroaryl, nitroheterocyclyl, nitroheteroaryl, nitroacyl, nitroaralkyl, cyano, sulfate and phosphate groups.
WO 2010/040188 PCT/AU2009/001342 -70 In some embodiments, it may be desirable that a group (for example the R group) is optionally substituted with a polymer chain. An example of such a polymer chain includes a polyester, polyurethane, or copolymers thereof. Such a polymer chain may, or may not, have one or more bioactive moieties appended thereto. For example, the R group of the 5 formulae disclosed herein may be substituted with a polymer chain. The skilled worker will recognise that the R group may therefore represent a point of branching of the polymer backbone within the polymer - bioactive moiety conjugate of the present invention. If R is substituted with a polymer chian, that polymer chain should also be biodegradable and not contain any repeat units that are coupled with a non-biodegradable moiety as described 10 herein. Preferred optional substituents include the aforementioned reactive functional groups or moieties, polymer chains and alkyl, (e.g. C 1
.
6 alkyl such as methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), hydroxyalkyl (e.g. hydroxymethyl, hydroxyethyl, hydroxypropyl), alkoxyalkyl (e.g. methoxymethyl, methoxyethyl, 15 methoxypropyl, ethoxymethyl, ethoxyethyl, ethoxypropyl etc) alkoxy (e.g. C 1
.
6 alkoxy such as methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy), halo, trifluoromethyl, trichloromethyl, tribromomethyl, hydroxy, phenyl (which itself may be further substituted e.g., by C 1
.
6 alkyl, halo, hydroxy, hydroxyC1.
6 alkyl, C 1
.
6 alkoxy, haloC 1
.
6 alkyl, cyano, nitro OC(O)C 1
.
6 alkyl, and amino), benzyl (wherein benzyl itself may 20 be further substituted e.g., by C 1
.
6 alkyl, halo, hydroxy, hydroxyC 1 -6alkyl, C 1 . alkoxy, haloCI- 6 alkyl, cyano, nitro OC(O)C 1
.
6 alkyl, and amino), phenoxy (wherein phenyl itself may be further substituted e.g., by C 1
.
6 alkyl, halo, hydroxy, hydroxyC1-6 alkyl, C 1
.
6 alkoxy, haloC 1
.
6 alkyl, cyano, nitro OC(O)CI- 6 alkyl, and amino), benzyloxy (wherein benzyl itself may be further substituted e.g., by C 1
.
6 alkyl, halo, hydroxy, hydroxyCl6 alkyl, C 1
.
6 alkoxy, 25 haloC 1
.
6 alkyl, cyano, nitro OC(O)CI- 6 alkyl, and amino), amino, alkylamino (e.g. C 1
.
6 alkyl, such as methylamino, ethylamino, propylamino etc), dialkylamino (e.g. C 1
.
6 alkyl, such as dimethylamino, diethylamino, dipropylamino), acylamino (e.g. NHC(O)CH 3 ), phenylamino (wherein phenyl itself may be further substituted e.g., by C 1
-
6 alkyl, halo, hydroxy hydroxyCi..
6 alkyl, C 1
-
6 alkoxy, haloC 1 6 alkyl, cyano, nitro OC(O)C 1
.
6 alkyl, and 30 amino), nitro, formyl, -C(O)-alkyl (e.g. C 1
-
6 alkyl, such as acetyl), O-C(O)-alkyl (e.g. C 1
.
WO 2010/040188 PCT/AU2009/001342 -71 6 alkyl, such as acetyloxy), benzoyl (wherein the phenyl group itself may be further substituted e.g., by C 1
.
6 alkyl, halo, hydroxy hydroxyC 1 6 alkyl, CI- 6 alkoxy, haloC 1
.
6 alkyl, cyano, nitro OC(O)C 1
.
6 alkyl, and amino), replacement of CH 2 with C=O, CO 2 H, CO 2 alkyl (e.g. CI- 6 alkyl such as methyl ester, ethyl ester, propyl ester, butyl ester), CO 2 phenyl 5 (wherein phenyl itself may be further substituted e.g., by CI- 6 alkyl, halo, hydroxy, hydroxyl C 1
.
6 alkyl, C 1
.
6 alkoxy, halo CI.
6 alkyl, cyano, nitro OC(O)CI- 6 alkyl, and amino),
CONH
2 , CONHphenyl (wherein phenyl itself may be further substituted e.g., by C 1
-
6 alkyl, halo, hydroxy, hydroxyl C 1
.
6 alkyl, C 1
.
6 alkoxy, halo C 1
.
6 alkyl, cyano, nitro OC(O)C 1
.
6 alkyl, and amino), CONHbenzyl (wherein benzyl itself may be further substituted e.g., by 10 CI- 6 alkyl, halo, hydroxy hydroxyl CI.
6 alkyl, C 1
.
6 alkoxy, halo C 1
.
6 alkyl, cyano, nitro OC(0)CI- 6 alkyl, and amino), CONHalkyl (e.g. C 1
.
6 alkyl such as methyl ester, ethyl ester, propyl ester, butyl amide) CONHdialkyl (e.g. C 1
.
6 alkyl) aminoalkyl (e.g., HN C 1
.
6 alkyl-,
C
1
.
6 alkylHN-Cs 6 alkyl- and (C 1
.
6 alkyl) 2 N-Ci.
6 alkyl-), thioalkyl (e.g., HS C 1
-
6 alkyl-), carboxyalkyl (e.g., HO 2
CC
1
.
6 alkyl-), carboxyesteralkyl (e.g., C 1
-
6 alkylO 2 CCI-6 alkyl-), 15 amidoalkyl (e.g., H 2
N(O)CC.
6 alkyl-, H(C 1
.
6 alkyl)N(O)CCI.
6 alkyl-), formylalkyl (e.g.,
OHCC
1
..
6 alkyl-), acylalkyl (e.g., C 1 s 6 alkyl(O)CCI- 6 alkyl-), nitroalkyl (e.g., 0 2
NCI-
6 alkyl-), sulfoxidealkyl (e.g., R 3
(O)SCI-
6 alkyl, such as CI- 6 alkyl(O)SCI.
6 alkyl-), sulfonylalkyl (e.g., R 3
(O)
2
SCI-
6 alkyl- such as C 1
.
6 alkyl(O) 2
SCI.
6 alkyl-), sulfonamidoalkyl (e.g., 2
HRN(O)SC
1 .- 6 alkyl, H(C 1
..
6 alkyl)N(O)SC1.
6 alkyl-). 20 As used herein, the term "alkyl", used either alone or in compound words denotes straight chain, branched or cyclic alkyl, for example CI.
40 alkyl, or C 1
..
20 or CIaj. Examples of straight chain and branched alkyl include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec butyl, t-butyl, n-pentyl, 1,2-dimethylpropyl, 1,1-dimethyl-propyl, hexyl, 4-methylpentyl, 1 methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3 25 dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 1,2,2-trimethylpropyl, 1,1,2 trimethylpropyl, heptyl, 5-methylhexyl, 1-methylhexyl, 2,2-dimethylpentyl, 3,3 dimethylpentyl, 4,4-dimethylpentyl, 1,2-dimethylpentyl, 1,3-dimethylpentyl, 1,4 dimethyl-pentyl, 1,2,3-trimethylbutyl, 1,1,2-trimethylbutyl, 1,1,3-trimethylbutyl, octyl, 6 methylheptyl, 1-methylheptyl, 1,1,3,3-tetramethylbutyl, nonyl, 1-, 2-, 3-, 4-, 5-, 6- or 7 30 methyloctyl, 1-, 2-, 3-, 4- or 5-ethylheptyl, 1-, 2- or 3-propylhexyl, decyl, 1-, 2-, 3-, 4-, 5-, WO 2010/040188 PCT/AU2009/001342 -72 6-, 7- and 8-methylnonyl, 1-, 2-, 3-, 4-, 5- or 6-ethyloctyl, 1-, 2-, 3- or 4-propylheptyl, undecyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-methyldecyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-ethylnonyl, 1-, 2-, 3-, 4- or 5-propyloctyl, 1-, 2- or 3-butylheptyl, 1-pentylhexyl, dodecyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- or 10-methylundecyl, 1-, 2-, 3-, 4-, 5-, 6-, 7- or 8-ethyldecyl, 1-, 2-, 3-, 4-, 5 5- or 6-propylnonyl, 1-, 2-, 3- or 4-butyloctyl, 1-2-pentylheptyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonoadecyl, eicosyl and the like. Examples of cyclic alkyl include mono- or polycyclic alkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl and the like. Where an alkyl group is referred to generally as "propyl", butyl" etc, it will be understood 10 that this can refer to any of straight, branched and cyclic isomers where appropriate. An alkyl group may be optionally substituted by one or more optional substituents as herein defined. As used herein, term "alkenyl" denotes groups formed from straight chain, branched or cyclic hydrocarbon residues containing at least one carbon to carbon double bond 15 including ethylenically mono-, di- or polyunsaturated alkyl or cycloalkyl groups as previously defined, for example C 2
-
40 alkenyl, or C 2
-
20 or C 2 1 0 . Thus, alkenyl is intended to include propenyl, butylenyl, pentenyl, hexaenyl, heptaenyl, octaenyl, nonaenyl, decenyl, undecenyl, dodecenyl, tridecenyl, tetradecenyl, pentadecenyl, hexadecenyl, heptadecenyl, octadecenyl, nondecenyt, eicosenyl hydrocarbon groups with one or more carbon to carbon 20 double bonds. Examples of alkenyl include vinyl, allyl, 1-methylvinyl, butenyl, iso butenyl, 3-methyl-2-butenyl, I-pentenyl, cyclopentenyl, 1-methyl-cyclopentenyl, 1 hexenyl, 3-hexenyl, cyclohexenyl, 1-heptenyl, 3-heptenyl, 1-octenyl, cyclooctenyl, 1 nonenyl, 2-nonenyl, 3-nonenyl, 1-decenyl, 3-decenyl, 1,3-butadienyl, 1,4-pentadienyl, 1,3 cyclopentadienyl, 1,3-hexadienyl, 1,4-hexadienyl, 1,3-cyclohexadienyl, 1,4 25 cyclohexadienyl, 1,3-cycloheptadienyl, 1,3,5-cycloheptatrienyl and 1,3,5,7 cyclooctatetraenyl. An alkenyl group may be optionally substituted by one or more optional substituents as herein defined. As used herein the term "alkynyl" denotes groups formed from straight chain, branched or cyclic hydrocarbon residues containing at least one carbon-carbon triple bond including 30 ethylenically mono-, di- or polyunsaturated alkyl or cycloalkyl groups as previously WO 2010/040188 PCT/AU2009/001342 - 73 defined, for example, C 2
..
40 alkenyl, or C 2
..
20 or C 2
-
10 . Thus, alkynyl is intended to include propynyl. butylynyl, pentynyl, hexaynyl, heptaynyl, octaynyl, nonaynyl, decynyl, undecynyl, dodecynyl, tridecynyl, tetradecynyl, pentadecynyl, hexadecynyl, heptadecynyl, octadecynyl, nondecynyl, eicosynyl hydrocarbon groups with one or more carbon to 5 carbon triple bonds. Examples of alkynyl include ethynyl, 1-propynyl, 2-propynyl, and butynyl isomers, and pentynyl isomers. An alkynyl group may be optionally substituted by one or more optional substituents as herein defined. An alkenyl group may comprise a carbon to carbon triple bond and an alkynyl group may comprise a carbon to carbon double bond (i.e. so called ene-yne or yne-ene groups). 10 As used herein, the term "aryl" (or "carboaryl)" denotes any of single, polynuclear, conjugated and fused residues of aromatic hydrocarbon ring systems. Examples of aryl include phenyl, biphenyl, terphenyl, quaterphenyl, naphthyl, tetrahydronaphthyl, anthracenyl, dihydroanthracenyl, benzanthracenyl, dibenzanthracenyl, phenanthrenyl, fluorenyl, pyrenyl, idenyl, azulenyl, chrysenyl. Preferred aryl include phenyl and 15 naphthyl. An aryl group may be optionally substituted by one or more optional substituents as herein defined. As used herein, the terms "alkylene", "alkenylene", and "arylene" are intended to denote the divalent forms of "alkyl", "alkenyl", and "aryl", respectively, as herein defined. The term "halogen" ("halo") denotes fluorine, chlorine, bromine or iodine (fluoro, chloro, 20 bromo or iodo). Preferred halogens are chlorine, bromine or iodine. The term "carbocyclyl" includes any of non-aromatic monocyclic, polycyclic, fused or conjugated hydrocarbon residues, preferably C 3
..
20 (e.g. C 3
-
10 or C 3
.
8 ). The rings may be saturated, e.g. cycloalkyl, or may possess one or more double bonds (cycloalkenyl) and/or one or more triple bonds (cycloalkynyl). Particularly preferred carbocyclyl moieties are 5 25 6-membered or 9-10 membered ring systems. Suitable examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cyclopentenyl, cyclohexenyl, cyclooctenyl, cyclopentadienyl, cyclohexadienyl, cyclooctatetraenyl, indanyl, decalinyl and indenyl.
WO 2010/040188 PCT/AU2009/001342 -74 The term "heterocyclyl" when used alone or in compound words includes any of monocyclic, polycyclic, fused or conjugated hydrocarbon residues, preferably C 3 2 0 (e.g.
C
3 .io or C 3
.
8 ) wherein one or more carbon atoms are replaced by a heteroatom so as to provide a non-aromatic residue. Suitable heteroatoms include 0, N, S, P and Se, 5 particularly 0, N and S. Where two or more carbon atoms are replaced, this may be by two or more of the same heteroatom or by different heteroatoms. The heterocyclyl group may be saturated or partially unsaturated, i.e. possess one or more double bonds. Particularly preferred heterocyclyl are 5-6 and 9-10 membered heterocyclyl. Suitable examples of heterocyclyl groups may include azridinyl, oxiranyl, thiiranyl, azetidinyl, 10 oxetanyl, thietanyl, 2H-pyrrolyl, pyrrolidinyl, pyrrolinyl, piperidyl, piperazinyl, morpholinyl, indolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, thiomorpholinyl, dioxanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyrrolyl, tetrahydrothiophenyl, pyrazolinyl, dioxalanyl, thiazolidinyl, isoxazolidinyl, dihydropyranyl, oxazinyl, thiazinyl, thiomorpholinyl, oxathianyl, dithianyl, trioxanyl, thiadiazinyl, dithiazinyl, trithianyl, 15 azepinyl, oxepinyl, thiepinyl, indenyl, indanyl, 3H-indolyl, isoindolinyl, 4H-quinolazinyl, chromenyl, chromanyl, isochromanyl, pyranyl and dihydropyranyl. The term "heteroaryl" includes any of monocyclic, polycyclic, fused or conjugated hydrocarbon residues, wherein one or more carbon atoms are replaced by a heteroatom so as to provide an aromatic residue. Preferred heteroaryl have 3-20 ring atoms, e.g. 3-10. 20 Particularly preferred heteroaryl are 5-6 and 9-10 membered bicyclic ring systems. Suitable heteroatoms include, 0, N, S, P and Se, particularly 0, N and S. Where two or more carbon atoms are replaced, this may be by two or more of the same heteroatom or by different heteroatoms. Suitable examples of heteroaryl groups may include pyridyl, pyrrolyl, thienyl, imidazolyl, furanyl, benzothienyl, isobenzothienyl, benzofuranyl, 25 isobenzofuranyl, indolyl, isoindolyl, pyrazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, quinolyl, isoquinolyl, phthalazinyl, 1,5-naphthyridinyl, quinozalinyl, quinazolinyl, quinolinyl, oxazolyl, thiazolyl, isothiazolyl, isoxazolyl, triazolyl, oxadialzolyl, oxatriazolyl, triazinyl, and furazanyl. The term "acyl" either alone or in compound words denotes a group containing the agent 30 C=O (and not being a carboxylic acid, ester or amide) Preferred acyl includes C(O)-R, WO 2010/040188 PCT/AU2009/001342 -75 wherein RX is hydrogen or an alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl residue. Examples of acyl include formyl, straight chain or branched alkanoyl (e.g. C 120 ) such as, acetyl, propanoyl, butanoyl, 2-methylpropanoyl, pentanoyl, 2,2 dimethylpropanoyl, hexanoyl, heptanoyl, octanoyl, nonanoyl, decanoyl, undecanoyl, 5 dodecanoyl, tridecanoyl, tetradecanoyl, pentadecanoyl, hexadecanoyl, heptadecanoyl, octadecanoyl, nonadecanoyl and icosanoyl; cycloalkylcarbonyl such as cyclopropylcarbonyl cyclobutylcarbonyl, cyclopentylcarbonyl and cyclohexylcarbonyl; aroyl such as benzoyl, toluoyl and naphthoyl; aralkanoyl such as phenylalkanoyl (e.g. phenylacetyl, phenylpropanoyl, phenylbutanoyl, phenylisobutylyl, phenylpentanoyl and 10 phenylhexanoyl) and naphthylalkanoyl (e.g. naphthylacetyl, naphthylpropanoyl and naphthylbutanoyl]; aralkenoyl such as phenylalkenoyl (eg. phenylpropenoyl, phenylbutenoyl, phenylmethacryloyl, phenylpentenoyl and phenylhexenoyl and naphthylalkenoyl (e.g. naphthylpropenoyl, naphthylbutenoyl and naphthylpentenoyl); aryloxyalkanoyl such as phenoxyacetyl and phenoxypropionyl; arylthiocarbamoyl such as 15 phenylthiocarbamoyl; arylglyoxyloyl such as phenylglyoxyloyl and naphthylglyoxyloyl; arylsulfonyl such as phenylsulfonyl and napthylsulfonyl; heterocycliccarbonyl; heterocyclicalkanoyl such as thienylacetyl, thienylpropanoyl, thienylbutanoyl, thienylpentanoyl, thienylhexanoyl, thiazolylacetyl, thiadiazolylacetyl and tetrazolylacetyl; heterocyclicalkenoyl such as heterocyclicpropenoyl, heterocyclicbutenoyl, 20 heterocyclicpentenoyl and heterocyclichexenoyl; and heterocyclicglyoxyloyl such as thiazolyglyoxyloyl and thienylglyoxyloyl. The Rx residue may be optionally substituted as described herein. The term "sulfoxide", either alone or in a compound word, refers to a group -S(O)Ry wherein RY is selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, 25 heterocyclyl, carbocyclyl, and aralkyl. Examples of preferred RI include C 1 20alkyl, phenyl and benzyl. The term "sulfonyl", either alone or in a compound word, refers to a group S(0) 2 -R , wherein RY is selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, carbocyclyl and aralkyl. Examples of preferred RY include CI.20alkyl, phenyl 30 and benzyl.
WO 2010/040188 PCT/AU2009/001342 - 76 The term "sulfonamide", either alone or in a compound word, refers to a group S(O)NR R' wherein each RY is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, carbocyclyl, and aralkyl. Examples of preferred RY include C 1 20alkyl, phenyl and benzyl. In a preferred embodiment at least one RY is hydrogen. In 5 another form, both RY are hydrogen. The term, "amino" is used here in its broadest sense as understood in the art and includes groups of the formula NRARB wherein RA and RB may be any independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, carbocyclyl, heteroaryl, heterocyclyl, aralkyl, and acyl. RA and RB, together with the nitrogen to which they are attached, may also form a 10 monocyclic, or polycyclic ring system e.g. a 3-10 membered ring, particularly, 5-6 and 9 10 membered systems. Examples of "amino" include NH 2 , NHalkyl (e.g. C 1 20alkyl), NHaryl (e.g. NHphenyl), NHaralkyl (e.g. NHbenzyl), NHacyl (e.g. NHC(O)C 20alkyl, NHC(O)phenyl), Nalkylalkyl (wherein each alkyl, for example C 1
.
20 , may be the same or different) and 5 or 6 membered rings, optionally containing one or more same or different 15 heteroatoms (e.g. 0, N and S). The term "amido" is used here in its broadest sense as understood in the art and includes A B A B groups having the formula C(O)NR R , wherein R and RB are as defined as above. Examples of amido include C(0)NH 2 , C(0)NHalkyl (e.g. C 1 2 oalkyl), C(O)NHaryl (e.g. C(O)NHphenyl), C(O)NHaralkyl (e.g. C(O)NHbenzyl), C(O)NHacyl (e.g. 20 C(O)NHC(O)C.
2 oalkyl, C(O)NHC(0)phenyl), C(0)Nalkylalkyl (wherein each alkyl, for example C 1 20 , may be the same or different) and 5 or 6 membered rings, optionally containing one or more same or different heteroatoms (e.g. 0, N and S). The term "carboxy ester" is used here in its broadest sense as understood in the art and includes groups having the formula CO 2 Rz, wherein R may be selected from groups 25 including alkyl, alkenyl, alkynyl, aryl, carbocyclyl, heteroaryl, heterocyclyl, aralkyl, and acyl. Examples of carboxy ester include CO 2
C
1 20alkyl, CO 2 aryl (e.g.. CO 2 phenyl),
CO
2 aralkyl (e.g. CO 2 benzyl). The term "heteroatom" or "hetero" as used herein in its broadest sense refers to any atom other than a carbon atom which may be a member of a cyclic organic group. Particular WO 2010/040188 PCT/AU2009/001342 -77 examples of heteroatoms include nitrogen, oxygen, sulfur, phosphorous, boron, silicon, selenium and tellurium, more particularly nitrogen, oxygen and sulfur. It is understood that the compounds of the present invention (including monomers and polymers) may exist in one or more stereoisomeric forms (eg enantiomers, diastereomers). 5 The present invention includes within its scope all of these stereoisomeric forms either isolated (in for example enantiomeric isolation), or in combination (including racemic mixtures). The following examples are intended to illustrate the scope of the invention and to enable reproduction and comparison. They are not intended to limit the scope of the disclosure in 10 any way. EXAMPLES General Proton NMR spectra were obtained on Bruker AV400 and Bruker AV200 spectrometers, operating at 400 MHz and 200 MHz respectively. All spectra were obtained at 23'C unless 15 specified. Chemical shifts are reported in parts per million (ppm) on the 6 scale and relative to the chloroform peak at 7.26 ppm (1H). Oven dried glassware was used in all reactions carried out under an inert atmosphere (either dry nitrogen or argon). All starting materials and reagents were obtained commercially unless otherwise stated. Removal of solvents "under reduced pressure" refers to the process of bulk solvent removal by rotary 20 evaporation (low vacuum pump) followed by application of high vacuum pump (oil pump) for a minimum of 30 min. Analytical thin layer chromatography (TLC) was performed on plastic-backed Merck Kieselgel KG60F254 silica plates and visualised using short wave ultraviolet light, potassium permanganate or phosphomolybdate dip. Flash chromatography was performed using 230-400 mesh Merck Silica Gel 60 following established guidelines 25 under positive pressure. Tetrahydrofuran and dichloromethane were obtained from a solvent dispensing system under an inert atmosphere. All other reagents and solvents were used as purchased.
WO 2010/040188 PCT/AU2009/001342 -78 Molecular weights of polymers were characterized by gel permeation chromatography (GPC) performed in tetrahydrofuran (THF) or dimethylformamide (DMF) 1.0 mL/min, 25'C using a Waters GPC instrument, with a Waters 2414 Refractive Index Detector, a series of four Polymer Laboratories PLGel columns (3 x5 tm Mixed-C and 1x3 tm 5 Mixed-E), and Empower Pro Software. The GPC was calibrated with narrow polydispersity polystyrene standards (Polymer Laboratories EasiCal, MW from 264 to 256000), and molecular weights are reported as polystyrene equivalents. Acid number and hydroxy number were performed using the methods outlined below 10 Acid Value Determination for Biodegradable Polymers References ASTM D1980-87 (vol 6.03). Standard Test Method for Acid Value of Fatty Acids and 15 Polymerised Fatty Acids - superseded by ASTM D1980-87(1998) (vol 6.03). Membranes of Polyurethanes Containing Crystalline Soft Segments: Oxygen Permeability and Morphology, Oh, H.-J.; Kim, W.-Y.; Jeong, Y.-S.; Lee, Y.-S., Bull. Korean Chem. Soc., 2001, 22(2), 194-8. 20 Method This test method determines the total amount of residual acid groups present in the polymers and any free acid groups present, reported as acid value (mg KOH/g polymer). Reagents 25 Chloroform and methanol, AR grade. KOH pellets, AR grade. Phenolphthalein indicator (1% in MeOH). Potassium hydrogen phthalate (KHCgH 4 0 4 ), dry at 120 'C for 2 hr before use. 30 **NOTE: all glassware should be clean and oven dried before use** WO 2010/040188 PCT/AU2009/001342 - 79 Preparation and Standardisation of 0.1 M KOH solution (do in triplicate) Dissolve 5.61 g of KOH in methanol to make a 1 L solution. (2/4/06) - dissolve 33g of KOH in carbon dioxide free water then filter. Add 71 mL water and 900 mL methanol Weigh out approximately but accurately, 0.74g of dried KHC 8
H
4 0 4 into a conical flask. 5 Add 100 mL of carbon dioxide-free water and 3 drops of the phenolphthalein indicator and mix well. Titrate with the 0. 1 M KOH solution. M =204.23 v 10 M = molarity of methanolic KOH solution (mol/L) m = mass of KHC 8
H
4 0 4 used (g) 204.23 = molecular weight of KHC 8
H
4 0 4 (g/mol) v = titre (L) 15 Procedure (do in triplicate) Weigh out approximately but accurately 0.5 g to 1 g of sample into a 100 mL round bottomed flask. Degas under high vacuum ( 0.5 mmHg) for 1 hr. 20 Dissolve the sample in 50 to 100 mL of neutralised chloroform*. It may be necessary to magnetically stir the mixture for a few minutes to achieve complete dissolution. * Use the same volume of solvent for the triplicate set. Methanol may be used if the sample does not dissolve in chloroform although it is slightly more acidic. Neutralise the 25 chloroform before dissolving the sample by adding 5 drops of the indicator solution and adding dilute KOH solution (1 part 0.1 M KOH solution to 10 parts MeOH) to the phenolphthalein endpoint. Do the same for the methanol but add 0.5 mL of the indicator instead of 5 drops as the colour change is more difficult to observe.
WO 2010/040188 PCT/AU2009/001342 -80 Add 0.5 mL of the phenolphthalein indicator solution to the sample mixture and titrate immediately with the 0.1 M KOH solution to the first pink colour that persists for 30 seconds. 5 Calculation VM x 56.1 (a) Acid Value (mg KOH/g polymer)= W v = sample titre (mL) M = molarity of the KOH solution (mol/L) 10 56.1 = molecular weight of KOH (g/mol) W = weight of the sample used (g) 56.1 x n x 1000 (b) Molecular weights = (OH + Acid) values 15 n = functionality of polymer (2 for linear, 4 for star etc.) Hydroxyl Value Determination for Biodegradable Polymers References 20 N-Methylimidazole as a Catalyst for Acetylation of Hydroxyl Terminated Polymers, Dee, L. A., Biggers, G. L., Fiske, M. E., Anal. Chem., 1980, 52, 572-3. ASTM D2849-69 (Sections 31 to 39). Standard Methods of Testing: Urethane Foam Polyol Raw Materials. Method A - Acetic Anhydride Pressure Bottle Section. - standard withdrawn in 1987, no replacement. 25 ASTM E200-97 (Sections 74 to 79). Standard Practice for Preparation, Standardisation and Storage of Standard and Reagent Solutions for Chemical Analysis - superseded by ASTM E200-97(2001)el (vol 15.05).
WO 2010/040188 PCT/AU2009/001342 -81 Hydroxy-Terminated Poly (e-Caprolactone-co-Valerolactone) Oligomers: Synthesis, Characterisation and Polyurethane Network Formation, Storey, R. F., Herring, K. R., Hoffman, D. C,, J. Polymer Science (Part A: Polymer Chemistry), 1991, 29, 1759-77. 5 Method This test method determines the total amount of hydroxyl end groups present in a polymer sample, reported as hydroxyl value (mg KOH/g polymer). 10 The OH groups are acetylated with acetic anhydride in 1,2-dichloroethane at 100 'C using N-methylimidazole as catalyst. The excess acetic anhydride is hydrolysed with water and the total acetic acid produced is back titrated with standard KOH solution. The hydroxyl content is calculated from the difference between the blank and sample titres. 15 If the samples contain free acids, these are also titrated with KOH during the back titration. Therefore if the samples contain significant amounts of acidity or alkalinity, it must be corrected by carrying out acidity or alkalinity determinations. Reagents 20 Acetic anhydride (AA), AR grade. 1,2-Dichloroethane (DCE), distil (bp 83.4 'C, 760 mmHg) and store at room temperature. N-Methylimidazole (NMIM), dry over KOH overnight, distil under reduced pressure (bp 197-198 'C, 760 mmHg), store under N 2 , keep refrigerated. Chloroform and methanol, AR grade. 25 Thymol blue indicator (10% in MeOH). 0.5 M KOH in MeOH. Benzoic acid, grind and dry at 80 'C for at least 2 hours before use. **NOTE: All glassware should be clean and oven dried before use.** 30 Preparation and Standardisation of 0.5 M Methanolic KOH solution (do in triplicate) WO 2010/040188 PCT/AU2009/001342 - 82 Dissolve 28.05 g of AR grade KOH in methanol to make a 1 L solution.TRY THIS dissolve 66g KOH in 60 mL water, filter. 79 mL solution obtained. Add 200 mL water then 2.5L methanol Accurately weigh out 0.735-0.745 g dry benzoic acid into a conical flask. Add 1 mL 5 degassed water, 7 mL MeOH, 1 mL NMIM, 50 mL CHC1 3 and mix well. Add 3 drops of the thymol blue indicator solution and titrate with the 0.5 M KOH solution to the endpoint (colour change from yellow to blue-violet). M'. M= 122.12 M molarity of methanolic KOH solution (mol/L) 10 m= mass of benzoic acid used (g) 122.12 = molecular weight of benzoic acid (g/mol) v = titre (L) Acetylation of Samples/Procedure 15 Prepare a stock solution (SS) of AA in DCE (1:6 ratio by volume) and keep in a dark bottle. This must be prepared fresh each time the procedure is carried out. Samples (do in triplicate): 20 Place 3 - 4 milliequivalents of polymer* into a 250 mL round-bottomed flask. Degas the sample at high pressure (< 0.5 mmHg) for 1 hr. Add 20 mL of DCE, followed by 4 mL of the SS and 4 mL of NMIM. Attach a condenser and drying tube and heat the mixture in a 110 'C oil bath (which has 25 been turned on for at least 1 hr prior), with stirring for 15 minutes. Cool the mixture in an ice bath, then add 3 mL of distilled water to hydrolyse the excess acetic anhydride and heat the mixture again as above for 5 minutes. Cool the mixture in an ice bath and then rinse the condenser down with 160 mL chloroform and 35 mL methanol into the reaction vessel.
WO 2010/040188 PCT/AU2009/001342 - 83 Add 5 drops of thymol blue indicator and titrate with the 0.5 M KOH solution to the final endpoint (colour change from orange to blue-green to bright blue). *Weight (W) of sample required for hydroxyl number determination 3 x 10-3mol x Mn 5 =n Mn = molecular weight of sample obtained from GPC trace n = OH functionality of polymer (2 for dihydroxy, 4 for tetrahydroxy etc.) 10 Blank (do once per stock solution): As above, omitting steps 1 - 2. The blank mixture should turn a green-yellow colour during step 4. Calculations [(B - A)M x 56.1] 15 Hydroxyl number (mg KOH/g polymer) W A = sample titre (mL) B = blank titre (mL) M = molarity of the KOH solution (mol/L) 20 W = weight of sample used (g) 56.1 x n x 1000 Molecular weights = (OH + Acid) values n = functionality of polymer (2 for linear, 4 for star, etc.) 25 Valproic Acid (2-propylpentanoic acid) Example 1: Valproic Acid Monoglyceride (VA-MG) - For comparative Examples WO 2010/040188 PCT/AU2009/001342 - 84 (a) 2-propylpentanoic acid, 2, 2-dimethyl-1,3-dioxolane-4-yl methyl ester 0 0 5 2-propylpentanoic acid (10.00 g; 0.07 mol) was dissolved in dichloromethane (anhydrous) (500 ml), under an argon atmosphere. 2,2-dimethyl-1,3-dioxolane-4-methanol (solketal) (11.00 g; 0.08 mol; 1.2 equiv) and p-dimethylaminopyridine (1.02 g; 8.30 mmol; 0.12 equiv) were added. The solution was cooled to 0 0 C and a solution of 1,3 10 dicyclohexylcarbodiimide (17.17 g; 0.08 mol; 1.20 equiv) in dichloromethane (anhydrous) (100 ml) was added dropwise over 30 minutes. A white precipitate formed during the addition. The reaction mixture was allowed to warm to ambient temperature and stirred at ambient temperature for 16 hours. The reaction mixture was cooled in a dry ice/acetone bath (-78'C) followed by filtration to remove the urea precipitate. The solvent was 15 removed in vacuo to obtain the crude product as a clear, colourless oil (23.29 g) which was purified by column chromatography (silica gel, 5% ethyl acetate/petroleum ether 40-60) to obtain a colourless oil (14.40 g, 80 %). 'H-NMR (CDCl, 200 MHz): a[pm] = 4.30 (quintet, 1H, J=5.8Hz); 4.03-4.17 (in, 3H); 20 3.74 (dd, lH, J=6.1 Hz, J=8.3Hz); 2.34-2.47 (in, 1 H); 1.19-1.69 (m,14H); 0.89 (t, 6H, J=7.1 Hz) (b) 2, 3-dihydroxypropyl 2-propylpentanoate (VA-MG) 0 IHO ' HO 25 2-propylpentanoic acid 2,2-dimethyl-1,3-dioxolane-4-yl methyl ester was dissolved in 95% (v/v) aqueous ethanol (200 ml). Amberlyst 15 (wet) ion exchange resin (sulfonic acid) WO 2010/040188 PCT/AU2009/001342 - 85 (6,40 g) and antibumping granules were added. The reaction mixture was refluxed for 5 hours without stirring. The reaction mixture was cooled to ambient temperature, followed by filtration and removal of the solvent in vacuo to obtain a pale brown oil (12.89 g) which was purified by column chromatography (silica gel, 50% ethyl acetate/petroleum ether 40 5 60) to obtain a colourless oil (10.40 g, 86%). 'H-NMR (CDC] 3 , 200 MHz): 6[pm] = 4.27-4.11 (m, 2H); 3.80-4.01 (m, 1H); 3.52-3.76 (m, 2H); 2.52 (d, I H, J=5.0Hz): 2.34-2.49 (m, IH); 2.09 (t, I H, J=6.0Hz); 1.20-1.70 (m, 8H); 0.90 (t, 6H, J=6.9Hz) 10 Example 2: 3-(1,3-dihydroxypropan-2-yloxy)-3-oxopropyl 2-propylpentanoate a) 3-hydroxypropyl 2-propylpentanoate 0 o OH 15 2-propylpentanoic acid (10.0 g, 69.3 mmol) was mixed with propane-1-3-diol (42.1 g, 555.0 minol) and methyl-sulfonic acid (5 drops) in toluene (200 ml) and the mixture was heated under reflux using a Dean Stark trap for 12 h. After that, toluene was removed 20 under reduced pressure and the crude mixture was dissolved in dichlormethane (200 ml) and extracted with water (pH 5, 3 x 200 ml). The combined organic layers were dried over sodium sulfate and the volatiles were removed under reduced pressure giving a clear oil (14.0 g, 60.0 mmol, 99%). 25 'H-NMR (CDCl 3 , 200 MHz): 6[pm] = 4.24 (tr, 2H, J = 6.1 Hz), 3.68 (tr, 2H, J = 6.1 Hz), 2.37-2.31 (m, IH), 1.93-1,77 (m, 2H), 1.69-1.16 (m, 8H), 0.89 (tr, 6H, 6.9 Hz) b) 3-(2-propylpentanoyloxy)propanoic acid WO 2010/040188 PCT/AU2009/001342 - 86 0 0 0 OH 3-hydroxypropyl 2-propylpentanoate (2.08 g, 10.3 mmol) was dissolved in 120 ml of 5 acetone. 3.1 ml of a solution of Jones Reagent (prepared by dissolving 26.72 g of chromium trioxide in 23 ml of concentrated sulfuric acid, and then diluting the mixture to 100 ml with water) was added. Propan-2-ol (5 ml) was added to the reaction mixture which was filtered through a pad of celite. The filtrate was washed with 0.01 M HCl solution (3 x 50 ml), dried over sodium sulfate, filtered and concentrated under reduced pressure. The 10 crude product (2.05 g, 9.5 mmol, 92 %)was used in the next step without any further purification. 'H-NMR (CDCla, 200 MHz): 8[pm] = 4.35 (tr, 2H, J = 6.3 Hz), 2.70 (tr, 2H, J= 6.3 Hz), 2.47-2.28 (m. I H), 1.70-1.15 (in, 8H), 0.88 (tr, 6H, J= 6.9 Hz) 15 c) 3 -oxo-3 -(2-phenyl- 1,3 -dioxan-5-yloxy)propyl 2-propylpentanoate o0 O O 0 0 0 0 r 20 3-(2-propylpentanoyloxy)propanoic acid (2.05 g, 9.5 mmol) was dissolved in anhydrous
CH
2
CI
2 (200 ml) under argon. 1,3-0-benzylideneglycerol (2.50 g, 13.67 mmol triethylamine (4.04 g, 40.0 mmol) and O-benzotriazol-1-yl-N, N, N', N'-trimethyluronium hexafluorophosphate (4.2 g, 11 .0 mmol) were added successively. The reaction mixture was stirred under argon for 72 h. The reaction mixture was washed with saturated NaHCO 3 WO 2010/040188 PCT/AU2009/001342 - 87 solution (1 x 90 ml), water (1 x 90 ml) and dried over Na 2
SO
4 . The organic solvent was removed under reduced pressure giving a pale, pink solid (2.99 g, 7.9 mmol, 83 %). 'H-NMR (CDCl 3 , 200 MHz): S[pm] = 7.63-7.29 (m, 5H), 5.55 (in, 5H), 4.75-4.66 (m, 5 IH), 4.42-4.06 (m, 4H), 3.01-2.78 (m, 2H), 2.74-2.24 (m, 3H), 2.07-1.18 (in, 8H), 0.92 (tr, 6H, J= 6.9 Hz) d) 3-(1,3-dihydroxypropan-2-yloxy)-3-oxopropyl 2-propylpentanoate 0 0 OH O OOH 10 3 -oxo-3-(2-phenyl-1,3-dioxan-5-yloxy)propyl 2-propylpentanoate (2.99 g, 7.9 mmol) was dissolved in ethanol (90 ml) under argon. Palladium catalyst (10 wt % Pd/C) (300 mg) was added, the flask was evacuated and allowed to stir 1 atm of hydrogen gas at room 15 temperature for 16 hours. The crude reaction mixture was passed through a glass microfiber on a sintered funnel. The volatiles were removed under reduced pressure yielding 2.01 g (6.95 mmol, 88%) of a clear oil. The product was used without any further purification 20 'H-NMR (CDCI 3 , 400 MHz): S[pm]= 4.99-4.90 (in, 1H), 3.86-3.80 (in, 4H), 2.80-2.70 (m, 2H), 2.48-2.37 (m, 2H), 1.89-1.80 (m, 2H), 1.68-1.54 (in, 2H), 1.50-1.22 (m, 6H), 0.91 (tr, 6H, J = 7.2 Hz) Example 3: Production of a mixture of 1,2-dihydroxy-5,14-dioxo-4,15-dioxa-6,13 25 diazanonadecan-19-yl 2-propylpentanoate and 1-hydroxy-2-(hydroxymethyl)-4,13-dioxo 3,14-dioxa-5,12-diazaoctadecan-18-yl 2-propylpentanoate a) 4-hydroxybutyl 2-propylpentanoate WO 2010/040188 PCT/AU2009/001342 - 88 0 2-propylpentanoic acid (40.16 g, 278.5 mmol) was mixed with butane-1-4-diol (114.65 g, 5 1272.2 mmol) and methyl-sulfonic acid (5 drops) in toluene (3500 ml) and the mixture was heated under reflux using a Dean Stark trap for 12 h. After that, toluene was removed under reduced pressure and the crude mixture was dissolved in chloroform (200 ml) and extracted with water (pH 5, 3 x 200 ml). The combined organic layers were dried over sodium sulfate and the volatiles were removed under reduced pressure giving a clear oil 10 (99%). The product was analysed by NMR and found to be VA-BDO b) 4-(6-isocyanatohexylcarbamoyloxy)butyl 2-propylpentanoate 15 0 0 C II 0 ~ N N 0 H Solution A: 4-hydroxybutyl 2-propylpentanoate (VA-BDO) ( 10.4518g 48.3) mmol) was dried under vacuum and placed in a dried flask fitted with a magnetic stir bar and closed 20 with a subaseal. The flask was also fitted with a dry nitrogen gas purge line. Approximately 100 mL of chloroform which had been previously dried over molecular sieve was introduced to the flask. Solution B. hexamethylene diisocyanate (HDI) ( 7.9001g 47.0 mmol) which had been 25 distilled under vacuum was placed in a round bottom flask fitted with a magnetic stir bar and closed with a subaseal. The flask was also fitted with a dry nitrogen gas purge line.
WO 2010/040188 PCT/AU2009/001342 - 89 Approximately 120 mL of chloroform which had been previously dried over molecular sieve was introduced to the flask. Additionally 5 drops of Tin 2-ethyl hexanoate was added to the flask as a catalyst. 5 The content of Solution A was slowly added over a 15 minute period to Solution B with stirring. The mixture was stirred overnight at room temperature under dry nitrogen. The reaction mixture / solvent = Solution C 10 A 10 mL subsample was removed and the chloroform removed by under vacuum by rotovap. The compound was analysed by NMR in CDCl3 and found to contain a high proportion of 4-(6-isocyanatohexylcarbamoyloxy)butyl 2-propylpentanoate (VA-BDO HDI.) 15 c) Mixture of 1,2-dihydroxy-5,14-dioxo-4,15-dioxa-6,13-diazanonadecan-19-yl 2 propylpentanoate and 1-hydroxy-2-(hydroxymethyl)-4,13-dioxo-3,14-dioxa-5,12 diazaoctadecan- 1 8-yl 2-propylpentanoate H OH N N Y 0H 0 H O 0 H OH SN N Y0, , OH 20 0 H 0 The remaining amount if Solution C from was added slowly over 15 mins to Solution D which consisted of glycerol ( 4.4499g 48.3 mmol) which was dried overnight at 11 OC under vacuum) and 100 mL dried chloroform. 25 WO 2010/040188 PCT/AU2009/001342 - 90 The amount of glycerol in solution D was adjusted to give a 1:1 mole ratio of VA-BDO HDI to Glycerol, with a slight excess of glycerol. The solution was stirred for 24 hours at 90C under a nitrogen purge. At various 5 timepoints 4 Ml samples were removed and the chloroform was removed by rotovap and the products were analysed by NMR. Once high conversion was confirmed by NMR the solution was cooled, more chloroform added to make up to 200mL and and extracted with water (pH 5, 3 x 200 ml). The 10 combined organic layers were dried over sodium sulfate and the volatiles were removed under reduced pressure giving a white solid A subsample was dissolved in d-DMSO for analysis by NMR. The sample appears to be a mixture of SNI and SN2 coupling of the VA-BDO-HDI to Glycerol. 15 The product was dried and stored under nitrogen for use in the production of polymers. Ciprofloxacin (1-cyclopropyl-6-fluoro-4-oxo-7-[4'-N-[(tert-butyloxy) carbonyllpiperazini-1-yi-quinoline-3-carboxylic acid) 20 Example 4:. Ciprofloxacin Monoglyceride (2,3-dihydroxypropyl 1-cyclopropyl-6-fluoro-4 oxo-7-(piperazin- I -yl)- 1,4-dihydroquinoline-3 -carboxylate) a) 7-(4-(benzyloxycarbonyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4 25 dihydroquinol ine-3 -carboxy lic acid 0 NN NO HO F 0 0 WO 2010/040188 PCT/AU2009/001342 -91 Ciprofloxacin (1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl)-1,4-quinoline-3-carboxylic acid (0.33 g, 1.0 mmol), was taken up in 2N NaOH solution (10 ml) and cooled to 0 0 C (ice/water bath). Benzyloxycarbonyl chloride (0.40 ml, 0.48 g, 2.8 mmol) was added 5 dropwise. The reaction mixture was stirred at 0 0 C for 1 h and then gradually warmed to room temperature and stirred for another 16 h. After that the reaction mixture was brought to pH 5 through dropwise addition of 2N HCL solution. The reaction mixture was extracted with CHC1 3 (3 x 50 ml). The combined organic layers were dried over Na 2
SO
4 and the solvent was removed under reduced pressure. The crude product was purified through 10 crystallisation from acetonitrile to give a colourless solid (0.23 g, 0.49 mmol, 49 %) 'H-NMR (CDCla, 400 MHz): 6[pm]= 8.78 (s, 1H, H-2); 8.10-8.00 (in, 1H, H-5); 7.44 7.28 (in, 6H, I H of H-8+5H of ArH); 5.17 (s, 2H, ArCi); 3.81-3.63 (m, 4H, 2xCH 2 of piperazine); 3.56-3.46 (in, 1H of cyclopropane); 3.38-3.23 (m, 4H, 2xCH 2 of piperazine); 15 1.44-1.33 (m. 2H, CH 2 of cyclopropane); 1.24-1.13 (in, 2H, CH 2 of cyclopropane) b) (2,2-dimethyl-1,3-dioxolan-4-yl)methyl 7-(4-(benzyloxycarbonyl)piperazin-1-yl)-1 cyclopropyl-6-fluoro-4-oxo- 1,4-dihydroquinoline-3 -carboxylate 0 7 N N O Y O F 20 0 0 7-(4-(benzyl oxycarbony l)piperazin- 1-yl)-l -cyclopropyl-6-fluoro-4-oxo- 1,4 dihydroquinoline-3-carboxylic acid (0.47 g, 1.0 mmol) was dissolved in anhydrous CH 2 C1 2 (47 ml) under argon. 2,2-dimethyl-1,3-dioxolane-4-methanol (0.20 g, 1.5 mmol) 25 triethylamine (0.40 g, 4.0 mmol) and 0-benzotriazol-1-yl-N, N, N', N'-trimethyluronium hexafluorophosphate (0.42 g, 1.1 mmol) were added successively. The reaction mixture was stirred under argon for 72 h. The reaction mixture was washed with saturated NaHCO 3 WO 2010/040188 PCT/AU2009/001342 - 92 solution (1 x 50 ml), water (1 x 50 ml) and dried over Na 2
SO
4 . The organic solvent was removed under reduced pressuregiving a pale, pink solid (0.54 g, 0.93 mmol, 93 %). 'H-NMR (CDCI, 400 MHz): S[pm]= 8.56 (s, 1H, H-2); 8.10-7.97 (in, IH, H-5); 7.42 5 7.13 (in, 6H, 5xArH+lH of H-8); 5.16 (s, 2H, ArCH 2 0); 4.52-4.40 (in, 1H, CH); 4.40-4.30 (in, 2H, IH of CH 2 0+1H of CH 2 0); 4.08-3.96 (in, 1H, 1H of CH 2 O); 3.86-3.81 (in, 1H, 1H of CH 2 0); 3.62-3.51 (in, 4H, 2xCH 2 of piperazine); 3.37-3.33 (in, 1H, CH of cyclopropane); 3.31-3.14 (in, 4H, 2xCH 2 of piperazine); 1.44 (s, 3H, CH 3 ); 1.36 (s, 3H,
CH
3 ); 1.34-1.26 (m, CH 2 of cyclopropane); 1.26-1.03 (m, CH 2 of cyclopropane) 10 MS (MeCN) 580 [M+1] 602 [M+23] c) 2,3-dihydroxypropyl 7-(4-(benzyloxycarbonyl)piperazin-1-yl)-l-cyclopropyl-6-fluoro 4-oxo-1,4-dihydroquinoline-3-carboxylate 15 0 OHN HO,, O O F 0 0 (2,2-dimethyl-1,3-dioxolan-4-yl)methyl 7-(4-(benzyloxycarbonyl)piperazin-1-yl)-1 cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (2.85 g, 4.9 mmol) was 20 dissolved in 95 % aqueous ehanol (100 ml). After addition of amberlyst 15 (wet) ion exchange resion and anti bumping granulates the reaction mixture was refluxed for 5 h. The ion exchange resion and the bumping-granulates were removed through filtrationand the solvent was removed under reduced pressure to give the crude product as a yellow solid. The crude product was purified through column chromatography (A1 2 0 3 1% MeOH 25 in CHCl 3 ) to yield the pure product as a pale yellow solid (1.66 g, 63 %).
WO 2010/040188 PCT/AU2009/001342 - 93 'H-NMR (CDCl 3 , 400 MHz): 6[pm]= 8.52 (s, 1H, H-2); 7.97-7.77 (m, 1H, H-5); 7.67 7.51 (m, I H, H-8); 7.51-7.26 (m, 5H, ArH); 5.17 (s, 2H, ArCH 2 ); 4.52-4.16 (m, 2H, 1H of
CH
2 O+1 H of CH 2 O); 3.97-3.82 (m, 1H, CHO); 3.82-3.43 (m, 6H, 4H of 2xCH 2 piperazine+1 H of CH 2 O+1H of CH cyclopropane); 3.19-2.98 (m, 4H, 2xCH 2 piperazine); 5 1.53-1.00 (m, 4H, 2xCH 2 cyclopropane) MS (MeCN) 540 [M+1] 562 [M+23] d) 2,3-dihydroxypropyl 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4 10 dihydroquinoline-3-carboxylate NH OHN N HO O F 0 0 '3 -dihydroxypropyl 7-(4-(benzyloxycarbonyl)piperazin-1-yl)-l-cyclopropyl-6-fluoro-4 15 oxo-1,4-dihydroquinoline-3-carboxylate (1.66 g, 3.1 mmol) was dissolved in ethanol (100 nl). Hydrogenation in a Thales Nano H-Cube Hydrogenator (10 % Pd/C cartridge, 11 bar) and evaporation of the organic solvent gave the crude product as a yellow solid. Crystallisation from acetone gave the crude product as a colourless solid (0.71 g, 57 %). 20 'H-NMR (d 6 -acetone). 500 MHz): S[pm] = 8.72 (s, 1H, H-2); 7.91-7.80 (m, 1H, H-5); 7.55-7.43 (m. I H, H-8); 4.42-4.20 (m, 2H, 1H of CH 2 0+1H of CH 2 O); 4.00-3.90 (m, 1H, CH); 3.82-3.75 (m, I H, I H of CH 2 O); 3.70-3.5 (m, 6H, 4H of 2xCH 2 piperazine+1H of
CH
2 0+1H CH of cyclopropane); 3.15-3.02 (m, 4H, 2xCH 2 of piperazine); 1.48-1.30 (m, 2H, CH 2 of cyclopropane); 1.25-1.10 (m, 2H, CH 2 of cyclopropane 25 MS (MeCN) 406 [M+1] 428 [M+23] WO 2010/040188 PCT/AU2009/001342 - 94 Example 6: 2,3-dihydroxypropyl I -cyclopropyl-6-fluoro-4-oxo-7-(4-propylpiperazin-1-yl) 1,4-dihydroquinoline-3-carboxylate a) 1-cyclopropyl-6-fluoro-4-oxo-7-(4-propylpiperazin-1-yl)-1,4-dihydroquinoline-3 5 carboxylic acid N HO 0 0 1 -cyclopropyl-6-fluoro-4-oxo-7-(piperazin- 1-yl)-1,4-dihydroquinoline-3-carboxylic acid 10 (5.00 g, 15.10 mmol) was taken up in dioxane/water (1:1, 100 ml). 1-iodopropane (3.08 g, 18.10 mmol), and sodiumhydrogencarbonate (3.81 g, 45.30 mmol) was added and heated at 80 'C for 16 h, The crude reaction mixture was cooled to room temperature and acidified with 1 M HCI to pH 6. The reaction mixture was extracted with chloroform (3 x 100 ml), the combined organic layer were dried over sodium sulfate and the volatiles were 15 removed under reduced pressure yielding 3.87 g (69 %) of pure product. 'H-NMR (CDC1 3 , 400 MHz): 6[pm] = 8.77 (s, 1H, H-2); 8.07-7.97 (m, 1H, H-5); 7.41 7.30 (m, I H, H-8); 3.57-3.46 (in, CH of cyclopropane ring); 3.41-3.24 (m, 4H, 2xCH 2 of piperazine); 2.74-2.58 (m, 2xCH 2 of piperazine); 2.44-2.33 (m, 2H, CH 2 N); 1.65-1.45 (m, 20 2H, CH 2 ); 1.45-1.28 (in, 2H, CH 2 of cyclopropane ring); 1.28-1.12 (in, 2H, CH 2 of cyclopropane ring); 0.94 (t, 3H, CH 3 ) MS (CH 2
CI
2 ) 374 [M+1] 747 [2M+1] 25 b) (2,2-dimethyl-1,3-dioxolan-4-yl)methyl 1-cyclopropyl-6-fluoro- 4 -oxo- 7
-(
4 propylpiperazin- 1-yl)-I1,4-dihydroquinoline-3 -carboxylate WO 2010/040188 PCT/AU2009/001342 - 95 N 0 N~ N, 0 0 1-cyclopropyl-6-fluoro-4-oxo-7-(4-propylpiperazin-1-yl)-1,4-dihydroquinoline-3 carboxylic acid (8.86 g, 23.70 mmol) was dissolved in anhydrous dichloromethane (370 5 ml) under argon. 2,2-dimethyl-1,3-dioxolane-4-methanol (4.71 g, 35.60 mrnol), triethylamine (9.59 g, 94.80 mmol) and HBTU (9.90 g, 26.10 mmol) were added and the reaction mixture was stirred at room temperature for three days (exclusion of light). The reaction mixture was washed with saturated NaHCO 3 solution (500 ml), aqueous (pH 5) hydrochloric acid (500 ml) and water (500 ml) successively. The organic layer was dried 10 over Na 2
SO
4 and the solvent was removed under reduced pressure, yielding 10.28 g (89 %) of a yellow solid. 'H-NMR (CDCl 3 , 400 MHz): S[pm] = 8.53 (s, 1H, H-2); 8.09-7.95 (m,1H, H-5); 7.32 7.17 (m, H-8); 4.51-4.41 (m, I H, CH); 4.41-4.31 (m, 2H, 1H of CH 2 0+ 1H of CH 2 0); 15 4.19-4.09 (m, 1H, CH 2 0); 3.98-3.86 (m, 1H, CH 2 O); 3.50-3.36 (m, 1H of cyclopropane ring); 3.36-3.15 (m, 4H, 2xCH 2 of piperazine); 2.76-2.61 (m, 4H, 2xCH 2 of piperazine); 2.49-2.31 (m, 2H, CH 2 N); 1.72-1.48 (m, 2H, CH2_CHZCH 3 ); 1.44 (s, 3H, CH 3 ), 1.36 (s, 3H,
CH
3 ); 1,33-1.25 (m, 2H, CH 2 of cyclopropane); 1.16-1.03 (m, 2H, CH 2 of cyclopropane); 0.93 (t, 3H, CH 3 ) 20 c) 2,3-dihydroxypropyl 1-cyclopropyl-6-fluoro-4-oxo-7-(4-propylpiperazin-1-yl)-1,4 dihydroquinoline-3-carboxylate 7 r N OOH N 205 25 WO 2010/040188 PCT/AU2009/001342 - 96 (2,2-dimethyl-1,3-dioxolan-4-yl)methyl 1-cyclopropyl-6-fluoro-4-oxo-7-( 4 propylpiperazin- 1-yl)-1,4-dihydroquinoline-3 -carboxylate (2.45 g, 5.03 mmol) was dissolved in anhydrous dichloromethane (245 ml) under argon. A 1 M solution of boron trichloride in dichloromethane (6.3 ml, 6.30 mmol) was added dropwise and the reaction 5 mixture was stirred at room temperature for 1 h. Methanol (25 ml) was added to the reaction mixture and the volatiles were removed under reduced pressure. The crude product was purified through flash column chromatography (5% MeOH in CHCl 3 ) giving a yellow oil (1.58 g, 3.53 mmol, 70 %), 10 MS (MeOH): 448.3 [M+1] Levofloxacin (9-fluoro-3-methyl- 10-(4-methylpiperazin-1-yl)-7-oxo-3,7-dihydro-2H [1,4]oxazino[2,3,4-ijiquinoline-6-carboxylic acid 15 Example 7: 2,3-dihydroxypropyl 9-fluoro-3-methyl-10-(-4-methylpiperazin-1-yl)-7-oxo 3,7-dihydro-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylate a) (2,2-dimethyl-1,3-dioxolan-4-yl)methyl 9-fluoro-3-methyl-10-(4-methylpipirazin-1-yl) 7-oxo-3 ,7-dihydro-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylate 20 N N ~ F 0 00 (9-fluoro-3 -methyl-10-(4-methylpiperazin-1-yl)-7-oxo-3,7-dihydro-2H-[1,4]oxazino[2,3,4 ij]quinoline-6-carboxylic acid (10.00 g, 27.7 mmol), was dissolved in CH 2 Cl 2 (500 ml) 25 under argon. 2,2-dimethyl-1,3-dioxolane-4-methanol (5.49 g, 41.5 mmol) triethylamine (11.21 g, 110.8 mmol) and O-benzotriazol-1-yl-N, N, N', N'-trimethyluronium hexafluorophosphate (11.56 g, 30.5 mmol) were added successively. The reaction mixture was stirred under argon for 72 h. The reaction mixture was washed with saturated NaHCO 3 WO 2010/040188 PCT/AU2009/001342 - 97 solution (1 x 500 ml), water (1 x 50 ml) and dried over Na 2
SO
4 . The organic solvent was removed under reduced pressuregiving a white solid. The crude product was crystallized from acetonitrile giving the product in 44 % yield (5.81 g). 5 'H-NMR (CDCl 3 , 400 MHz): S[pm] = 8.29 (s, 1H, H-5); 7.65 (m, 1H, H-8); 4.53-4.41 (m, IH, CH); 4.41-4.25 (m, 5H, 1H of CH 2 0, 1H of CH 2 0, 2H of CH 2 0, 1H of CHN); 4.21-4.09 (m. IIH, I H of CH 2 0); 3.96-3.85 (m, IH of CH 2 0); 3.43-3.23 (m, 4H, 2xCH 2 piperazine); 2.65-2.45 (m, 4H 2xCH 2 piperazine); 2.36 (s, 3H, NCH 3 ); 1.58 (d, 3H, CH 3 ); 1.44 (s, 3H, CH 3 ), 1.37 (s, 3H, CH 3 ). 10 MS (EtOH) 475 [M+1]. b) 4-(6-((2,3-dihydroxypropoxy)carbonyl)-9-fluoro- 3 -methyl-7-oxo-3,7-dihydro-2H [1,4]oxazino[2,3,4-ij]quinolin-10-yl)-1-methylpiperazin-1-ium 2,2,2-trifluoroacetate 15 H N N 0 OH HO O ./ F F 3 C 0 00 (2,2-dimethyl-1,3-dioxolan-4-yl)methyl 9-fluoro-3-methyl-10-(4-methylpipirazin-1-yl)-7 oxo-3,7-dihydro-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylate (1.00 g, 2.1 mmol), was 20 dissolved in CH 2 Cl 2 (42 ml) under argon and cooled to 0 0 C. Trifluoro acetic acid (2.00 ml, 2.96 g, 26.0 mmol) was added and the reaction mixture was allowed to stir at 0 0 C for 4 h and then over night at room temperature. The reaction mixture was flushed through a plug of A1 2 0 3 (10% MeOH in CHCl 3 ) (2x). After that the organic solvents were collected and removed under reduced pressure giving the product as a yellow gum (0.24 g, 104 %). 25 'H-NMR (CDCl 3 , 400 MHz): S[pm] = 8.76 (s, H-5); 7.63-7.50 (m, H-8); 4.74-4.61 (m, IH, H-3 of benzoxazine ring); 4.61-4.50 (m, IH, NHCHCHO); 4.50-4.33 (m, 2H, 1H of
NHCHCH
2 O+IH of CH 2 OCO); 4.33-4.24 (m, 1H, CH 2 OCO); 4.03-3.93 (m, 1H, CHOH); WO 2010/040188 PCT/AU2009/001342 - 98 3.73-3.53 (m, 6H, 2xCH 2 piperazine +CH20H); 3.43-3.22 (m, 4H, 2xCH 2 piperazine); 3.01 (s, 3H, +NHCH 3 ); 1.55 (d, 3H, CH 3 ). NIS (MeOH) 436 [M+ 1]; 458 [M+23] 5 c) 2,3-dihydroxypropyl 9-fluoro-3-methyl-10-(-4-methylpiperazin-1-yl)-7-oxo-3,7 dihydro-2H- [1,4]oxazino[2,3,4-ij]quinoline-6-carboxylate N O N OH N N HO O ' F 10 4-(6-((2,3 -dihydroxypropoxy)carbonyl)-9-fluoro- 3 -methyl-7-oxo-3,7-dihydro-2H [1,4]oxazino[2,3 ,4-ij]quinolin-10-yl)-1-methylpiperazin-1-ium 2,2,2-trifluoroacetate (0.50 g, 0.91 mmol) was dissolved in methanol under argon and cooled to 0 0 C (ice/salt bath). 1 equiv. of NaOH dissolved in methanol (25 ml) was added slowly until the solution reached 15 pH 7 - pH 8. The reaction mixture was passed through a plug of A1 2 0 3 (10% MeOH in CHCl 3 ). The organic solvent was removed under reduced pressure giving a yellow solid (0.35 g, 88 %) 'H-NMR (CDCl 3 , 400 MHz): 6[pm]= 8.67 (s, H-5); 7.56-7.40 (m, H-8); 4.71-4.56 (m, 20 IH, H-3 of benzoxazine ring); 4.56-4.33 (m, 3H, 2H of NHCHCHO+1H of CH 2 0CO); 4.33-4.21 (m, 1H, CH 2 OCO); 4.02-3.91 (m, 1H, CHOH); 3.57-3.52 (m, 2H, CH 2 OH); 3.52-3.34 (m, 4H, 2xCH 2 piperazine);'2.85-2.
56 (m, 4H, 2xCH 2 piperazine); 2.43 (s, 3H,
NHCH
3 ); 1.52 (d, 3H, CH 3 ). 25 MS (MeOH) 436 [M+1] 458 [M+23] Example 8: (S)-1,3-dihydroxypropan-2-yl 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl) 7-oxo-3,7-dihydro-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylate WO 2010/040188 PCT/AU2009/001342 -99 a) (S)-2-phenyl-1,3-dioxan-5-y1 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-3,7 dihydro-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylate
H
3 C O N N N 0 F S 0 0 5 (S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-3,7-dihydro-2H-[1,4] oxazino [2,3,4-ij] quinoline-6-carboxylic acid (4.18 g, 11.56 mmol) was dissolved in anhydrous dichloromethane (210 ml) under argon. 1,3-0-benzylideneglycerol (2.50 g, 13.67 mmol), 10 triethylamine (4.68 g, 46.24 mmol) and HBTU (4.38 g, 11.56 mmol) were added successively. The reaction mixture was stirred at room temperature (exclusion of light) for 3 days. The reaction mixture was washed with saturated NaHCO 3 solution (500 ml), aqueous (pH 5) hydrochloric acid (500 ml) and water (500 ml) successively. The organic layer was dried over Na 2
SO
4 and the solvent was removed under reduced pressure. The 15 crude product was purified through flash column chromatography (Si02/10 % MeOH in CHC1 3 ) yielding 4.32 g, 71 %) of a yellow, crystalline solid. 'H-NMR (CDCI 3 , 400 MHz): S[pm] = 8.22 (s, IH, H-5); 7.64-7.52 (m, 1H, H-8); 7.46 7.31 (m,4H, ArH); 7.10 (d, lH, ArH); 5.65 (s, 1H, CHOCO); 4.91 (s, 1H, ArCH); 4.64 20 4.01 (m, 7H, 1H of CH{N+2H of CH 2 0+4H of 2xCH 2 0); 3.38-3.22 (m, 2xCH 2 of piperazine ring); 2.62-2.43 (in, 4H, 2xCH 2 of piperazine ring); 2.36 (s, NCH 3 ); 0,95 (d, 3H,
CHCH
3 ) MS (MeOH) 524 [M+1] 546 [M+23] 25 b) (S)-1,3-dihydroxypropan-2-yl 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo 3,7-dihydro-2H-[ 1,4]oxazino [2,3,4-ij]quinoline-6-carboxylate WO 2010/040188 PCT/AU2009/001342 - 100 H 3 C O N N N HO F 0 00 HO (S)-2-phenyl-1,3-dioxan-5-yl 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-3,7 5 dihydro-2H- [1,4]oxazino [2,3,4-ij ]quinoline-6-carboxylate (0.50 g, 9.55 mmol), was dissolved in a mixture of dichloromethane/methanol (2:1.5, 87.5 ml) under argon. Palladium catalyst (10 wt % Pd/C) (180 mg) was added, the flask was evacuated and allowed to stir 1 atm of hydrogen gas at room temperature for 16 hours. The crude reaction mixture was passed through a glass microfiber on a sintered funnel. The volatiles were 10 removed under reduced pressure yielding 370 mg (88%) of a yellow gum 'H-NMR (CDC1 3 , 400 MHz): 6[pm]= 8.72 (s, 1H), 7.57 (dd, 1H, J' = 12.6 Hz, J 2 = 1.8 Hz), 4.67-4.60 (m, IH), 4.55-4.49 (m, 1H), 4.41-4.35 (m, 2H), 4.31-4.25 (m, 1H), 4.00 3.92 (m, 1H), 3.69-3.63 (m, 2H), 3.46-3.33 (m, 4H), 2.71-2.60 (m, 4H), 2.40 (s, 3H), 1.53 15 (d, 3H, J=6.8 Hz) Benzocaine (ethyl 4-aminobenzoate) Example 9: Ethyl 4-((1,3-dihydroxypropan-2-yloxy)carbonylamino)benzoate 20 a) 2-phenyl-1,3-dioxan-5-yl carbonochloridate 0 Cl O 0 WO 2010/040188 PCT/AU2009/001342 - 101 Triphosgene (bis(trichloromethyl)carbonate (13.35 g, 45.0 mrnmol) was added under argon at room temperature to a solution of 1,3-O-benzylideneglycerol (18.02 g, 100.0 mmol) in dry CH 2 Cl 2 (300 ml). The reaction mixture was cooled to -40'C and a solution of pyridine (10.9 ml, 135.0 mmol) was added over 35 min under stirring. Upon completion of the 5 addition the reaction mixture was stirred for 30 min at -40'C. Then it was allowed to warm to 0 0 C over 60 min and subsequently warmed to rt over 3.5 h under stirring. The reaction product was used in the next step without any further purification 'H-NMR (CDCl 3 , 400 MHz): 6[pm] = 7.42-7.33 (in, 2H), 7.31-7.21 (in, 3H), 5.50 (s, 10 1 H), 4.72-4.70 (in, IH), 4.34-4.28 (m, 2H), 4.18-4.09 (in, 2H) b) Ethyl 4-((2-phenyl- 1,3 -dioxan-5 -yloxy)carbonylamino)benzoate 0 0 0 ~ N 0 H 15 Ethyl 4-aminobenzoate (benzocaine) (16.53 g, 0.10 mol) was dissolved in dry CH 2
CI
2 (160 ml) under argon. The reaction mixture was cooled to 0 0 C and triethylamine (16.7 ml, 0.12 mol) was added. 2-phenyl-1,3-dioxan-5-yl carbonochloridate (224.27 g, 0.10 mol) (as a solution in 300 ml CH 2 Cl 2 - obtained in the previous reaction step) was added gradually 20 over 40 min. The reaction mixture was stirred for 1 h at 0 0 C and then gradually warmed to room temperature and allowed to stirr over night. The crude reaction mixture was was washed with I M aqueous HC (2 x 300 ml), saturated NaHCO 3 solution (2 x 300 ml) and water (2 x 300 ml) successively. The organic layer was dried over Na 2
SO
4 and the solvent was removed under reduced pressure. The crude product was purified through flash 25 column chromatography (SiO 2 /CHCl 3 ) yielding (25.9 g, 70.0 mmol, 71 %) of a colourless crystalline solid.
WO 2010/040188 PCT/AU2009/001342 - 102 'H-NMR (CDCl 3 , 400 MHz): 8[pm] = 8.00 (d, 2H, J = 8.8 Hz), 7.55-7.50 (m, 2H), 7.44 (d, 2H, J = 8.8 Hz), 7.41 -7.36 (m, 3H), 7.11 (s, 1H), 5.62 (s, 1H), 4.41-4.33 (m, 4H), 4.25 4.22 (m, 2H), 1.38 (tr, 3H, J = 7.1 Hz) 5 c) Ethyl 4-((1 ,3-dihydroxypropan-2-yloxy)carbonylamino)benzoate 0 O OH N O HOH H Ethyl 4-((2-phenyl- 1,3- dioxan-5-yloxy)carbonylamino)benzoate (4.70 g, 12.7 mmol) was 10 dissolved in ethanol (500 ml) under argon and Pd/C (2.48 g, 2.3 mmol) was added. The flask was flushed with hydrogen and allowed to stirr under I atm H 2 at room temperature for 16 h. The crude reaction mixture was passed through a plug of celite and the solvent was removed under reduced pressure yielding (3.14 g, 11.2 mmol, 88 %). The product was used without any further purification. 15 'H-NMR (CDCl 3 , 400 MHz): 6[pm] = 8.00 (d, 2H, J = 8.8 Hz), 7.46 (d, 2H, J = 8.8 Hz), 7.17 (s, 1H), 4.97-4.93 (m, 1H), 4.35 (quart, J = 7.1 Hz), 3.99-3.86 (m, 4H), 2.62-2.11 (br, 2H), 1.38 (tr, 3H, J = 7.1 Hz) 20 Menthol (1R,2S,5R)-2-isopropyl-5-methyleyclohexanol) Example 10: (1R,2S,5R)-2-isopropyl-5-methyleyclohexyl 2,3-dihydroxypropanoate a) Sodium (R)-(+)-2,2-dimethyl-1,3-dioxolane-4-carboxylate 25 0 O 0 Na 00(D( WO 2010/040188 PCT/AU2009/001342 - 103 Methyl (R)-(+)-2,2-dimethyl-1,3-dioxolane-4-carboxylate (1.00 g, 6.2 mmol) was dissolved in 80 % aqueous 1,4-dioxane. 1.2 M aqueous NaOH solution was added (5.2 ml) and the reaction mixture was stirred at room temperature for 3 h. After that the solvents were removed under reduced pressure and a colourless solid was obtained (1.03 g, 6.1 5 mmol, 98 %). The product was used immediately in the next reaction step without further purification. b) (R)-(+)-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid 0 00 OH 10 0 Sodium (R)-(+)-2,2-dimethyl-1,3-dioxolane-4-carboxylate (1.03 g, 6.1 mmol) was dissolved in a mixture of water (1.2 ml) and ethyl acetate (1.2 ml) and cooled to 0 0 C. 2 M aqueous H 3
PO
4 solution (7 ml) was added until the reaction mixture reached pH 2. After 15 that the reaction mixture was saturated with NaCL and the reaction mixture was extracted withethyl acetate (3 x 20 ml). The organic layer was dried over Na 2
SO
4 and the solvent was removed under reduced pressure. The product (0.73 g, 4.9 mmol, 81 %) was used in the next step without any further purification. 20 'H-NMR (CDCl 3 , 400 MHz): S[pm] = 8.99-8.13 (br, 1H), 4.64-4.61 (m, 1H), 4.32-4.25 (m, 1H), 4.22-4.17 (in, I H), 1.52 (s, 3H), 1.41 (s, 3H) c) (1 R,2S,5R)-2-isopropyl-5-methylcyclohexyl 2,2-dimethyl-1,3-dioxolane-4-carboxylate
CH
3 00 25 WO 2010/040188 PCT/AU2009/001342 - 104 (R)-(+)-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid (2.86 g, 19.6 mmol) was dissolved in anhydrous CH 2
CI
2 (120 ml) under argon. Menthol (1R,2S,5R)-2-isopropyl-5 methylcyclohexanol) (3.67 g, 23.5 mmol), triethylamine (7.93 g, 78.4 mmol) and 0 benzotriazol-1-yl-N, N, N', N'-trimethyluronium hexafluorophosphate (8.18 g, 21.6 mmol) 5 were added successively. The reaction mixture was stirred under argon for 72 h. The reaction mixture was washed with saturated NaHCO 3 solution (3 x 50 ml), aqueous HCI (pH 5) (3 x 50 ml) and water (3 x 50 ml) and dried over Na 2 S04. The organic solvent was removed under reduced pressuregiving a yellow oil. (0.54 g, 0.93 mmol, 93 %). The crude product was purified through flash column chromatography (SiO 2 /15% - 25% graduent of 10 ethyl acetate in hexane) yielding 3.16 (11.2 mmol, 57 %) of a yellow oil. 'H-NMR (CDCl 3 , 400 MHz): 6[pm]= 4.82-4.69 (m, 1H), 4.59-4.50 (m, 1H), 4.25-4.18 (m, 1H), 4.10 -4.01 (m, IH), 2.03-1.94 (m, IH), 1.89-1.77 (m, 1H), 1.70-1.62 (m, 2H), 1.55-1.35 (m, 8H), 1.09-0.95 (m, 2H), 0.92-0.79 (m, 7H), 0.74 (d, J= 7.0 Hz) 15 d) (1 R,2S,5R)-2-isopropyl-5-methylcyclohexyl 2,3-dihydroxypropanoate
CH
3 ' 0 O 0 OH 20 (1 R,2S,5R)-2-isopropyl-5-methylcyclohexyl 2,2-dimethyl-1,3-dioxolane-4-carboxylate (1.00 g, 35.2 rnrnol) was dissolved in 98 % aqueous ethanol (10 ml). Amberlyst 15 (wet) ion exchange resin (0.30 g) and bumping granulate were added. The reaction mixture was refluxed for 4 h without stirring (under argon). After that, the reaction was brought to room temperature, the resin and bumping granulate were removed and the solvent was removed 25 under reduced pressure. The product was obtained in quantitative yield (0.94 g) WO 2010/040188 PCT/AU2009/001342 - 105 'H-NMR (CDC1 3 , 400 MHz): S[pm] = 4.86-4.74 (m, 1H),4.26-4.19 (m, 1H), 3.92-3.87 (m, 1IH), 3.85-3.79 (m, IH), 3.25-3.14 (m, 1H), 2.22-2.08 (m, 1H), 2.06-1.96 (m, 1H), 1.93-1.79 (m, 1IH), 1.74-1.65 (m, 2H), 1.56 5 Example 11: 1,3-dihydroxypropan-2-yl (2S,5R)-2-isopropyl-5-methylcyclohexyl phosphonate a) Dichloro((I R,2S,5R)-2-isopropyl-5-methylcyclohexyloxy)phosphine OPC1 2 10 The phosphorus trichloride (56.0ml, 87.89g, 0.640mol) was added to dichloromethane (anhydrous) under argon gas to obtain a solution. The solution was cooled to -30 0 C and (-) menthol (1 R,2S,5R) (10.00g, 0.0640mol) was added portion wise over 10mins. The 15 solution was allowed to warm to ambient temperature and was allowed to stir at ambient temperature for 16 hours. The solvent was removed in vacuo to obtain a colourless oil (1 6.46g). The crude product was used directly in the subsequent step. 20 b) (2S,5R)-2-isopropyl-5-methylcyclohexyl 2-phenyl-1,3-dioxan-5-yl phosphonate
OH
3 0" o' 'O The dichloro(2S,5R)-2-isopropyl-5-methylcyclohexyloxyphosphine (8.23g, 0.0320mol) 25 was dissolved in dichloromethane (anhydrous) (100ml) under argon gas. Cooled to OUC.
WO 2010/040188 PCT/AU2009/001342 - 106 Added a solution of cis-l,3-benzylideneglycerol (7.21g, 0.0400mol) and tert-butanol (2.97g, 0.040mol) (1:1) in dichloromethane (anhydrous) dropwise over 30 mins. Then added triethylamine (8.9ml, 6.47g, 0.0640mol) dropwise. Allowed to stir at 0 0 C for 1 Omins. And then allowed to gradually warm to ambient temperature. And removed 5 solvent in vacuo to obtain a colourless crystalline solid (26.67g). The crude product was chromatographed on silica gel using EtOc/pet spirit 60-80 to obtain the product fraction as a colourless oil (1.29g) 10 'H-NMR (CDCla, 400 MHz): 6[pm] = 7.93-7.92 (m, 0.5H, P-H), 7.58-7.29 (m, 5H), 6.17 6.16 (m, 0.5H, P-H), 5.56 (s, 1H), 4.53-3.98 (m, 6H), 2.31-1.89 (m, 3H), 1.88-0.57 (m, 15H) c) 1,3-dihydroxypropan-2-yl (2S,5R)-2-isopropyl-5-methylcyclohexyl phosphonate 15
CH
3 O O OH P-. OH * ' 0G The The dichloro(2S,5R)-2-isopropyl-5-methylcyclohexyl-2-phenyl-1,3-dioxan-5-yl phosphonate (0.97g; 2.54mmol) was dissolved in 80% (v/v) aqueous acetic acid (10ml) 20 and allowed to stir at 70 0 C for 3hrs. The solvent was removed in vacuo followed by pumping under high vacuum to obtain an oil (0.69 g, 2.37 mmol). 'H-NMR (CDCla, 400 MHz): 6[pm]= 7.89-7.87 (m, 0.5H, P-H), 6.01-5.89 (m, 0.5H, P H), 4.42-3.28 (m, 8H), 2.29-0.51 (m, 18H) 25 Phenol Example 12: 1,3-dihydroxypropan-2-yl phenyl succinate WO 2010/040188 PCT/AU2009/001342 - 107 a) 4-oxo-4-phenoxybutanoic acid 0 OH r 0 5 Phenol (1.88 g, 20.0 mmol) was dissolved in a solution of sodium carbonate (anhydrous) (1.06 g, 10.0 mmol) in water (20 ml) and cooled to 0 0 C. Succinic anhydrid (2.00 g, 20.0 mmol) was added and the suspension was allowed to stirr at 0 0 C for I h. The reaction mixture was gradually warmed to room temperature and stirred over night. The clear 10 solution was cooled to 0 0 C and acidified to pH 0 (addition of IM aqueous HCl). The reaction mixture was extracted with chloroform (3 x 25 ml), dried over Na 2
SO
4 , filtered and the solvent removed under reduced pressure to obtain a white solid (1.63 g, 8.4 mmol, 42%). The product was used without any further purification. 15 'H-NMR (CDCI, 200 MHz): S[pm]= 7.44-7.03 (m, 5H), 2.95-2.77 (m, 4H) b) Phenyl 2-phenyl-1,3-dioxan-5-yl succinate 20 00 20 4-oxo-4-phenoxybutanoic acid (1.00 g, 5.15 mmol) was dissolved in anhydrous CH 2
CI
2 (55 ml) under argon. Menthol 1,3-0-benzylideneglycerol (1.11 g, 6.18 mmol), triethylamine (2.09 g, 20.6 mmol) and 0-benzotriazol-1-yl-N, N, N', N'-trimethyluronium hexafluorophosphate (2.15 g, 5.67 mmol) were added successively. The reaction mixture 25 was stirred under argon for 72 h. The reaction mixture was washed with saturated NaHCO 3 solution (3 x 50 ml), aqueous HCl (pH 5) (3 x 50 ml) and water (3 x 50 ml) and dried over WO 2010/040188 PCT/AU2009/001342 - 108 Na 2
SO
4 . The organic solvent was removed under reduced pressuregiving a yellow oil. (0.54 g, 0.93 mmol, 93 %). The crude product was purified through flash column chromatography (SiO 2 /10 % MeOH in chloroform) yielding 0.98 g (2.58 mmol, 50 %) of a yellow solid. 5 'H-NMR (CDCI, 400 MHz): 8[pm] = 7.54-7.48 (in, 2H), 7.41-7.31 (in, 5H), 7.23-7.19 (m, 1H), 7.13-7.06 (in, 2H), 5.57 (s, 1H), 4.78 (in, 1H), 4.33-4.29 (m, 2H), 4.20-4.16 (in, 2H), 2.97-2.86 (in, 4H) 10 c) 1,3-dihydroxypropan-2-yl phenyl succinate OH 0 O OH - 0 Phenyl 2-phenyl-1,3-dioxan-5-yl succinate (0.11 g, 0.3 mmol) was dissolved in ethanol (20 15 ml) under argon and Pd/C (0.09 g, 0.1 mmol) was added. The flask was flushed with hydrogen and allowed to stirr under 1 atm H 2 at room temperature for 16 h. The crude reaction mixture was passed through a plug of celite and the solvent was removed under reduced pressure yielding (0.9 g, 0.26mmol, 89 %). The product was used without any further purification. 20 'H-NMR (CDCl 3 , 400 MHz): S[pm] = 7.43-7.33 (in, 2H), 7.25-7.21 (in, 1H), 7.12-7.05 (in, 2H), 4.97 (quint, I H, J = 4.4 Hz), 3.88-3.80 (in, 4H), 2.95-2.91 (m, 2H), 2.82-2.75 (in, 2H), 2.58-1.60 (br, 2H) 25 (6) Synthesis of the protected monoglyceride - linker-building blocks (a) Synthesis of protected monoglycerides with a diacid linker WO 2010/040188 PCT/AU2009/001342 - 109 0 0 OH O0 O 0 04 O 0k0 0 OH 1,3-Benzylideneglycerol and solketal ((2,2-dimethyl-1,3-dioxolan-4-yl)methanol) are each separately dissolved in organic solvent and each reacted with a diacid (succinic, glutaric, 5 adipic, pimelic, suberic, azelaic, sebacic) under appropriate conditions. (b) Synthesis of protected monoglycerides with an omega hydroxy acid linker 0 H 00 - 0 0OWH OD - n nH 10 1,3-Benzylideneglycerol and solketal are each separately dissolved in organic solvent and each reacted with an omega hydroxy acid under appropriate conditions. (c) Synthesis of protected monoglycerides with a chloroformate linker 15 CC 0 Hn n 0>4 -KO 0 0 n 1,3-Benzylideneglycerol and solketal are each separately dissolved in organic solvent and each reacted with an omega hydroxy acid under appropriate conditions. The product of this 20 conversion is reacted with triphosgene to give the protected monoglycerides with a chloroformate linker, (d) Synthesis of chloroformate functionalised protected monoglycerides WO 2010/040188 PCT/AU2009/001342 -110 0 ~ -C0 0 0 -- 11 0 1,3-Benzylideneglycerol and solketal are each separately dissolved in organic solvent and each reacted with triphosgene under appropriate conditions. 5 (7) Synthesis of the monoglyceride-linker-bioactive agent-conjugates (a) Coupling of hydroxy containing bioactive agents with protected monoglycerides with a diacid linker 0 HO 0 10 HO =- Bioactive agent A hydroxy containing bioactive agent - such as Codeine, Fluconazole, Latanoprost or Dexamethasone - (after conversion into a prodrug by protecting additional functional groups with appropriate bioerodable protection groups) is reacted with protected monoglycerides with a diacid linker, The monoglyceride protection groups are removed 15 under appropriate conditions giving the monoglyceride functionalised (at the primary or secondary alcohol positions of the glyceride) bioactive agent monomers. (b) Coupling of hydroxy containing bioactive agents with protected monoglycerides with an omega hydroxy acid linker 20 WO 2010/040188 PCT/AU2009/001342 -111 00 0 o~~ - o 0 H Bioactive agent HO0 A carboxy acid containing bioactive agent - such as Ciprofloxacin, Levofloxacin or Valproic acid - (after conversion into a prodrug by protecting additional functional groups 5 with appropriate bioerodable protection groups) is reacted with protected monoglycerides with a omega hydroxy acid linker. The monoglyceride protection groups are removed under appropriate conditions giving the monoglyceride functionalised (at the primary or secondary alcohol positions of the glyceride) bioactive agent monomers. 10 (c) Coupling of amine containing bioactive agents with protected monoglycerides with a chloroformate linker N H - 0 0 H2N Bioactive agent 15 An amine containing bioactive agent - such as Benzocaine - (after conversion into a prodrug by protecting additional functional groups with appropriate bioerodable protection groups) is reacted with protected monoglycerides with a chloroformate linker. The monoglyceride protection groups are removed under appropriate conditions giving the monoglyceride functionalised (at the primary or secondary alcohol positions of the WO 2010/040188 PCT/AU2009/001342 -112 glyceride) bioactive agent monomers. (d) Coupling of amine containing bioactive agents with chloroformate functionalised protected monoglycerides 5 0 HO OHO HO NH NH HO O O
H
2 N -- Bioactive agent An amine containing bioactive agent - such as Benzocaine - (after conversion into a prodrug by protecting additional functional groups with appropriate bioerodable protection 10 groups) is reacted with chloroformate functionalised protected monoglycerides. The monoglyceride protection groups are removed under appropriate conditions giving the monoglyceride functionalised (at the primary or secondary alcohol positions of the glyceride) bioactive agent monomers. 15 (e) Coupling of amine containing bioactive agent with carboxylic acid functionalised protected monoglyceride 0 HO H2N - --- Bioactive agent 20 An amine containing bioactive agent - such as Benzocaine - (after conversion into a prodrug by protecting additional functional groups with appropriate bioerodable protection groups) is converted into the corresponding isocyanate. Reaction of the isocyanate with a carboxylic acid functionalised protected monoglyceride produces (via release of C0 2 ) the WO 2010/040188 PCT/AU2009/001342 -113 corresponding aide derivative which is subsequently deprotected. f) Conversion of an amine containing bioactive agent to an aromatic carbamate containing functionalised protected monoglyceride 5 H H N 0 ~O' Y O N O XOH N 0 OH OH H2N- Bioactive agent An amine containing bioactive agent - after conversion into a prodrug by protecting additional functional groups with appropriate bioerodable protection groups - is converted 10 into the corresponding functionalised protected monoglyceride containing an aromatic carbamate. (8) Synthesis of bioactive agent-linker conjugates 15 (a) Synthesis of diacid-bioactive agent conjugates SHO Bioactive agent H O A hydroxy containing bioactive agent - such as Codeine, Fluconazole, Latanoprost or Dexamethasone - (after conversion into a prodrug by protecting additional functional groups with appropriate bioerodable protection groups) is reacted with a diacid or a diacid 20 derivative.
WO 2010/040188 PCT/AU2009/001342 -114 (b) Synthesis of acid/omega hydroxy-bioactive agent conjugates 00 0 0-H Bioactive agent n HO HO An carboxy acid containing bioactive agent - such as Ciprofloxacin, Levofloxacin or Valproic acid - (after conversion into a prodrug by protecting additional functional groups 5 with appropriate bioerodable protection groups) is reacted with an acid/omega hydroxy linker or a derivative thereof. (c) Synthesis of an acid/chloroformate-bioactive agent conjugates HN-Q H2N J - Bioactive agent HO 10 An amine containing bioactive agent - such as Benzocaine - (after conversion into a prodrug by protecting additional functional groups with appropriate bioerodable protection groups) is reacted with a an acid/chloroformate linker or a derivative thereof . d) Conversion of an carboxy acid containing bioactive agent to functionalised protected 15 monoglyceride containing a spacer group. 0 0 0 0 0 0 o o N O O 0 0 N N O OH ~ N )" HOOC == BHoaH ci a eOH U/UN/~N~J OH HOOC- -Q Bioactive agent WO 2010/040188 PCT/AU2009/001342 - 115 An carboxy acid containing bioactive agent - after conversion into a prodrug by protecting additional functional groups with appropriate bioerodable protection groups - is converted into the corresponding functionalised protected monoglyceride with a spacer group that can be modified to meet the required polymer properties and release kinetics. 5 e) Conversion of an alcohol containing bioactive agent to functionalised protected monoglyceride containing a spacer group. OH Q O O 'N NO OH O OUN*N)O OH OH 10 HO- = Bloactive agent An alcohol containing bioactive agent - after conversion into a prodrug by protecting additional functional groups with appropriate bioerodable protection groups - is converted into the corresponding functionalised protected monoglyceride with a spacer group that 15 can be modified to meet the required polymer properties and release kinetics. (9) Synthesis of monoglyceride-linker-bioactive agent-conjugates (a) Coupling of diacid-bioactive agent conjugates with protected monoglycerides WO 2010/040188 PCT/AU2009/001342 -116 0 Q0 0H0 HO OHO 0 HO n HO-O = Bioactive agent A diacid-bioactive agent conjugate, containing a bioactive agent such as Codeine, Fluconazole, Latanoprost or Dexamethasone - (after conversion into a prodrug by protecting additional functional groups with appropriate bioerodable protection groups) is 5 reacted with protected monoglycerides. The monoglyceride protection groups are removed under appropriate conditions giving the monoglyceride functionalised (at the primary or secondary alcohol positions of the glyceride) bioactive agent monomers. (b) Coupling of an omega hydroxy acid-bioactive agent conjugate with protected 10 monoglycerides 0 0 0 - a 0 HO -Bioactive agent An omega hydroxy acid-bioactive agent conjugate containing a bioactive agent - such as Ciprofloxacin, Levofloxacin or Valproic acid - (after conversion into a prodrug by protecting additional functional groups with appropriate bioerodable protection groups) is 15 reacted with protected monoglycerides. The monoglyceride protection groups are removed under appropriate conditions giving the monoglyceride functionalised (at the primary or secondary alcohol positions of the glyceride) bioactive agent monomers. (c) Coupling of an acid/chloroformate-bioactive agent conjugates with protected WO 2010/040188 PCT/AU2009/001342 -117 monoglycerides HNH / 0 0 H -Q 00
H
2 N Q Bioactive agent An an acid/chloroformate-bioactive agent conjugate containing a bioactive agent - such as Benzocaine - (after conversion into a prodrug by protecting additional functional groups 5 with appropriate bioerodable protection groups) is reacted with protected monoglycerides. The monoglyceride protection groups are removed under appropriate conditions giving the monoglyceride functionalised (at the primary or secondary alcohol positions of the glyceride) bioactive agent monomers. 10 Conversion of a phosphate containing bioactive agent to functionalised protected monoglyceride (as phosphate ester) with and/or without a spacer group. X=spacer - as described in the previous text, R=protection group WO 2010/040188 PCT/AU2009/001342 - 118 00 - -O OH Q -O OH O OH OH O 0 -0-0 - ~0 R X-0 OH OR X-0 OH OH OH 0 H-P1 -~0 Bioactive agent OH A phosphate containing bioactive agent - after conversion into a prodrug by protecting additional functional groups with appropriate bioerodable protection groups - is converted 5 into the corresponding functionalised protected monoglyceride (as phosphate ester) withor without a spacer group that can be modified to meet the required polymer properties and release kinetics. Polymer Production 10 This section describes how the functionalised bioactive-monomers conjugates have been covalently linked to the polymer backbone and formed part of the bioactive-polymer conjugates containing the selected bioactive as a pendant attachment. The pendant attached bioactive is able to be released by the breakdown of the covalent bonds through hydrolysis 15 and the degradation of the linkages attaching the bioactive to the polymer. Synthesis of Polyols (a) DLLA 1000 WO 2010/040188 PCT/AU2009/001342 -119 The DLLA 1000 was produced by the polycondensation reaction of an 88% DL Lactic acid solution (Fluka) using 1-4 butane diol (Aldrich) as the initiator and 2 Ethyl Hexanoate (Aldrich) as the catalyst. The polycondensation reaction was undertaken in a stainless steel vessel (Buchi BEP280 reactor). The reagents were added to the reaction 5 vessel [ 1-4 BDO; 167.5g; DL-Lactic acid solution 2418g; 2 Ethyl Hexanoate; 0.12% , 2.4g] and the mixture was stirred at 350prm while bubbling nitrogen gas through the solution ( 3mL/min). A tube was attached to the reactor outlet to collect the water evolved. Heating was applied (jacket oil temperature 145'C) and the mixture was left to stir for 2 10 days. Approximately 280mL of water from collected from the reaction mixture. Samples were taken and the acid number determined by titration using the methods outlined above. The low acid number obtained [0.09 mg/KOH / g] was used to indicate the reaction was completed. The mixture was cooled and subsamples taken for GPC, 15 NMR and hydroxyl number analysis using the methods outlined above. (b) PLGA (50:50) 1000 Purasorb DL Lactide (1000g) and Purasorb Glycolide (805.5g) was added to the 3L stainless steel Buchi reactor. The reactor was heated under a nitrogen blanket without 20 stirring to a jacket oil temperature of 145'C. The stirrer was started and the jacket temperature adjusted to 120'C. To the stirred reaction mixture was added 156.3g of 1-4 BDO and 2.2g 2-Ethyl Hexanoate. An exotherm was observed with the reaction temperature rising to 143'C in 8 minutes. 25 The mixture was heated for 40hrs at a stirring rate of 300rpm under a nitrogen blanket. Samples were taken and the acid number determined by titration using the methods outlined above.
WO 2010/040188 PCT/AU2009/001342 - 120 Polyurethane and Polyester-Urethane Formulations Polylactic Acid (Mw 1000 g/mol) and polycaprolactone diol (Mw 1000 g/mol) were both dried under high vacuum overnight at 75'C before use. Hexamethylene diisocyanate (HDI) 5 and Ethyl-lysine diidocyanate (ELDI) were distilled before use. Polyurethane Bulk Synthesis Method The required amounts of DLLA, PLGA or PCLD (ERA Chemicals Pty Ltd) polyester 10 polyols were weighed into a beaker and kept warmed in a pre-heated nitrogen purged oven. The required amount of bioactive-monomer conjugate was first dried under vacuum with mild heat then mix added to the reaction beaker containing the DLLA, PLGA or PCLD components and retuned to an oven to equilibrate. 15 The required amount of diisocyanate HDI was weighed into a syringe for addition to the other components. Three drops of Dibutyltin Dilaurate (DBTDL) or 2 Ethyl Hexanoate ((Sn2EH) catalyst were first added to the bioactive-monomer conjugate and/polyol mixture. The monomer/s and catalyst were mixed well before either the HDI or ELDI was added via a syringe. The whole mixture was mixed and stirred vigorously with a spatula 20 until the mixture thickened considerably before it was poured onto a baking tray. The tray was then placed in an oven overnight at 80'C to cure the polymer. Optimisation of the molecular weight was achieved by varying the HDI or ELDI index. The molecular weights of the polymers were characterised by Gel Permeation 25 Chromatography (GPC) using THF or DMF as the solvent. Reaction completion and structural integrity were confirmed by means of 'H NMR. Polyurethane Solution Synthesis Method Bioactive-monomer conjugates were dried under vacuum with mild heat then added to dry 30 DMF (typically > Ig) in a small round bottle flask. Two drops of DBTDL or Sn2EH were added and the mixture warmed in an oil bath at 85'C before injecting in a slight excess of WO 2010/040188 PCT/AU2009/001342 - 121 HDI or ELDI. The mixture was typically found to have thickened considerably after stirring overnight at 85CC. The DMF solvent was removed and the material was then analysed or further purified. 5 Polyurethane Precipitation Purification Method The resulting PU was dried to remove any DMF present. The polymer was then dissolved in a minimal amount of DMSO then precipitated from solution into acetonitrile. Any unreacted bioactive-monomer conjugate remained dissolved in the DMF/Acetonitrile solution. 10 Aliphatic Polyurethanes containing Valproic Acid Monoglyceride (VA-MG) Comparative Example 1: PU polymer bioactive-coniugate containing 50mole% VA-MG 15 A polymer-bioactive conjugate containing 50mole% VA-MG was formed by the reaction of 1:1 molar ratio of VA-MG and HDI according to the Polyurethane Bulk Synthesis Method. The VA-MG synthesised in Example I above was dried under vacuum. The VA MG (1.005g, 4.6mmol) was added to a dried 150ml polypropylene (PP) beaker. DBTDL (dibutyl tin dilaurate) catalyst was added to the beaker (0.0041 g). The mixture was 20 stirred and heated in the beaker at 70'C for 5 mins. HDI was then added by syringe (1.003g 5.9 mmol) with stirring. The mixture was then poured into a Teflon coated tray and allowed to cure for 4 hours in an oven at 70'C. Films of the polymer were pressed using a melt press set at 90'C. Teflon coated metal press plates were used. The thickness was controlled using a 200 micron shim plate. The sample was pressed for 5 mins at 90'C 25 and then cooled to room temperature using tap water (flowing through the press platterns). The polymer film was found to be clear, flexible and tough. The nominal loading the valproic acid in the polymer is approximately 30wt%.
WO 2010/040188 PCT/AU2009/001342 - 122 Example 13: Flexible PU polymer bioactive-conjugate containing 33mole% VA-MG A polymer-bioactive conjugate containing 33mole% VA-MG was formed by the reaction of VA-MG, PCLD1000 and HDI according Polyurethane Bulk Synthesis Method in the 5 proportions 34mole%, 15mole% and 51mole%, respectively. PCLD 1000 (2.508g, 2.524 mmol) and VA-MG (I.185g, 5,428 mmol) were added to a dried glass beaker and mixed thoroughly with a spatula. Three drops of DBTDL (dibutyltin dilaurate) catalyst was then added to the polyols mixture. HDI (1.393g, 8.281 mmol) was delivered by a syringe and vigorous mixing was applied. The hot mixture was then poured onto a Teflon coated tray 10 and placed in an oven to cure overnight at 85'C. Through isocyanate index optimisation, polyurethanes of high molecular weights and strength were synthesised from this formulation. A 250 micron thick film prepared by the process described above was clear, tough. The loading of VA-MG achieved by this formulation is approximately 23.3 wt%. 15 Aliphatic Polyurethanes containing Levofloxacin Monoglyceride (LVX-MG) Example 20: Polyurethane Bioactive-Polymer conjugate containing > 50wt% LVX-MG LVFX-MG (0.20g, 0.457 mmol) was dissolved in 2.5 ml of dry DMF solvent. Two drops of the DBTDL catalyst was added to the solution and heated to 65'C in a small round 20 bottle flask with a rubber seal. HDI (0.078g, 0.464 mmol) added via a micro syringe and allowed to react overnight. After removing the DMF, flaky but brittle solid was produced. After precipitation in acetonitrile solvent, a whitish material was collected. Example 22: Polyurethane Bioactive-Polymer conjugate containing 13wt% bound LVX ( 25 as LVX-MG). DLLA (l.35g, 1.20 mmol), PCLD (0.38g, 0.384 mmol) and 3 drops of DBTDL was mixed in a beaker and warmed in an oil bath at 65'C. LVFX-MG (0.65g, 1.04 mmol) was dissolved in 3 ml of dry DMF solvent. The two mixtures were then combined before 30 injecting in the HDI (0.52g, 3.09 mmol). Over the course of a few hours, the mixture's viscosity has increased considerably. Transferred the material into a crucible and heated in WO 2010/040188 PCT/AU2009/001342 - 123 an oven at 80'C overnight. After removing the solvent, a sticky waxy material was produced.
WO 2010/040188 PCTIAU2009/001342 - 124 0 0 (~1 _ ,. 0 0 C-) ~2 '2 cO0 75 1:5 -~I cn cm - ~ 0 o o o o 00 0 F-o C-,-F- F- F mcln M en00 > oj ( ( C:) C)(- ) 0' O - 00 WO 2010/040188 PCT/AU2009/001342 -125 72 2 c,- 2 a CL V) a. 0 C) C C-D 0l ol 0-C 00 C/C ~ r~ cr c 0 w 00 V) Cl Cl rn cl rC n4~ WO 2010/040188 PCT/AU2009/001342 - 126 00 EN E bi) a)~ 75 a CCV)j 000 N2 00 ON 0O A bf) -. a0 0 I Co 0 DO 00 I~q 0 -4 0 00 rn - CD 00 N0 'D 00 m.c OIR r- WO 2010/040188 PCT/AU2009/001342 - 127 It was found that polymer produced by selective precipitation was too brittle to melt press. It was decided to melt blend these materials with the amorphous PU's produced for the earlier Levoflocaxin / amorphous PU blend work. 5 Film samples of the melt blend of the LVX-MG bioactive polymer conjugate ( Example 15) with amorphous PU have been produced which contain 1 Owt% LVX. POLYESTERS 10 Reaction of VA-MG with Di-Acids or Anhydrides VA-MG was dried under high vacuum with magnetic stirring at room temperature in the flasks used for conducting the reaction. The reactions was carried out at 1 10 C in 5OmL 15 round bottom flasks fitted with magnetic stirrer bar, a 10mL capacity Dean and Stark trap and a reflux condenser in the presence of a condensation catalyst (DBTDL). The apparatus were blanketed with nitrogen to prevent moisture ingress. Toluene distilled from sodium was used as a solvent for the reaction. The collection arm 20 of the Dean and Stark trap was filled with dried molecular sieve (4A) to further promote the removal of water from the reaction mixture Reaction work-up involved the removal of the toluene by rotovap and high vacuum. All samples were washed with 0.1M HCl then water and dried under high vacuum. Reaction 25 completion and structural integrity was confirmed by 'H NMR and molecular weights determined by GPC. Reaction of VA-MG with Acid Chlorides 30 VA-MG was dried under high vacuum with magnetic stirring at room temperature in the flasks used for conducting the reaction.
WO 2010/040188 PCT/AU2009/001342 - 128 The acid chlorides were distilled under vacuum and stored under nitrogen in a freezer before use. DCM was dried over molecular sieve using a solvent delivery system (SDS). Reactions were carried out in DCM within a 50mL round bottom flask fitted with 5 magnetic stirrer bar and a reflux condenser. The flasks were blanketed with nitrogen to prevent moisture ingress. Triethylamine (TEA) was added to the reaction flask in 20% excess to drive the reaction by promoting the formation of the acid chloride salt. The TEA was dried by distillation 10 off calcium hydride under a nitrogen blanket. Reaction work-up involved washing of the TEA-HCl salt in 0.IM HCL and water, drying the organic layer over anhydrous sodium sulphate, filtering and removal of the DCM by rotovap. All samples were washed with 0.IM HCL then water and dried under high 15 vacuum. Reaction completion and structural integrity was confirmed by 'H NMR and molecular weights determined by GPC.
WO 2010/040188 PCT/AU2009/001342 - 129 u cu od a- C 5 CI c u lu C)) CA C 0 C) ) C, ~ 41 t0 00 C C) C) 00 C> 00C,0O a)t a) C) q
(NI
WO 2010/040188 PCT/AU2009/001342 -130 -2 -2 .2 . 0n 1 C, at CO 1 Q . S . CDO) : C)1 00~ 00 00)
-
In 0 u WO 2010/040188 PCT/AU2009/001342 - 131 Drug Release Following in vitro release guidelines recommended by the International Organisation of Standardisation 9 , polymer-coated discs or cylindrical samples were suspended in wire baskets which were immersed in isotonic phosphate buffer (IPB), adjusted to pH 7.4 using 5 orthophosphoric acid and containing 0.01% sodium azide as a preservative, and incubated at 37'C with continuous stirring. Aliquots of the receptor solution were removed for analysis at predetermined time points until the release from the polymer no longer increased. 10 The amount of drug released from the polymer-coated discs at the various time points was quantified by reserve phase high performance liquid chromatography (HPLC) with a UV absorbance detector (levofloxacin) and refractive index (valproic acid) and drug separation was performed on a C 18 column. Levofloxacin and Valproic Acid were eluted isocratically using a degassed mobile phase. 15 In vitro assessment of antimicrobial activity The antimicrobial activity of polymer-coated discs was assessed using the disc diffusion test based on protocols recommended by the Clinical and Laboratory Standards Institutem Colonies selected from an overnight culture of S. aureus ATCC strain 29213 were 20 suspended in phosphate-buffered saline (PBS) at a density of 1.5 x 108 CFU/ml. The suspension was then used to inoculate the surface of a Mueller-Hinton agar plate. Discs coated on one side only were placed coated-side-down onto the freshly inoculated agar and the plates were incubated at 37*C in air for 18 hr. Growth inhibition was inspected visually the following day. Discs were then transferred to freshly inoculated agar plates 25 each day until no inhibition of growth occurred. Example 50: Release of Levofloxacin The following charts show the release of levofloxacin from the polymer systems WO 2010/040188 PCT/AU2009/001342 - 132 described in Examples 20, 25, 26, 28 ,27, and 36. The amount of levofloxacin was determined by HPLC as previously described at the time intervals given in the chart. Figure 2 shows the release of both levofloxacin (LVX) and the levofloxacin incorporating monomer, levofloxacin monoglyceride (LVX-MG), from the polymer described in 5 Example 20. The data shows that levofloxacin is released from the polymer as the free active drug with very little released as the inactive levofloxacin-monoglyceride. Figure 3 shows the release of levofloxacin from a number of different polymers described in Examples 25, 26 ,27 and 28. The data shows levofloxacin is released from each of the polymers 25, 26, 27 and 28. Figure 4 shows an in vitro assessment of antimicrobial 10 activity from polymers described in Examples 20 and 36. Antimicrobial activity is demonstrated in both polymers. Example 51: Release of Valproic Acid 15 The following charts show the release of Valproic Acid from the polymers described in examples CEl, 14, 16 and 17. The amount of Valproic Acid was determined by HPLC as previously described at the time intervals given in the chart. Figure 5 shows the release of Valproic Acid from the polymers described in examples CE1, 14, 16, 17. The data shows that Valproic Acid is released from the polymers 14, 16 and 17 but not from polymer 20 CEl. Polymer from example CEl was produced with Valproic Acid attached directly to the incorporating diol, Glycerol, and from two monomers, Valproic Acid Monoglyceride and HDI, in 1:1 ratio. Polymer examples 16 and 17 used a linker to distance the Valproic Acid from the polymer backbone. Polymer example 13 was produced with an additional polyester polyol component, PCL. 25 Comparative Example 2: No Release of Valproic Acid The polymer described in Example 47 was incubated in phosphate buffer (pH 7.4) at 37 'C for 120 hours, Both Valproic Acid and Valproic Acid Monoglyceride were measured 30 by GC-MS. After 120 hours release of VA-MG could be detected but not trace of VA WO 2010/040188 PCT/AU2009/001342 - 133 was found, The polymer described in Example 47 was produced from a 1:1 molar ratio of Valproic Acid Monoglyceride and Adipic Acid. As the amount of VA-MG released was greater than the amount of VA released from the polymer, such a polymer lies outside the claims of this patent but serves as a comparator to the polymer claimed within the 5 invention. Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or 10 steps but not the exclusion of any other integer or step or group of integers or steps. The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or 15 information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.

权利要求:
Claims (23)
[1] 2. The biodegradable polymer according to claim 1 having general formula (I): 10 A-X-R-Y-B D (1) where: A and B, which are the same or different, represent the remainder of the polymer backbone and (i) comprise one or more -X-R(ZD)-Y- as shown in formula (I), and 15 (ii) are each formed from monomeric units that are coupled via a biodegradable moiety, wherein each X, Y, R, Z and D in a given -X-R(ZD)-Y- moiety of the biodegradable polymer is the same or different; X and Y are each independently a biodegradable moiety; R represents a linear or branched optionally substituted hydrocarbon; 20 Z is a spacer moiety; and D is a releasable bioactive moiety; wherein the bioactive moieties (D) are capable of being released at a rate equal to or faster than the rate of biodegradation of the polymer backbone. 25 3. The biodegradable polymer according to claim 2, wherein X and Y in each -X R(ZD)-Y- moiety are each independently an ester or carbamate moiety.
[2] 4. The biodegradable polymer according to any one of claims 1 to 3 which comprises WO 2010/040188 PCT/AU2009/001342 - 135 less than 25 mol% of polymerised residues that are derived from a C 2 - 1 0 diol, relative to the total number of moles of polymerized diol residues.
[3] 5. The biodegradable polymer according to any one of claims I to 3 which comprises at least 30 mol% of releasable bioactive agent (D), relative to the total number moles of 5 monomer polymerised to form the polymer.
[4] 6. The biodegradable polymer according according to claim 1 or 2, wherein the monomeric units that form the polymer backbone are coupled with biodegradable moieties selected from aide, carbamate, ester, anhydride and urea.
[5] 7. The biodegradable polymer according to claim 2, wherein D is coupled through Z 10 to R by an ester, aide, thiol, anhydride, imide, carbonate, peroxide, peroxyester, phosphate ester, thioester, sulphate ester, carbamate, azo or boronate ester moiety.
[6] 8. The biodegradable polymer according to claim 7, wherein D is coupled through Z to R by an ester, imide, carbonate, carbamate, or phosphate ester moiety. 15 9. The biodegradable polymer according to any one of claims 2, 7 and 8, wherein Z is selected from -0-; -C(0)-; and optionally substituted: -OC(O)-Cj-salkylene-C(O)-; C(O)O-C-j 8 alkylene-C(O)-; -NRaC(O)-C . 18 alkylene-C(O)-; -C(O)O-C 1 salkylene-O-; O-C- 1 8alkylene-O-; -0-C -jsalkylene-NRa-; -OC(O)-C- salkylene-NRa-; -C(0)-C 1 .. 18 alkylene-NR"-; -OC(O)-CI 1 8alkylene-O-; -C(O)-C 1 .1salkylene-0-; and -C(O)NR-Cl. 20 Igalkylene-NR- where Ra is selected from hydrogen, C 18 alkyl, Cl-. 8 alkenyl, C 1 i8alkynyl, C6-18aryl, C3-18carbocyclyl, C 3 .18heteroaryl, C3-isheterocyclyl, and C 7 . I 8 arylalkyl.
[7] 10. The biodegradable polymer according to any one of claims 2, and 7 to 9, wherein 25 R a linear or branched optionally substituted hydrocarbon having from 1 to 12 carbon atoms. WO 2010/040188 PCT/AU2009/001342 - 136
[8] 11. The biodegradable polymer according to any one of the preceding claims, wherein the bioactive moieties (D) is selected from 5-alpha-reductase inhibitors, amebicides, aminosalicylates, anaesthetics (general and local), analgesics, angiotensin inhibitors, anorexiants, antacid agents, anti-angiogenic agents, antianginal agents, antiarrythmic 5 agents. antiarthritic agents, antibiotics, antibacterial agents, antibodies, anticoagulants, anticonvulsants, antidepressants, antiepileptic agents, antifungals, anthelmintics, antihistamines, antihypertensives, antihyperlipidemic agents, antiinfectives, antiinfl amrnatories, antiernetics, antimalarial, antimetabolites, antimigraine, antimitotics, antiparasitic agents, antiparkinson agents, antipsychotics, antiprotozoals, antitussives, 10 antiulcer agents, antivirals, anxiolytics, bronchodilators, decongestants and expectorants, cancer therapy and related pharmaceuticals, cardiovascular pharmaceuticals, central nervous system pharmaceuticals, benzopidazepines, beta-adrenergic blocking agents, bisphosphonates, calcium channel blockers, carbonic anhydrase inhibitors, chemokine receptor antagonist, coumarins and indadiones, cox-2 inhibitors, contraceptives, 15 cytotoxics, diuretics, diabetes therapies, growth hormones, fertility pharmaceuticals, hematinics, glucose modifying agents, growth promoters, H2 antagonists, heparin and heparin antagonists, hormone replacement therapies, hemostatics, immunosuppressants, immunosti mul ants, inotropic agents, interferons, hormones and analogs, impotence agents, kinase inhibitors, laxatives, leukotriene modifiers, macrolides, mast cell 20 stabilizers, muscle relaxants/stimulants. mydiratics, neuromuscular blocking agents, obesity therapeutics, ophthalmic pharmaceuticals, osteoporosis drugs, pain therapeutics, peptides and polypeptides, peripheral vasodilators, platelet inhibitors/stimulating agents, prolactin inhibitors, protease inhibitors, protein therapeutics, proton pump inhibtors, radiopharmaceuticals, respiratory pharmaceuticals, sedatives, spermicides, steroids, 25 smoking cessation agents, statins, stimulants and tranquilizers, sulphonamides, thyroid drugs, urinary acidifiers/alkalinisers, and vasodilators.
[9] 12. The biodegradable polymer according to any one of the preceding claims, wherein the bioactive moeties (D) is selected from alatrofloxacin, balofloxacin, ciprofloxacin, 30 clinafloxacin, danofoxacin, delafloxacin, dextrofloxacin, difloxacin, enoxacin, enrofloxacin, garenoxacin, gatifloxacin, gemifloxacin, grepafloxacin, levofloxacin, WO 2010/040188 PCT/AU2009/001342 - 137 lomefloxacin, marbofloxacin, moxifloxacin, nadifloxacin, norfloxacin, ofloxacin, orbifloxacin, pefloxacin, sitafloxacin, sparfloxacin, temafloxacin, tosufloxacin, tosulfloxacin, trovafloxacin, valproic acid, benzocaine and procaine. 5 13. The biodegradable polymer according to any one of the preceding claims, wherein the bioactive moeities (D) is selected from dextrofloxacin, levofloxacin, benzocaine and procaine.
[10] 14. The biodegradable polymer according to any one of the preceding claims, wherein 10 the bioactive moieties (D) are capable of being released at a rate faster than the rate of biodegradation of the polymer backbone
[11] 15. The biodegradable polymer according to claim 2, wherein D is coupled through Z to R by a biodegradable moiety that has a higher susceptibility to hydrolytic cleavage than the biodegradable moieties that couple the monomeric units that form the polymer 15 backbone.
[12] 16. The biodegradable polymer according to claim 15, wherein the biodegradable moieties are selected from, presented in decreasing order of their susceptibility to hydrolytic cleavage, anhydride moiety > ester moiety > carbamate > amide. 20 17. A method of delivering a bioactive moiety to a subject, the method comprising administering to the subject a biodegradable polymer according to any one of claims 1 to 16.
[13] 18. The method according to claim 17, wherein the mode by which the biodegradable 25 polymer is administered is selected from implantation, oral, parenteral, inhalation, buccal, pulmonary, aural, ocular, nasal, topical, rectal, vaginal and combinations thereof.
[14] 19. A sustained bioactive moiety delivery system, the system comprising a biodegradable polymer according to any one of claims I to 16. WO 2010/040188 PCT/AU2009/001342 - 138 20. A method for preparing a biodegradable polymer according to any one of claims 1 to 16, said method comprising the step of polyrnerising a monomer - bioactive moiety conjugate of formula (II): X-R-Y' D (II) 5 where: X' and Y' are each independently functional groups that (a) are capable of undergoing polymerisation with monomer having compatible chemical functionality, and (b) react with the compatible chemical functionality to afford a biodegradable moiety; and 10 R, Z and Z are as defined in any one of the preceding claims; with at least one monomer comprising compatible chemical functionality.
[15] 21. The method according to claim 20, wherein X' and Y' are each independently selected from hydroxyl, amine, carboxylic acid, isocyanate, and carboxylic acid halide.
[16] 22. The method according to claim 20, wherein X' and Y' are both hydroxyl and the 15 monomer - bioactive agent conjugate is polymerised with a monomer selected from a polyiisocyanate, polyacid and combination thereof.
[17] 23. The method according to claim 22, wherein the polyiisocyanate is selected from m-phenylene diisocyanate, p-phenylene diisocyanate, 2,4-toluene diisocyanate, 2,6 20 toluene diisocyanate, 1,6-hexamethylene diisocyanate, 1,4-hexamethylene diisocyanate, 1.3-cyclohexane diisocyanate, 1,4-cyclohexane diisocyanate, hexahydro-toluene diisocyanate and its isomers, isophorone diisocyanate, dicyclo-hexylmethane diisocyanates, 1,5-napthylene diisocyanate, 4,4'-diphenylmethane diisocyanate, 2,4' diphenylmethane diisocyanate, 4,4'-biphenylene diisocyanate, 3,3'-dimethoxy-4,4' 25 biphenylene diisocyanate, 3,3'-dimethyl-diphenylpropane-4,4'-diisocyanate, 2,4,6-toluene triisocyanate, and 4,4'-dimethyl-diphenylmethane-2,2',5,5'-tetraisocyanate. WO 2010/040188 PCT/AU2009/001342 - 139
[18] 24. The method according to claim 22, wherein the polyacid is selected from oxalic acid, fumaric acid, maleic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, phthalic acid, dodecanediacid, isophthalic acid, terephthalic acid, dodecylsuccinic acid, napthalene-2,6-dicarboxylic acid, naphthalene 5 2,7-dicarboxylic acid, cyclohexane dicarboxylic acid, itaconic acid, malonic acid, and mesaconic acid. 25, The method according to claim 20, wherein the monomer - bioactive moiety conjugate is selected such that the bioactive moieties (D) are capable of being released at 10 a rate faster than the rate of biodegradation of the so formed polymer backbone.
[19] 26. The method according to claim 20, wherein D is coupled through Z to R by a biodegradable moiety that has a higher susceptibility to hydrolytic cleavage than the biodegradable moieties that are formed upon reaction of X' and Y' with the monomer comprising compatible chemical functionality. 15 27. The method according to claim 26, wherein the biodegradable moieties are selected from, presented in decreasing order of their susceptibility to hydrolytic cleavage, anhydride moiety > ester moiety > carbamate > amide.
[20] 28. A suture, dental device, orthopaedic fixation device, transdermal patch, ligating 20 clip, vascular graft, ocular implant, stent, device coating or tissue-engineering scaffold comprisng the biodegradable polymer according to any one of claims I to 16.
[21] 29. A monomer - bioactive moiety conjugate that is suitable for use in preparing a biodegradable polymer, the monomer - bioactive moiety conjugate having a structure of general formula (II): 25 X'-R-Y' D (") WO 2010/040188 PCT/AU2009/001342 - 140 where: X' and Y' are each independently functional groups that (a) are capable of undergoing polymerisation with monomer having compatible chemical functionality so as to form a biodegradable polymer, and (b) react with the 5 compatible chemical functionality to afford a biodegradable moiety; R represents a linear or branched optionally substituted hydrocarbon; Z is a spacer moiety; and D is a releasable bioactive moiety.
[22] 30. The monomer - bioactive moiety conjugate according to claim 29, wherein X' and 10 Y' are each independently selected from hydroxyl, amine, carboxylic acid, isocyanate, and carboxylic acid halide. 31, The monomer - bioactive agent conjugate according to claim 29 or 30, wherein D is coupled through Z to R by an ester, imide, carbonate, carbamate, or phosphate ester 15 moiety.
[23] 32. The monomer - bioactive moiety conjugate according to claim 29, 30 or 31, wherein the bioactive agent (D) is selected from alatrofloxacin, balofloxacin, ciprofloxacin, clinafloxacin, danofoxacin, delafloxacin, dextrofloxacin, difloxacin, 20 enoxacin, enrofloxacin, garenoxacin, gatifloxacin, gemifloxacin, grepafloxacin, levofloxacin, lomefloxacin, marbofloxacin, moxifloxacin, nadifloxacin, norfloxacin, ofloxacin, orbifloxacin, pefloxacin, sitafloxacin, sparfloxacin, temafloxacin, tosufloxacin, tosulfloxacin, trovafloxacin, valproic acid, benzocaine and procaine.

类似技术:

---

公开号 | 公开日 | 专利标题

---

JP6290823B2|2018-03-07|Biodegradable polymer-bioactive moiety complex

---

US9408919B2|2016-08-09|Biodegradable polymer—bioactive moiety conjugates

---

EP2340271B1|2018-12-05|Polymer-bioactive agent conjugates

---

AU2014225305B2|2019-01-31|Polymer conjugate for delivery of a bioactive agent

---

AU2012243434A1|2013-11-28|Polymer conjugated prostaglandin analogues

---

CA2876728C|2021-02-16|Polymer-nsaid conjugate

---

AU2012258480B2|2014-10-23|Biodegradable polymer - bioactive moiety conjugates

---

DK2340271T3|2019-03-25|POLYMER BIOACTIVE CONJUGATES

---

US10758626B2|2020-09-01|Polymer conjugate comprising a bioactive agent

同族专利:

---

公开号 | 公开日

---

EP2355853A4|2014-01-15|

---

EP2355853A1|2011-08-17|

---

NZ592139A|2013-03-28|

---

ZA201102501B|2011-11-30|

---

ES2617913T3|2017-06-20|

---

JP2012505161A|2012-03-01|

---

WO2010040188A1|2010-04-15|

---

DK2355853T3|2017-03-06|

---

CN102245214B|2014-10-29|

---

EP2355853B1|2016-12-07|

---

CA2739078C|2017-01-03|

---

JP6290823B2|2018-03-07|

---

NZ603964A|2014-12-24|

---

SI2355853T1|2017-04-26|

---

IL212053A|2015-11-30|

---

CA2949337A1|2010-04-15|

---

CA2739078A1|2010-04-15|

---

KR101726715B1|2017-04-13|

---

JP2015180651A|2015-10-15|

---

HUE030895T2|2017-06-28|

---

WO2010040188A9|2010-06-17|

---

AU2009301646B2|2013-09-05|

---

SG195531A1|2013-12-30|

---

IL229996D0|2014-01-30|

---

JP5746629B2|2015-07-08|

---

CN102245214A|2011-11-16|

---

IL212053D0|2011-06-30|

---

PT2355853T|2017-03-15|

---

IL229996A|2016-06-30|

---

MY155629A|2015-11-13|

---

CA2949337C|2019-03-26|

---

KR20110091854A|2011-08-16|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

CN105377319A|2013-03-15|2016-03-02|界面生物公司|Compounds and compositions for drug release|WO1997029778A2|1996-02-15|1997-08-21|Santerre J Paul|Bioresponsive pharmacologically-active polymers and articles made therefrom|

---

JP2004509628A|2000-09-21|2004-04-02|メルク　エンド　カムパニー　インコーポレーテッド|Method for producing recombinant polynucleotide|

---

AR032052A1|2000-12-29|2003-10-22|Artimplant Ab|LINEAR BLOCK POLYMER, PROCEDURE FOR PREPARATION, USE, IMPLANTS, FILLING MATERIAL, PHARMACEUTICAL COMPOSITIONS AND POROUS POLYMER MATERIAL THAT INCLUDE SUCH LINEAR BLOCK POLYMER|

---

CA2349989A1|2001-06-07|2002-12-07|Paul J. Santerre|Bioactive surface modifiers for polymers and articles made therefrom|

---

AU2003267540A1|2002-08-13|2004-02-25|Sirus Pharmaceuticals Ltd|Biodegradable polymer|

---

CA2467321A1|2004-05-14|2005-11-14|Paul J. Santerre|Polymeric coupling agents and pharmaceutically-active polymers made therefrom|

---

BRPI0515118A|2004-08-31|2008-07-01|Pharmacia & Upjohn Co Llc|human growth hormone conjugates with polyethylene glycol|

---

AU2007262448A1|2006-04-14|2007-12-27|Interface Biologics Incorporated|Grafted polymers and uses thereof|

---

EP2040758A4|2006-06-30|2014-09-17|Interface Biologics Inc|Bioresponsive polymers|

---

US20100041872A1|2006-10-04|2010-02-18|Defrees Shawn|Glycerol linked pegylated sugars and glycopeptides|

---

CA2715815A1|2008-02-15|2009-08-20|University Of Southern Mississippi|Monomers and polymers with covalently-attached active ingredients|EP2340271B1|2008-10-10|2018-12-05|PolyActiva Pty Ltd.|Polymer-bioactive agent conjugates|

---

US8889193B2|2010-02-25|2014-11-18|The Johns Hopkins University|Sustained delivery of therapeutic agents to an eye compartment|

---

WO2011141341A1|2010-05-14|2011-11-17|Iberhospitex, S.A.|Compounds for the synthesis of biostable polyurethane, polyurea or polyurea urethane polymers|

---

US20130184835A1|2010-07-09|2013-07-18|Board Of Regents Of The Unversity Of Texas System|Biodegradable scaffolds|

---

US10307372B2|2010-09-10|2019-06-04|The Johns Hopkins University|Rapid diffusion of large polymeric nanoparticles in the mammalian brain|

---

EP2804632B1|2012-01-19|2019-09-18|The Johns Hopkins University|Nanoparticle formulations with enhanced mucosal penetration|

---

WO2012109363A2|2011-02-08|2012-08-16|The Johns Hopkins University|Mucus penetrating gene carriers|

---

WO2013130985A1|2012-03-01|2013-09-06|The University Of Akron|Biodegradable polymers with pendant functional groups attached through amide bonds|

---

CA2867381C|2012-03-16|2016-09-20|The Johns Hopkins University|Controlled release formulations for the delivery of hif-1 inhibitors|

---

US10159743B2|2012-03-16|2018-12-25|The Johns Hopkins University|Non-linear multiblock copolymer-drug conjugates for the delivery of active agents|

---

JP6360040B2|2012-05-03|2018-07-18|カラ ファーマシューティカルズ インコーポレイテッド|Mucus-permeable coated particles, compositions, pharmaceutical compositions, pharmaceutical formulations, and methods for forming them|

---

KR102310775B1|2012-05-03|2021-10-07|칼라 파마슈티컬스, 인크.|Pharmaceutical nanoparticles showing improved mucosal transport|

---

US20210386661A1|2012-05-03|2021-12-16|The Johns Hopkins University|Compositions and methods for ophthalmic and/or other applications|

---

US9827191B2|2012-05-03|2017-11-28|The Johns Hopkins University|Compositions and methods for ophthalmic and/or other applications|

---

AU2013256008B2|2012-05-04|2016-02-25|The Johns Hopkins University|Lipid-based drug carriers for rapid penetration through mucus linings|

---

SG11201408202UA|2012-06-26|2015-01-29|Polyactiva Pty Ltd|Polymer-nsaid conjugate|

---

CN102827035A|2012-08-21|2012-12-19|江苏恒祥化工有限责任公司|1, 4-cyclohexyl diisocyanate synthesis method|

---

WO2014124006A1|2013-02-05|2014-08-14|The Johns Hopkins University|Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof|

---

NZ711392A|2013-03-08|2020-05-29|Polyactiva Pty Ltd|Polymer conjugate for delivery of a bioactive agent|

---

US10113033B2|2013-03-08|2018-10-30|Polyactiva Pty Ltd|Polymer conjugate for delivery of a bioactive agent|

---

US9572832B2|2013-08-29|2017-02-21|Holy Stone Healthcare Co., Ltd.|Compound of glycosaminoglycan and its fabrication method as well as application|

---

WO2015127368A1|2014-02-23|2015-08-27|The Johns Hopkins University|Hypotonic microbicidal formulations and methods of use|

---

US10335500B2|2014-05-12|2019-07-02|The Johns Hopkins University|Highly stable biodegradable gene vector platforms for overcoming biological barriers|

---

CN104004001B|2014-05-28|2016-03-30|苏州大学|Contain cyclic carbonate monomer of two sulphur five-ring functional group and preparation method thereof|

---

CN105770900B|2014-05-28|2018-11-02|博瑞生物医药（苏州）股份有限公司|The application of carbonate polymer of the side chain containing double sulphur five-membered ring functional groups|

---

CN104031248B|2014-05-28|2016-09-07|博瑞生物医药（苏州）股份有限公司|Side chain contains carbonate polymer and the application thereof of double sulphur five-membered ring functional groups|

---

US9359316B1|2014-11-25|2016-06-07|Concentric Analgesics, Inc.|Prodrugs of phenolic TRPV1 agonists|

---

AU2016211696B2|2015-01-27|2018-05-10|The Johns Hopkins University|Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces|

---

CN108472273A|2015-09-11|2018-08-31|波利艾克蒂瓦有限公司|Include the polymer conjugate of bioactivator|

---

TW201726144A|2015-09-21|2017-08-01|梯瓦製藥國際有限公司|Sustained release olanzapine formulations|

---

CN108532126B|2017-03-02|2021-04-16|江苏华龙无纺布有限公司|Antibacterial biodegradable polyester non-woven fabric and preparation method thereof|

---

EP3600258A1|2017-03-20|2020-02-05|Teva Pharmaceuticals International GmbH|Sustained release olanzapine formulaitons|

---

US11116211B2|2018-03-09|2021-09-14|The University Of Akron|Modification of segmented polyurethane properties by copolymerizing with pendant functionalized diols|

---

RU2737425C1|2020-02-17|2020-11-30|Елена Евгеньевна Масталыгина|Mulching biodegradable polymer film and method for production thereof |

法律状态:
2011-04-28| DA3| Amendments made section 104|Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PRIORITY DETAILS TO READ 2008905262 10 OCT 2008 AU; 61/139,722 22 DEC 2008 US AND 2008905263 10 OCT 2008 AU |

---

2013-08-22| PC1| Assignment before grant (sect. 113)|Owner name: POLYACTIVA PTY LTD Free format text: FORMER APPLICANT(S): THE BIONIC EAR INSTITUTE |

---

2014-01-16| FGA| Letters patent sealed or granted (standard patent)|

优先权:

---

申请号 | 申请日 | 专利标题

---

AU2008905262A|AU2008905262A0||2008-10-10|Polymer-bioactive agent conjugates|

---

AU2008905263A|AU2008905263A0||2008-10-10|Drug polymer conjugates|

---

AU2008905263||2008-10-10||

---

AU2008905262||2008-10-10||

---

US13972208P| true| 2008-12-22|2008-12-22||

---

US61/139,722||2008-12-22||

---

AU2009301646A|AU2009301646B2|2008-10-10|2009-10-09|Biodegradable polymer - bioactive moiety conjugates|

---

PCT/AU2009/001342|WO2010040188A1|2008-10-10|2009-10-09|Biodegradable polymer - bioactive moiety conjugates|AU2009301646A| AU2009301646B2|2008-10-10|2009-10-09|Biodegradable polymer - bioactive moiety conjugates|

---

AU2012258480A| AU2012258480B2|2008-10-10|2012-11-29|Biodegradable polymer - bioactive moiety conjugates|